

BMJ Open

Chinese herbal medicine Jian Ling Decoction for essential hypertension: a systematic review and meta-analysis of randomized controlled trials

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-006502
Article Type:	Research
Date Submitted by the Author:	02-Sep-2014
Complete List of Authors:	Xiong, Xing-jiang; Guang'anmen Hospital, Li, Xiaoke; McLean Hospital, Harvard medical school, Bio-organic and Natural Products Laboratory Zhang, Yuqing; McMaster University, Department of Clinical Epidemiology and Biostatistics
Primary Subject Heading:	Complementary medicine
Secondary Subject Heading:	Complementary medicine
Keywords:	essential hypertension, Chinese herbal medicine, Jian Ling Decoction, systematic review

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

Chinese herbal medicine Jian Ling Decoction for essential hypertension: a systematic review and meta-analysis of randomized controlled trials

Xingjiang Xiong^{1*}, Xiaoke Li², and Yuqing Zhang³

¹ Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China

² Bio-organic and Natural Products Laboratory, McLean Hospital, Harvard medical school, Belmont, USA

³ Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada

* Correspondence: Xingjiang Xiong, MD, Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beixiang 5#, Xicheng District, Beijing 100053, China. (xiongxingjiangtcm@163.com or 5administration@163.com).

ABSTRACT

Objectives: Jian Ling Decoction (JLD) is often prescribed for improving hypertension-related symptoms in China. However, it has not been systematically reviewed for the treatment of essential hypertension (EH). This review aims to assess the current clinical evidence of JLD for EH.

Design: Seven electronic databases including PubMed, EMBASE, The Cochrane Central Register of Controlled Trials, Chinese National Knowledge Infrastructure, Chinese Scientific Journal Database, Wanfang Database, and Chinese Biomedical Literature Database were searched up to March 2014. Randomized control trials (RCTs) comparing JLD or combined with antihypertensive drugs versus antihypertensive drugs were included. We assessed the methodological quality, extracted the valid data, and conducted the meta-analysis according to criteria from Cochrane group. Primary outcome was blood pressure (BP) and the secondary was quality of life (QOL).

Results: Ten trials (655 patients) with unclear-to-high risk of bias were identified. Meta-analysis showed that JLD alone showed no more better effect on BP, but positive effect on QOL was found when compared to antihypertensive drugs. Significant reduction on systolic BP and diastolic BP were observed on JLD plus antihypertensive drugs when compared to antihypertensive drugs alone. No serious adverse effect was found.

Conclusion: Some encouraging clinical evidence of JLD as a kind of complementary therapy for EH was found. However, more well-designed trials are needed due to poor

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

methodological quality and high risk of bias.

KEY WORDS

essential hypertension; Chinese herbal medicine; Jian Ling Decoction; systematic review

For peer review only

ARTICLE SUMMARY

Article focus

Jian Ling Decoction (JLD), a traditional Chinese herbal formula, is often prescribed for patients with essential hypertension (EH).

Key messages

This systematic review indicates that there are some encouraging clinical evidence of JLD as a kind of complementary therapy for EH. However, more well-designed trials are needed.

Strengths and limitations of this study

The strength of this systematic review is its comprehensive, unbiased search of seven electronic databases, especially in four main Chinese databases, without language and publication restrictions. The included trials were small with poor methodological quality and significant heterogeneity.

INTRODUCTION

Hypertension is one of the most important preventable causes of death and one of the commonest conditions treated in primary health care, which represents an important public health challenge because of its high prevalence and concomitant increase in risk of cardiovascular, cerebrovascular and renal diseases [1, 2]. It has been ranked as the leading global risk factor for mortality and as the third leading risk factor for disease burden according to the comparative Risk Assessment Collaborating Group [3, 4]. Currently, about 1 billion patients have been affected [5]. The association between blood pressure (BP) and mortality has been discovered approximately one hundred years ago [6]. Recent studies also confirmed that BP level is closely related to vascular outcomes, and even a minor reduction of BP could reduce cardiovascular events, especially stroke [7, 8]. Therefore, early diagnosis and effective treatment is of great importance for patients with essential hypertension (EH). Nevertheless, despite remarkable achievements on research and development of antihypertensive drugs, the current awareness, curative and control rates of hypertension among different age-groups still far from satisfactory [9, 10]. Additionally, in the light of the undesirable effects of antihypertensive drugs, in the western countries, some patients with EH and other cardiovascular diseases are increasingly using complementary and alternative medicine (CAM) [11-13], including traditional Chinese medicine (TCM), hoping for another adjunctive approach with few adverse effects [14-16].

1
2
3
4 Chinese herbal medicine (CHM), one of the most common treatment measures,
5
6 has played an important role for relieving hypertension related signs and symptoms
7
8 for centuries in East Asia [17, 18]. Recently, more robust evidence from systematic
9
10 reviews (SRs) suggested the efficacy and safety of CHM for EH [19-26]. In TCM
11
12 theory, liver yang hyperactivity syndrome (LYHS) and liver-kidney yin deficiency
13
14 syndrome (LKYDS) are the two most important patterns of EH, which often appear at
15
16 the same time. They are manifested as headache, vertigo, tinnitus, irritability,
17
18 insomnia, lassitude in waist and legs, dysphoria with feverish sensation, dry mouth,
19
20 bright red tongue with less fur, and wiry pulse [14, 17, 21, 27, 28]. Jian Ling
21
22 Decoction (JLD) is a traditional CHM dispensed by *Zhang Xichun* in *Yi Xue Zhong*
23
24 *Zhong Can Xi Lu* (also named as Integrating Chinese and Western Medicine) in 1920s.
25
26 It contains eight commonly used herbs: Common Yam Rhizome (*Shanyao, Rhizoma*
27
28 *Dioscoreae*), Twotooth Achyranthes Root (*Niuxi, Radix Achyranthis Bidentatae*), Red
29
30 Ochre (*Daizheshi, Ochre Haematitum*), Dragon's Bones (*Longgu, Os Draconis*),
31
32 Oyster Shell (*Muli, Concha Ostreae*), Rehmannia Root (*Dihuang, Radix Rehmanniae*),
33
34 White Peony Root (*Baishao, Radix Paeoniae Alba*), and Platycladi Seed (*Baiziren,*
35
36 *Semen Platycladi*). All of these herbs have been recorded in Pharmacopoeia of the
37
38 People's Republic of China (2010 edition). Both LYHS and LKYDS could be well
39
40 relieved by JLD [19]. Currently, it is often prescribed for the management of EH by
41
42 TCM practitioners in China. The pharmacological mechanisms may be related to the
43
44 reduction of angiotensin II, IL-6, tumor necrosis factor- α (TNF- α), leptin, insulin
45
46 resistance, blood lipids, etc [29-34]. Clinically, a large number of studies (including
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 case reports, case series, controlled observational studies, randomized trials, etc) have
5
6 reported the effect of JLD on EH, including lowering BP, reducing inflammation,
7
8 reversing cardiovascular risk factors, and improving clinical symptoms and quality of
9
10 life (QOL) [35-37]. However, there's no comprehensive evaluation of clinical trials on
11
12 the efficacy and adverse effects of JLD. This review aims to systematically review the
13
14 published and unpublished randomized controlled trials (RCTs) to evaluate the
15
16 current evidence of JLD in treating EH.
17
18
19
20
21
22
23

24 **METHODS**

25
26
27
28
29 This study was conducted according to the Cochrane practice [38].
30
31
32
33

34 **Search strategies**

35
36
37
38
39 RCTs on JLD for treating hypertensive patients were screened *via* the following
40
41 electronic databases from their respective inceptions up to March 2014: Cochrane
42
43 Central Register of Controlled Trials (CENTRAL, 1996-2014), PubMed (1959-2014),
44
45 and EMBASE (1980-2014). In addition, as JLD is mainly prescribed in China, 4
46
47 Chinese electronic databases including Chinese National Knowledge Infrastructure
48
49 (CNKI, 1980-2014), Chinese Scientific Journal Database (VIP, 1989-2014), Chinese
50
51 Biomedical Literature Database (CBM, 1978-2014), and Wanfang Database
52
53 (1998-2014) were searched to retrieve the maximum possible number of trials. We
54
55
56
57
58
59
60

1
2
3
4 also conducted literature searching in the website of Chinese clinical trial registry
5
6 (available at: <http://www.chictr.org/>) and international clinical trial registry by US
7
8 National Institutes of Health (available at: <http://clinicaltrials.gov/>) for all the ongoing
9
10 registered clinical trials and unpublished articles. Bibliographies of studies identified
11
12 in the systematic search were checked for potentially relevant publications. No
13
14 restriction on publication status or language was imposed.
15
16

17
18 Keywords for databases searching were ('hypertension' OR 'essential
19
20 hypertension' OR 'primary hypertension' OR 'high blood pressure' OR 'blood
21
22 pressure') AND ('*jian ling* decoction' OR '*jianling* decoction' OR '*jian ling tang*' OR
23
24 '*jianling tang*' OR '*jianlingtang*') AND ('clinical trial' OR 'randomized controlled
25
26 trial') (Additional file 1).
27
28
29
30
31
32

33 34 **Study selection**

35 36 37 38 *Types of studies*

39
40 RCTs about the use of JLD for the treatment of EH were included.
41
42

43
44 Quasi-randomized trials and animal experiments were excluded.
45
46
47
48

49 50 51 *Participants*

52
53
54
55
56 Trials focused on the patients suffering from EH were included. All patients
57
58

1
2
3
4 should meet the following diagnostic criteria: systolic blood pressure (SBP) \geq 140
5
6 mmHg, and/or, diastolic blood pressure (DBP) \geq 90 mmHg. Those without
7
8 description of diagnostic criteria but stated patients with definite EH were also
9
10 considered. Patients with secondary hypertension should be excluded. There is no
11
12 restriction on gender, age, or ethnic origin.
13
14

15 16 17 18 19 **Interventions**

20
21
22
23
24 Studies comparing JLD or combined with antihypertensive drugs versus
25
26 antihypertensive drugs were included. Studies assessing the combined effect of JLD
27
28 with other interventions (e.g. another CHM, qigong, Tai Chi, acupuncture,
29
30 moxibustion and massage) were excluded. Interventions in control group include
31
32 antihypertensive drugs. Studies which used non-conventional medicine or CAM as
33
34 control groups were excluded as well.
35
36
37

38
39 According to the principle of the similarity of TCM formula [39], modified JLD
40
41 should contain at least 6 out of 8 herbs used in JLD, or, only few herbs could be added
42
43 into JLD based on TCM syndrome theory. However, the new prescription should
44
45 contain the following four principal drugs: Twotooth Achyranthes Root (Niuxi, *Radix*
46
47 *Achyranthis Bidentatae*), Red Ochre (Daizheshi, *Ochre Haematitum*), Dragon's
48
49 Bones (Longgu, *Os Draconis*), and Oyster Shell (Muli, *Concha Ostreae*). Duration of
50
51 treatment was at least 2 weeks.
52
53
54
55
56
57
58
59
60

Outcome measures

Primary outcome measure analyzed for this review was BP. Secondary outcome measures analyzed for this review was QOL.

Data extraction

All articles were read by two independent reviewers (XX and XL). Then, eligible studies were retrieved for further identification according to the above inclusion and exclusion criteria. Duplicated papers were excluded. The data extraction form comprised the items of authors, title, publication year, sample size, age, sex distribution, diagnosis standard, study design, interventions for treatment and control groups, composition of JLD, trial duration, outcome measurements, and adverse effects. If missing information was found, we contacted the primary authors via email, telephone or fax whenever possible. Any disagreement was solved by discussion.

Assessment of methodological quality

The risk of bias of included studies was evaluated independently by two reviewers (XX and YZ) according to the criteria in *Cochrane Handbook for Systematic Review of Interventions Version 5.1.0 (updated March 2011)* [38]. It included the following seven items: sequence generation (selection bias), allocation

1
2
3
4 concealment (selection bias), blinding of participants and personnel (performance
5
6 bias), blinding of outcome assessments (detection bias), incomplete outcome data
7
8 (attrition bias), selective reporting (reporting bias), and other sources of bias (from
9
10 Chapter 8: assessing risk of bias in included studies) [38]. Each domain was assessed
11
12 to be low/unclear/high risk of bias. Then, methodological quality of trials was ranked
13
14 into three levels: low risk of bias (all items with low risk of bias), high risk of bias (at
15
16 least one item with high risk of bias), and unclear risk of bias (at least one item with
17
18 unclear).
19
20
21
22
23
24
25
26

27 **Data synthesis**

28
29
30
31 Review Manager, Version 5.1 (The Nordic Cochrane Centre, Copenhagen,
32
33 Denmark) was used for data analysis. Values of outcome measures after treatment
34
35 were retrieved to assess differences between JLD groups and control groups.
36
37 Weighted mean difference (WMD) was used when continuous data presented, while
38
39 risk ratio (RR) was used when binary data presented. Subgroups analysis was
40
41 conducted among different types of comparisons (including JLD *versus*
42
43 antihypertensive drugs and JLD plus antihypertensive drugs *versus* antihypertensive
44
45 drugs). If trials with good quality could be got, comparisons between all studies and
46
47 studies with good quality would be conducted. In a three-group design study that had
48
49 two treatment groups of JLD and JLD plus antihypertensive drugs, two comparisons
50
51 were split in the meta-analysis. Heterogeneity was assessed by I^2 statistics [38].
52
53
54
55
56
57
58
59
60

1
2
3
4 Funnel plots were applied to detect for the publication bias when the number of
5
6 included studies of any particular outcome was more than ten. $P < 0.05$ was
7
8 considered to be statistically significant.
9
10

11 12 13 **RESULTS**

14 15 16 17 18 **Study characteristics**

19
20
21
22
23
24 Figure 1 shows the process of study selection. Three hundred and eight
25
26 potentially relevant articles were extracted in the initial screening of the seven
27
28 databases. Ten RCTs with a total of 655 participants met the eligibility criteria were
29
30 included [40-49]. Basic characteristics of included trials were summarized in Table 1.
31
32
33 Six diagnostic criteria of EH were specified: two trials [40, 41] used Guidelines of
34
35 Clinical Research of New Drugs of Traditional Chinese Medicine (GCRNDTCM);
36
37 four trials [42, 44, 46, 47] used WHO-ISH guidelines for the management of
38
39 hypertension-1999 (WHO -ISH GMH-1999); one trial [43] used WHO-ISH
40
41 GMH-1985; one trial [45] used Chinese Guidelines for the Management of
42
43 Hypertension-2005 (CGMH-2005); one trial [48] used Seventh Report of the Joint
44
45 National Committee on Prevention, Detection, Evaluation, and Treatment of High
46
47 Blood Pressure (JNC 7); and one trial [49] used Chinese Guidelines for the
48
49 Management of Hypertension-2010 (CGMH-2010). All were conducted in China and
50
51 published in Chinese language. Among them, one was three-arm study design (two
52
53
54
55
56
57
58
59
60

1
2
3
4 intervention groups versus one control group) [44], and others used two-arm study
5
6 design (one intervention group versus one control group). Clinical efficacy of JLD
7
8 was observed in all trials. However, the evaluation criteria on BP was different, in
9
10 which three adopted TCM standards recommended by Chinese government in
11
12 GCRNDTCM [40-42], and seven used BP values [43-49]. QOL was only tested in
13
14 one trial [42] (Table 1).
15
16
17
18
19
20

21 **Treatment groups**

22
23
24
25
26 Types of intervention were classified as JLD (n = 4) and combination therapy
27
28 (JLD plus antihypertensive drugs, n = 7). The variable prescriptions based on JLD
29
30 were presented in Table 1. Different compositions of either JLD or modified JLD
31
32 were presented in Table 2.
33
34
35
36
37
38

39 **Control groups**

40
41
42
43
44 All patients in control groups were received antihypertensive drugs treatment
45
46 including felodipine [40-42], nifedipine [43, 47, 49], enalapril [44, 45, 48], and
47
48 benazepril hydrochloride [46].
49
50
51
52
53

54 **Duration of follow-up**

1
2
3 The total treatment duration in the studies ranged from three to four weeks.
4
5
6 Mostly were four weeks (n = 8). Duration of follow-up was only mentioned in one
7
8
9 trial with three months [43].
10

11 12 13 **Methodological quality**

14
15
16
17
18
19 As shown in Table 3, four trials reported the method to generate the allocation
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
As shown in Table 3, four trials reported the method to generate the allocation
sequence (random number table) [41, 44, 45, 48]. Information about allocation
concealment was provided in two trials [44, 48]. Blinding of participants and
personnel was reported in three trials [44, 45, 48]; however, no trial used blinding of
outcome assessment. Reporting of drop-out or withdraw was provided for three trials
[44, 45, 49]. No trial had a pre-trial estimation of sample size. Selective reporting
could not be evaluated as no preregistered protocols could be got.

40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 **Outcomes**

44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 **Primary outcome: BP**

49
50
51
52
53
54
55
56
57
58
59
60
JLD *versus* antihypertensive drugs (4 studies):

54
55
56
57
58
59
60
The clinical efficacy of JLD as monotherapy on BP was assessed in four trials
(Table 1) [40-42, 44]. Three trials [40-42] didn't use BP value to evaluate the efficacy

1
2
3
4 of JLD, but use of evaluation criteria in GCRNDTCM, which was defined as follows:
5
6 “significant improvement” (DBP decreased by 10 mmHg reaching the normal range,
7
8 or, DBP hasn’t yet returned to normal but reduced by more than 20 mmHg),
9
10
11 “improvement” (DBP decreased by less than 10 mmHg but reaching the normal range,
12
13 or, DBP decreased by 10 to 19 mmHg but not reaching the normal range, or, SBP
14
15 decreased by more than 30 mmHg), and “no improvement” (not meeting above
16
17 standards) [50]. These outcomes were converted into binary data for further overall
18
19 analysis. Both “significant improvement” and “improvement” were classified as
20
21 “effective”, and “no improvement” as “ineffective”. Meta-analysis showed that JLD
22
23 had no significant effect on BP as compared with antihypertensive drugs (n = 170; RR:
24
25 0.99; 95% CI: 0.90 to 1.08; $P = 0.79$; Figure 2) with no significant heterogeneity
26
27 (chi-square = 0.22, $P = 0.90$; $I^2 = 0\%$). Another one trial used BP value to evaluate
28
29 the efficacy of modified JLD when compared with enalapril [44]. No significant
30
31 difference was found on both SBP and DBP ($P > 0.05$).
32
33
34
35
36
37
38
39
40

41 JLD plus antihypertensive drugs *versus* antihypertensive drugs (7 studies):
42
43
44
45

46 Seven RCTs evaluated the effect of JLD combined with antihypertensive drugs
47
48 versus antihypertensive drugs (Table 1) [43-49]. BP value was applied in all these
49
50 studies. When it comes to SBP, it was significantly reduced in JLD plus
51
52 antihypertensive drugs group when compared with antihypertensive drugs (n = 485;
53
54 WMD: -8.37; 95% CI: -9.84 to -6.90; $P < 0.00001$; Figure 3) with no significant
55
56
57
58
59
60

1
2
3
4 heterogeneity (chi-square = 8.45, $P = 0.21$; $I^2 = 29\%$). When it comes to DBP,
5
6 significant beneficial effect was also found in JLD plus antihypertensive drugs group
7
8 (n = 485; WMD: -6.71; 95% CI: -9.32, -4.10; $P < 0.00001$; Figure 4) with significant
9
10 heterogeneity (chi-square = 9.47, $P < 0.0001$; $I^2 = 80\%$).
11
12

13 14 15 16 **Secondary outcome: QOL** 17

18
19
20
21 Only one trial [42] conducted by Fan et al used the Croog Scale [51] to assess the
22
23 effectiveness of JLD on QOL in aged hypertension patients. At the end of the trial,
24
25 JLD showed a statistically significant improvement when compared with felodipine
26
27 group ($P < 0.05$). The trial demonstrated that long-term use of JLD can improve QOL
28
29 for hypertensive patients.
30
31
32

33 34 35 36 **Adverse effect** 37

38
39
40
41 Adverse effect monitoring was only reported in five studies [43-45, 48, 49],
42
43 while not mentioned in the other trials. Among these, no severe adverse effect was
44
45 found in two trials [43, 49]. Three trials reported dry cough caused by enalapril in
46
47 both groups [44, 45, 48]. Two trials reported severe dry cough in antihypertensive
48
49 drugs groups [44, 45]. All adverse effects were not serious in JLD groups.
50
51
52

53 54 55 56 **Evaluation of publication bias** 57 58 59 60

1
2
3
4
5
6 As the number of included trials in each subgroup was so small, we can't
7
8
9 conduct any sufficient additional analysis of publication bias.
10

11 12 13 **DISCUSSION**

14 15 **Summary of evidence**

16
17
18
19
20
21
22
23
24 Taking into account the gap between the lack of scientific evidence about the
25
26 efficacy of JLD and the widespread application by TCM practitioners, the objective of
27
28 this study was therefore to systematically review the current English and Chinese
29
30 literatures to evaluate the efficacy and safety of JLD for EH. To our knowledge, this
31
32 is the first SR of JLD in English.
33
34

35
36 Ten claimed RCTs with 655 hypertensive patients met the inclusion criteria were
37
38 included in this review. The result suggested that both SBP and DBP were
39
40 significantly improved in patients receiving JLD plus antihypertensive drugs therapy
41
42 although the effect was not significant in JLD alone group. Moreover, JLD was found
43
44 to be effective in QOL when in comparison with antihypertensive drugs. However,
45
46 the evidence suggesting JLD represented an effective modality for treating EH was
47
48 limited by limited number of trials, poor methodological qualities, and the high risk if
49
50 bias in primary studies.
51
52
53
54
55
56
57
58
59
60

Limitations

The following limitations should be considered before accepting the findings of this review.

(1) Although there are two randomized, single-blind, controlled trials, the methodology of most included trials was assessed to be generally poor. The main reasons are analyzed as follows:

Firstly, although all studies claimed randomization, only four trials demonstrated the random sequence generation and two trials reported allocation concealment; most of the trials might have selection bias. Secondly, only three trials described blinding of participants and personnel, however, none of them reported blinding of outcome assessment; most of the trials might have both selection bias and detection bias. Thirdly, only three trials reported drop-out or withdraw, which might lead to a high risk of attrition bias. Fourthly, most of the included studies did not mention intention to treat analysis, which might lead to some other bias. Fifthly, no trials had a pre-estimation of sample size. Sixthly, no trial had placebo control, which might downgrade the quality of positive conclusions. Last but not least, due to the variations in study quality, participants, intervention, control, and outcome measures, significant clinical heterogeneity was found, especially in DBP ($I^2 = 80\%$).

(2) Publication bias should also be considered. In this review, all included trials were conducted in China and published in Chinese language. Almost all studies claimed similar beneficial effect or better effect when compared with antihypertensive

1
2
3
4 drugs alone. No negative conclusions could be found. What is more, a funnel plot
5
6 checking for possible publication bias for BP can't be conducted due to small number
7
8 of included studies.
9

10
11 (3) Although one trial had a short-term follow up, most of the studies had no
12
13 follow up, indicating there was a lack of knowledge for some critical outcomes such
14
15 as all-caused mortality and progression to severe complications, which was also the
16
17 most common problem in TCM studies.
18
19

20
21 (4) Small number of included trials and different subgroup comparisons in this
22
23 review restricted us from conducting meaningful subgroup analyses to explore effect
24
25 modifiers such as duration of intervention and types of antihypertensive drugs
26
27 therapies.
28
29

30
31 (5) We also assessed the quality of evidence for BP outcome according to the
32
33 Grading of Recommendations Assessment, Development and Evaluation (GRADE)
34
35 approach recommended by the Cochrane Collaboration with caution. However, the
36
37 overall quality of evidence in two subgroup comparison was poor, which can weaken
38
39 the reliability and validity of recommendation.
40
41
42

43
44 (6) As the use of natural products occurs at a very high rate among patients
45
46 attending a variety of health care settings, the safety of CHM and the potential
47
48 herb-drug interaction has hence become widely concerned. This review suggested that
49
50 JLD may be safe for the management of EH. In fact, no parallel double blind
51
52 randomized placebo-controlled trials indicating the adverse effects of JLD for EH
53
54 could be found. Due to the insufficient clinical data, it is difficult to draw a definite
55
56
57
58
59
60

1
2
3
4 conclusion on safety of JLD for EH at present. We, therefore, suggest the adverse
5
6 effect of JLD need to be monitored rigorously in the future studies.
7
8
9

10 11 **CONCLUSION** 12

13
14
15
16 There is some encouraging clinical evidence of JLD as a kind of complementary
17
18 therapy for EH. However, the findings were limited due to poor methodological
19
20 qualities and high risk of bias of the current inconclusive studies. More rigorously
21
22 designed randomized trials using TCM syndrome diagnosis with adequate sample size
23
24 and long-term follow-up according to the CONSORT Statement [52-54] are
25
26 warranted for further evaluation.
27
28
29
30
31
32
33

34 **Additional material**

35
36 Additional file 1: Search Strategy.
37
38
39
40
41

42 **Contributorship statement**

43
44 XX Conceived and designed the experiments. XX, XL, and YZ performed the
45
46 experiments and analyzed the data. XX wrote the manuscript.
47
48
49
50
51

52 **Competing interests**

53
54
55 None.
56
57
58
59
60

Funding

XJX was supported by the National Natural Science Foundation Project of China (No. 81403375). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Data sharing statement

No additional data available.

REFERENCES

1. Lawes CM, Hoorn SV, Rodgers A, and for the International Society of Hypertension. Global burden of blood-pressure-related disease 2001. *Lancet* 2008, 371: 1513-18.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ and the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. *Hypertension* 2003, 42: 1206-1252.
3. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJL. Comparative risk assessment collaborative group: selected major risk factors and global and regional burden of disease. *Lancet* 2002, 360:1347-1360.
4. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. *Lancet* 2005, 365: 217-223.

- 1
2
3
4 5. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional
5
6 burden of disease and risk factors 2001: systematic analysis of population health
7
8 data. *Lancet* 2006, 367: 1747-1757.
- 9
10
11 6. Fisher JW. The diagnostic value of the sphygmomanometer in examinations for
12
13 life insurance. *JAMA* 1914, 63: 1752-1754.
- 14
15
16 7. Lewington S, Clarke R, Qizilbash N, et al. Prospective Studies Collaboration.
17
18 Age-specific relevance of usual blood pressure to vascular mortality: a
19
20 meta-analysis of individual data for one million adults in 61 prospective studies.
21
22 *Lancet* 2002, 360: 1903-13.
- 23
24
25 8. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the
26
27 prevention of cardiovascular disease: meta-analysis of 147 randomised trials in
28
29 the context of expectations from prospective epidemiological studies. *BMJ* 2009,
30
31 338: b1665.
- 32
33
34 9. Xiong XJ, Yang XC, Liu YM, Zhang Y, Wang PQ, Wang J. Chinese herbal
35
36 formulas for treating hypertension in traditional Chinese medicine: perspective of
37
38 modern science. *Hypertens Res* 2013, 36: 570-579.
- 39
40
41 10. Bramlage P, Böhm M, Volpe M, et al. A global perspective on blood pressure
42
43 treatment and control in a referred cohort of hypertensive patients. *J Clin*
44
45 *Hypertens* 2010, 12: 666-677.
- 46
47
48 11. Brook RD, Appel LJ, Rubenfire M, Ogedegbe G, Bisognano JD, Elliott WJ,
49
50 Fuchs FD, Hughes JW, Lackland DT, Staffileno BA, Townsend RR, Rajagopalan
51
52 S, on behalf of the American Heart Association Professional Education
53
54
55
56
57
58
59
60

- 1
2
3
4 Committee of the Council for High Blood Pressure Research, Council on
5
6 Cardiovascular and Stroke Nursing, Council on Epidemiology and Prevention,
7
8 and Council on Nutrition, Physical Activity and Metabolism. Beyond medications
9
10 and diet: alternative approaches to lowering blood pressure. *Hypertension* 2013,
11
12 61: 1360-1383.
13
14
15
16 12. Mansoor GA. Herbs and alternative therapies in the hypertension clinic. *Am J*
17
18 *Hypertens* 2001, 14: 971-975.
19
20
21 13. Mashour NH, Lin GI, Frishman WH. Herbal medicine for the treatment of
22
23 cardiovascular disease. *Arch Intern Med* 1998, 9: 2225-2234.
24
25
26 14. Wang J, Xiong XJ. Current situation and perspectives of clinical study in
27
28 integrative medicine in China. *Evid Based Compl Alt* 2012, 2012: e268542.
29
30
31 15. Wang J, Feng B, Yang XC, Liu W, Xiong XJ. Chinese herbal medicine for the
32
33 treatment of prehypertension. *Evid Based Compl Alt* 2013, 2013: e493521.
34
35
36 16. Tachjian A, Maria V, Jahangir A. Use of herbal products and potential
37
38 interactions in patients with cardiovascular diseases. *J Am Coll Cardiol* 2010, 55:
39
40 515-525.
41
42
43 17. Xiong XJ, Yang XC, Liu W, Chu FY, Wang PQ, Wang J. Trends in the Treatment
44
45 of Hypertension from the Perspective of Traditional Chinese Medicine. *Evid*
46
47 *Based Compl Alt* 2013, 2013: e275279.
48
49
50
51 18. Wang J, Xiong XJ. Control strategy on hypertension in Chinese medicine. *Evid*
52
53 *Based Compl Alt* 2012, 2012: e284847.
54
55
56 19. Wang J, Xiong XJ. Evidence-based Chinese Medicine for Hypertension. *Evid*
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Based Compl Alt* 2013, 2013: e978398.
20. Wang J, Xiong XJ. Outcome measures of Chinese herbal medicine for hypertension: an overview of systematic reviews. *Evid Based Compl Alt* 2012, 2012: e697237.
21. Wang J, Feng B, Yang XC, Liu W, Liu YM, Zhang Y, Yu G, Li SJ, Zhang YQ, Xiong XJ. Tianma gouteng yin as adjunctive treatment for essential hypertension: a systematic review of randomized controlled trials. *Evid Based Compl Alt* 2013, 2013: e706125.
22. Xiong XJ, Yang XC, Feng B, Liu W, Duan L, Gao A, Li HX, Ma JZ, Du XL, Li N, Wang PQ, Su KL, Chu FY, Zhang GH, Li XK, Wang J. Zhen gan xi feng decoction, a traditional Chinese herbal formula, for the treatment of essential hypertension: a systematic review of randomized controlled trials. *Evid Based Compl Alt* 2013; 2013: 982380.
23. Wang J, Yang XC, Feng B, Liu W, Li HX, Li XK, Qian WD, Chu FY, Xiong XJ. Is Yangxue Qingnao Granule combined with antihypertensive drugs, a new integrative medicine therapy, more effective than antihypertensive therapy alone in treating essential hypertension?. *Evid Based Compl Alt* 2013, 2013: e540613.
24. Xiong XJ, Yang XC, Liu W, Feng B, Ma JZ, Du XL, Wang PQ, Chu FY, Li J, Wang J. Banxia baizhu tianma decoction for essential hypertension: a systematic review of randomized controlled trials. *Evid Based Compl Alt* 2012, 2012: e271462.
25. Wang J, Yao KW, Yang XC, Liu W, Feng B, Ma JZ, Du XL, Wang PQ, Xiong XJ.

- 1
2
3
4 Chinese patent medicine liu wei di huang wan combined with antihypertensive
5
6 drugs, a new integrative medicine therapy, for the treatment of essential
7
8 hypertension: a systematic review of randomized controlled trials. *Evid Based*
9
10 *Compl Alt* 2012, 2012: e714805.
- 11
12
13
14 26. Wang J, Feng B, Xiong XJ. Chinese herbal medicine for the treatment of
15
16 obesity-related hypertension. *Evid Based Compl Alt* 2013, 2013: e757540.
- 17
18
19 27. Lu AP, Jia HW, Xiao C, Lu QP. Theory of traditional Chinese medicine and
20
21 therapeutic method of diseases. *World J Gastroenterol* 2004, 10: 1854-1856.
- 22
23
24 28. Jiang WY. Therapeutic wisdom in traditional Chinese medicine: a perspective
25
26 from modern science. *Trends Pharmacol Sci* 2005, 26: 558-563.
- 27
28
29 29. Ge HX, Dai XM, Zhang ZX, Wang HH. Modern application and experimental
30
31 research progress of jian ling decoction. *Zhong Yi Yao Xue Bao* 2002; 30: 21-23.
- 32
33
34 30. Yu HW. Effect of modified jian ling decoction on insulin resistance and serum
35
36 levels of TNF- α in patients with essential hypertension. *Haerbin: Heilongjiang*
37
38 *Zhong Yi Yao Da Xue*. 2008.
- 39
40
41 31. Cao JM. Effect of modified jian ling decoction on serum leptin and angiotensin II
42
43 in hypertension with insulin resistance. *Haerbin: Heilongjiang Zhong Yi Yao Da*
44
45 *Xue*. 2012.
- 46
47
48 32. Jiang CX. Effect of modified jian ling decoction on blood pressure and
49
50 angiotensin II in elderly hypertensive patients. *Haerbin: Heilongjiang Zhong Yi*
51
52 *Yao Da Xue*. 2012.
- 53
54
55
56 33. Zhang N, Sun JL, Dong ZZ, Chen SJ. Effect of modified jian ling decoction on
57
58
59
60

- 1
2
3
4 insulin resistance and serum interleukin-6 of essential hypertension patients.
5
6 *Zhongguo Zhong Yi Yao Xin Xi Za Zhi* 2011, 18: 19-21.
7
8
9 34. Feng DR, Wei B. Effects of jian ling decoction on the blood lipid and lipid
10 peroxidation in experimental hyperlipidemia rats with yin deficiency of liver
11 and kidney. *Guangxi Zhong Yi Yao* 2009, 32: 51-54.
12
13
14 35. Huang YT, Wu CB, Zeng QM. Effect of jian ling decoction on 120 patients of
15 essential hypertension. *Zhongguo Zhong Xi Yi Jie He Za Zhi* 1996, 16: 561.
16
17
18 36. Hao HY, Wang QH, Sun CJ, Yang GQ, Liu XY, You FH. Effect of modified jian
19 ling decoction on 30 patients of essential hypertension. *Shanxi Zhong Yi* 1998, 19:
20 541.
21
22
23 37. Guan DM, Du SQ. Clinical observation on the effect of jian ling decoction
24 combined with urapidil on stage □ hypertension with high-risk. *Zhongguo She*
25 *Qu Yi Shi* 2013, 15: 214-215.
26
27
28 38. Higgins JPT, Green S. *Cochrane Handbook for Systematic Reviews of*
29 *Interventions, Version 5.1.0.* The Cochrane Collaboration.
30 <http://handbook.cochrane.org/>. 2011.
31
32
33 39. Li YB, Cui M, Yang Y, Yu Q, Zhu XB, Tian Y, Xi HP. Similarity of traditional
34 Chinese medicine formula. *Zhong Hua Zhong Yi Yao Xue Kan* 2012; 30:
35 1096-1097.
36
37
38 40. Tong WH. Analysis on clinical therapeutic effect of jian ling decoction on
39 essential hypertension with yin deficiency and yang hyperactivity syndrome.
40 *Zhongguo Yi Yao Zhi Nan* 2013, 11: 258-259.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 41. He T, Zhu YQ, Xu SX. Effect of jian ling decoction on 30 hypertensive patients
5
6 with yin deficiency and yang hyperactivity syndrome. *Zhong Yi Yao Dao Bao*
7
8 2012, 18: 50-51.
9
10
11 42. Fan R, Zhou H, Tan HY. Effect of jian ling decoction on aged hypertension
12
13 patient's life mass and CAT. *Zhongguo Xian Dai Yi Xue Za Zhi* 2005, 15:
14
15 1706-1708.
16
17
18 43. Cai XP. Combined traditional Chinese and western medicine in the treatment of
19
20 50 patients with essential hypertension. *Guangdong Yi Xue* 1995, 16: 400-402.
21
22
23 44. Zhang N. Effect of modified jian ling decoction on essential hypertension.
24
25 *Haerbin: Heilongjiang Zhong Yi Yao Da Xue*. 2004, 1-34.
26
27
28 45. Zhang N. Effect of modified jian ling decoction on insulin resistance and serum
29
30 levels of IL-6 in essential hypertension. *Haerbin: Heilongjiang Zhong Yi Yao Da*
31
32 *Xue*. 2009, 1-51.
33
34
35 46. Jiang CX, Cao JM. Effect of modified jian ling decoction on renin-angiotensin II
36
37 in patients with senile hypertension. *Zhongguo Zhong Yi Yao Ke Ji* 2012, 19: 145.
38
39
40 47. Chu GM, Xu JY. Effect of modified jian ling decoction on high-sensitivity
41
42 C-reactive protein on 67 cases of hypertensive patients. *Zhong Yi Yao Xin Xi* 2013,
43
44 30: 66-67.
45
46
47 48. Liu L, Jin J, Yu HW. Effect of modified jian ling decoction on insulin resistance
48
49 and TNF- α level in patients of EH. *Zhong Yi Yao Xin Xi* 2008, 25: 68-70, 80.
50
51
52 49. Li CM. Effect of modified jian ling decoction on senile primary hypertension.
53
54
55 *Jinan: Shandong Zhong Yi Yao Da Xue*. 2013, 1-30.
56
57
58
59
60

- 1
2
3
4 50. Xiong XJ, Liu W, Yang XC, Feng B, Wang J. Moxibustion for essential
5
6 hypertension. *Complement Ther Med* 2014, 22: 187-195.
7
8
9 51. Croog SH, Levine S, Testa MA, Brown B, Bulpitt CJ, Jenkins D, Klerman G,
10
11 Williams GH. The effect of antihypertensive therapy on the quality of life. *N Engl*
12
13 *J Med* 1986, 314: 1657-1659.
14
15
16 52. Liu JP, Han M, Li XX, Mu YJ, Lewith G, Wang YY, Witt CM, Yang GY,
17
18 Manheimer E, Snelling T, Berman B, Gluud C. Prospective registration, bias
19
20 risk and outcome-reporting bias in randomised clinical trials of traditional
21
22 Chinese medicine: An empirical methodological study. *BMJ Open* 2013, 3:
23
24 e002968.
25
26
27
28
29 53. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines
30
31 for reporting parallel group randomized trials. *Ann Intern Med* 2012, 152:
32
33 726-732.
34
35
36 54. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C. Reporting
37
38 randomized, controlled trials of herbal interventions: an elaborated CONSORT
39
40 statement. *Ann Intern Med* 2006, 144: 364-367.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Basic characteristics of the included studies.

Table 2. Composition of Chinese herbal medicine Jian Ling Decoction in treatment group.

Table 3. Methodological quality of included studies based on the Cochrane handbook.

For peer review only

1
2
3
4
5
6
7
8
9
10
11 **Figure 1. PRISMA 2009 Flow Diagram**
12
13

14
15
16 **Figure 2. Forest plot of comparison of JLD versus antihypertensive drugs for the**
17 **outcome of BP**
18
19

20
21
22
23 **Figure 3. Forest plot of comparison of JLD plus antihypertensive drugs versus**
24 **antihypertensive drugs for the outcome of SBP**
25
26

27
28
29
30
31 **Figure 4. Forest plot of comparison of JLD plus antihypertensive drugs versus**
32 **antihypertensive drugs for the outcome of DBP**
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table1. Basic characteristics of the included studies.

Study ID	Sample size (randomized /analyzed) M/F	Age(yrs)	Diagnosis standard	Intervention	Control	Course (week)	Outcome measures
Tong 2013 [40]	60/60 T: 30 C: 30 F/M: NR	40-60 (T/C: NR)	GCRNDTC M	JLD (1 dose/d)	felodipine (5 mg, qd)	4	BP
He et al. 2012 [41]	60/60 T: 15/15 C: 17/13	T: 54.89 ± 5.34 C: 57.36 ± 6.47	GCRNDTC M	JLD (1 dose/d)	felodipine (5 mg, qd)	4	BP
Fan 2005 [42]	50/50 T: 14/11 C: 13/12	T: 64.80 ± 7.40 C: 63.70 ± 6.90	WHO -ISH GMH-1999	JLD (1 dose/d)	felodipine (2.5 mg, qd)	4	BP; QOL
Cai 1995 [43]	100/100 T: 35/15 C: 34/16	T: 50-81 C: 47-84	WHO -ISH GMH-1985	modified JLD (1 dose/d) + control	nifedipine (10 mg, tid)	4	BP; adverse effect
Zhang 2004 [44]	90/89 T1: 16/14 T2: 17/13 C: 15/14	T1: 58.23 ± 8.26 T2: 58.45 ± 6.87 C: 59.16 ± 9.28	WHO -ISH GMH-1999	T1: modified JLD (1 dose/d) T2: modified JLD (1 dose/d) + control	enalapril (10 mg, bid)	4	BP; adverse effect
Zhang 2009 [45]	60/57 T: 15/14 C: 12/16	T: 56.41 ± 10.98 C: 58.57 ± 8.21	CGMH-200 5	modified JLD (1 dose/d) + control	enalapril (10 mg, bid)	3	BP; adverse effect
Jiang and Cao 2012 [46]	82/82 T: 26/16 C: 23/17	T: 60-75 C: 62-75	WHO -ISH GMH-1999	modified JLD (100 mL/d) + control	benazepril hydrochloride (10 mg, tid)	4	BP
Chu and Xu 2013 [47]	67/67 T: 19/15 C: 17/16	T: 67.00 ± 7.20 C: 68.00 ± 5.90	WHO -ISH GMH-1999	modified JLD (100 mL/d) + control	nifedipine controlled release tablet (30 mg, qd)	4	BP
Liu et al. 2008 [48]	60/60 T: 30 C: 30 F/M: NR	18-70 (T/C: NR)	JNC 7	modified JLD (100 mL/d) + control	enalapril (10 mg, bid)	3	BP; adverse effect
Li 2013 [49]	60/60 T: 16/14	T: 64.33 ± 7.96 C: 61.20 ± 10.23	CGMH-201 0	modified JLD (400 mL/d) +	nifedipine controlled release tablet (30 mg, qd) and	4	BP; adverse effect

C: 17/13 control irbesartan (150 mg, qd)

Abbreviations: BP: blood pressure; C: control group; CGMH: Chinese Guidelines for the Management of Hypertension; F: female; GCRNDTCM: Guidelines of Clinical Research of New Drugs of Traditional Chinese Medicine; JLD: Jian Ling Decoction; JNC 7: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; M: male; NR: not reported; QOL: quality of life; T: treatment group; WHO-ISH GMH: WHO-ISH guidelines for the management of hypertension.

Table 2. Composition of Chinese herbal medicine Jian Ling Decoction in treatment group.


Study ID	Formula	Composition of formula
Tong 2013 [40]	JLD	Platycladi Seed 10 g, White Peony Root 10 g, Rehmannia Root 15 g, Oyster Shell 10 g, Dragon's Bones 10 g, Red Ochre 10 g, Common Yam Rhizome 15 g, and Twotooth Achyranthes Root 20 g.
He et al. 2012 [41]	JLD	Common Yam Rhizome 15 g, Twotooth Achyranthes Root 20 g, Red Ochre 10 g, Oyster Shell 10 g, Dragon's Bones 10 g, Rehmannia Root 15 g, White Peony Root 10 g, and Platycladi Seed 10 g.
Fan 2005 [42]	JLD	Common Yam Rhizome 30 g, Twotooth Achyranthes Root 30 g, Red Ochre 24 g, Oyster Shell 18 g, Dragon's Bones 18 g, Rehmannia Root 18 g, White Peony Root 12 g, and Platycladi Seed 12 g.
Cai 1995 [43]	modified JLD	Twotooth Achyranthes Root 30 g, Common Yam Rhizome 30 g, Sea-ear Shell 30 g, Red Ochre 24 g, Oyster Shell 18 g, Dragon's Bones 18 g, Rehmannia Root 18 g, White Peony Root 12 g, and Platycladi Seed 12 g. Headache plus Puncturevine Caltrop Fruit 10 g; constipation plus Rhubarb 5 g.
Zhang 2004 [44]	modified JLD	Common Yam Rhizome 30 g, Twotooth Achyranthes Root 30 g, Red Ochre 24 g, Oyster Shell 18 g, Dragon's Bones 18 g, Rehmannia Root 18 g, White Peony Root 12 g, and Platycladi Seed 12 g. Headache, dizziness, and irritability plus Tall Gastrodia Tuber 15 g and Sea-ear Shell 30 g; irritability, bitty mouth and red face plus Golden Thread 10 g and gardenia 10 g; and constipation plus Rhubarb 5 g.
Zhang 2009 [45]	modified JLD	Common Yam Rhizome 30 g, Twotooth Achyranthes Root 30 g, Red Ochre 24 g, Oyster Shell 18 g, Dragon's Bones 18 g, Rehmannia Root 18 g, White Peony Root 12 g, and Platycladi Seed 12 g. excessive accumulation of phlegm-dampness plus Pinellia Tuber 15 g, Indian Buead 15 g, Tangerine Peel 10 g, Bamboo Shavings 10 g, and Liquoric Root 3 g.
Jiang and Cao 2012 [46]	modified JLD	Common Yam Rhizome 30 g, Tortoise Shell 30 g, Twotooth Achyranthes Root 30 g, Red Ochre 20 g, Oyster Shell 20 g, Dragon's Bones 20 g, Rehmannia Root 20 g, White Peony Root 15 g, and Platycladi Seed 15 g.
Chu and Xu 2013 [47]	modified JLD	Rehmannia Root 25 g, Tortoise Shell 25 g, Common Yam Rhizome 30 g, Red Ochre 15 g, Oyster Shell 25 g, Dragon's Bones 25 g, Twotooth Achyranthes Root 25 g, White Peony Root 20 g, and Platycladi Seed 20 g.
Liu et al. 2008 [48]	modified JLD	Common Yam Rhizome 30 g, Rehmannia Root 18 g, Red Ochre 24 g, Oyster Shell 18 g, Dragon's Bones 18 g, Twotooth Achyranthes Root 30 g, White Peony Root 20 g, and Platycladi Seed 20 g.
Li 2013 [49]	modified JLD	Dragon's Bones 30 g, Oyster Shell 30 g, Rehmannia Root 20 g, Red Ochre 20 g, Common Yam Rhizome 30 g, Twotooth Achyranthes Root 30 g, White Peony Root 20 g, Platycladi Seed 15 g, Gambir Plant 30 g, Kudzuvine Root 30 g, Tall Gastrodia Tuber 15 g, Chinese Taxillus Twig 30 g, Eucommia Bark 15 g, and Golden Thread 9 g.

Table 3. Methodological quality of included studies based on the Cochrane handbook.

Included trials	A	B	C	D	E	F	G
Tong 2013 [40]	?	?	?	?	?	?	?
He et al. 2012 [41]	+	?	?	?	?	?	?
Fan 2005 [42]	?	?	?	?	?	?	?
Cai 1995 [43]	?	+	?	?	?	?	?
Zhang 2004 [44]	+	+	+	?	+	?	?
Zhang 2009 [45]	+	?	+	?	+	?	?
Jiang and Cao 2012 [46]	?	?	?	?	?	?	?
Chu and Xu 2013 [47]	?	?	?	?	?	?	?
Liu et al. 2008 [48]	+	+	+	?	?	?	?
Li 2013 [49]	?	?	?	?	+	?	?

Abbreviations: A: Adequate sequence generation; B: Concealment of allocation; C: Blinding (participants and personnel); D: Blinding (assessor); E: Incomplete outcome data addressed (ITT analysis); F: Free of selective reporting; G: other potential threat to validity; +: low risk; -: high risk; ?: unclear.

Figure 1. PRISMA 2009 Flow Diagram



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2. Forest plot of comparison of JLD versus antihypertensive drugs for the outcome of BP




Figure 3. Forest plot of comparison of JLD plus antihypertensive drugs versus antihypertensive drugs for the outcome of SBP





Figure 4. Forest plot of comparison of JLD plus antihypertensive drugs versus antihypertensive drugs for the outcome of DBP





PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Section/Topic	#	Checklist Item	Reported on Page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	P1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	P2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	P5-7
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	P6-7
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	NA
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	P10-11
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	P8
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	P8-10
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	P10-11
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	P11-12
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	P11-12
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	P12
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	P12-13
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	P12-13



PRISMA 2009 Checklist

Page 1 of 2

Section/Topic	#	Checklist Item	Reported on Page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	P12-13
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	P12-13
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	P13-14
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	P13-14
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	P15
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	P15-21
Synthesis of results	21	Present the main results of the review. If meta-analyses done, include for each, confidence intervals and measures of consistency.	P15-21
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	P15
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	P15-21
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	P21-24
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	P24-25
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	P26-27
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	P27

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>



PRISMA 2009 Checklist

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Additional file 1. Search strategy**CNKI**

#1 ‘建瓴汤’ AND ‘血压’

#2 ‘建瓴汤’ AND ‘高血压’

#3 ‘建瓴汤’ AND ‘原发性高血压’

VIP

#1 ‘建瓴汤’ AND ‘血压’

#2 ‘建瓴汤’ AND ‘高血压’

#3 ‘建瓴汤’ AND ‘原发性高血压’

CBM

#1 ‘建瓴汤’ AND ‘血压’

#2 ‘建瓴汤’ AND ‘高血压’

#3 ‘建瓴汤’ AND ‘原发性高血压’

Wanfang Database

#1 ‘建瓴汤’ AND ‘血压’

#2 ‘建瓴汤’ AND ‘高血压’

#3 ‘建瓴汤’ AND ‘原发性高血压’

BMJ Open

Chinese herbal medicine Jian Ling Decoction for essential hypertension: A systematic review and meta-analysis of randomized controlled trials

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-006502.R1
Article Type:	Research
Date Submitted by the Author:	27-Oct-2014
Complete List of Authors:	Xiong, Xing-jiang; Guang'anmen Hospital, Wang, Pengqian; China Academy of Chinese Medical Sciences, Institute of Basic Research in Clinical Medicine Li, Xiaoke; McLean Hospital, Harvard medical school, Bio-organic and Natural Products Laboratory Zhang, Yuqing; McMaster University, Department of Clinical Epidemiology and Biostatistics
Primary Subject Heading:	Complementary medicine
Secondary Subject Heading:	Complementary medicine, Cardiovascular medicine
Keywords:	essential hypertension, Chinese herbal medicine, Jian Ling Decoction, systematic review, blood pressure

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

Chinese herbal medicine Jian Ling Decoction for essential hypertension: A systematic review and meta-analysis of randomized controlled trials

Xingjiang Xiong^{1*}, Pengqian Wang², Xiaoke Li³, and Yuqing Zhang⁴

¹ Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China

² Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China

³ Bio-organic and Natural Products Laboratory, McLean Hospital, Harvard Medical School, Belmont, CA, USA

⁴ Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada

Total word count: 3201.

Number of tables and figures: 3 tables and 2 figures.

Running head: Jian Ling Decoction for essential hypertension.

53
54
55
56
57
58
59
60

* *BMJ Open* 2014

Correspondence to: Xingjiang Xiong, MD, Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beixiange 5#, Xicheng District, Beijing 100053, China. Tel: +10 88001817. Fax: +10 88001229. E-mail: xiongxingjiangtcm@163.com or 5administration@163.com.

ABSTRACT

Objectives: Jian Ling Decoction (JLD) is often prescribed to improve hypertension-related symptoms in China. However, this treatment has not been systematically reviewed for its efficacy against essential hypertension (EH). This review aims to assess the current clinical evidence of JLD in the treatment of EH.

Design: Seven electronic databases including the Cochrane Central Register of Controlled Trials, PubMed, EMBASE, the Chinese National Knowledge Infrastructure (CNKI), the Chinese Scientific Journal Database (VIP), the Chinese Biomedical Literature Database (CBM), and the Wanfang Database were searched up to March 2014. Randomized control trials (RCTs) comparing JLD or combined with antihypertensive drugs versus antihypertensive drugs were included. We assessed the methodological quality, extracted the valid data, and conducted the meta-analysis according to criteria from the Cochrane group. The primary outcome was categorical or continuous blood pressure (BP), and the secondary outcome was quality of life (QOL).

Results: Ten trials (655 patients) with unclear-to-high risk of bias were identified. Meta-analysis showed that JLD used alone showed no BP reduction effect; however, improvement on QOL was found when compared to antihypertensive drugs. A significant reduction on systolic BP and diastolic BP were observed for JLD plus antihypertensive drugs when compared to antihypertensive drugs alone. No serious adverse effects were reported.

Conclusion: Due to insufficient clinical data, it is difficult to draw a definite

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

conclusion regarding the effectiveness and safety of JLD for EH, and better trials are needed.

For peer review only

KEY WORDS

essential hypertension; blood pressure; Chinese herbal medicine; Jian Ling Decoction;
systematic review

For peer review only

ARTICLE SUMMARY

Article focus

- Jian Ling Decoction (JLD), a traditional Chinese herbal formula, is often prescribed for patients with essential hypertension (EH).

Key messages

- No definitive conclusion regarding the efficacy and safety of JLD for EH could be drawn based on the insufficient clinical data

Strengths and limitations of this study

- The strength of this article is its use of a comprehensive and unbiased literature searching of seven electronic databases without language and publication restrictions.
- The included trials were of small sample size, with poor methodological quality and significant heterogeneity.

INTRODUCTION

Hypertension is one of the most important preventable causes of death and one of the most common conditions treated in primary health care. In addition, hypertension represents an important public health challenge because of its high prevalence and the concomitant increase in the risk of cardiovascular, cerebrovascular and renal diseases.^{1,2} This condition has been ranked as the leading global risk factor for mortality and is the third leading risk factor for disease burden according to the comparative Risk Assessment Collaborating Group.^{3,4} Currently, about one billion patients have been affected.⁵ The association between blood pressure (BP) and mortality was discovered approximately 100 years ago.⁶ Recent studies also confirmed that BP is closely related to vascular outcomes, and even a minor reduction in BP could reduce cardiovascular events, especially stroke.^{7,8} Therefore, early diagnosis and effective treatment is of great importance for patients with essential hypertension (EH). Nevertheless, despite remarkable achievements in the research and development of antihypertensive drugs, the current awareness, curative and control rates of hypertension among different age groups is still far from satisfactory.^{9,10} Additionally, in the light of the adverse effects of antihypertensive drugs and hoping for an adjunctive approach with few adverse effects, patients in Western countries with EH and other cardiovascular diseases increasingly use complementary and alternative medicine (CAM),¹¹⁻¹³ including traditional Chinese medicine (TCM).¹⁴⁻¹⁶

1
2
3
4 Chinese herbal medicine (CHM), one of the commonly used TCM therapies, has
5
6 played an important role in relieving hypertension-related signs and symptoms for
7
8 centuries in East Asia.^{17,18} Recently, more robust evidence from systematic reviews
9
10 (SRs) has suggested the efficacy and safety of CHM for EH.¹⁹⁻²⁶ In TCM theory, liver
11
12 yang hyperactivity syndrome (LYHS) and liver-kidney yin deficiency syndrome
13
14 (LKYDS) are the two most important patterns of EH, which often appear at the same
15
16 time.¹⁷ These patterns manifest as headache, vertigo, tinnitus, irritability, insomnia,
17
18 lassitude in the waist and legs, dysphoria with feverish sensation, dry mouth, bright
19
20 red tongue with less fur, and a wiry pulse.^{14,17,21,27,28} Jian Ling Decoction (JLD) is a
21
22 traditional CHM invented by *Zhang Xichun* in *Yixue Zhongzhong Canxilu* (Records of
23
24 Traditional Chinese in Combination with Western Medicine) in the 1920s. It contains
25
26 the following eight commonly used herbs: Dioscorea Root (Shanyao, *Dioscoreae*
27
28 *Rhizoma*), Achyranthes Root (Niuxi, *Achyranthis Bidentatae Radix*), Hematite
29
30 (*Daizheshi*, *Haematitum*), Fossilized Mammal Bones (Longgu, *Os Draconis*), Oyster
31
32 Shell (*Muli*, *Concha Ostreae*), Rehmannia (*Dihuang*, *Radix Rehmanniae Glutinosae*),
33
34 White Peony Root (*Baishao*, *Radix Albus Paeoniae Lactiflorae*), and Arbor Vitae
35
36 Seed (*Baiziren*, *Semen Platycladi*). All of these herbs have been recorded in the
37
38 Pharmacopoeia of the People's Republic of China (2010 edition). Both LYHS and
39
40 LKYDS can be effectively treated with JLD.¹⁹ Currently, JLD is often prescribed for
41
42 the management of EH by TCM practitioners in China. It is worth noting that in the
43
44 context of CAM therapies, add-on designs are very popular for the treatment of
45
46 hypertension.^{14,20-25} JLD is usually used in combination with antihypertensive drugs
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 to achieve greater improvement in the signs and symptoms of hypertension and to
5
6 enhance the antihypertensive effect of conventional drugs with less adverse effects.
7
8
9 The pharmacological mechanisms of these effects may be related to the reduction in
10
11 levels of angiotensin II, IL-6, tumor necrosis factor- α (TNF- α), and leptin, as well as
12
13 insulin resistance and decreased blood lipids.²⁹⁻³⁴ Regarding the clinical use of JLD, a
14
15 large number of studies (including case reports, case series, controlled observational
16
17 studies, and randomized trials) have reported its effects on EH, including lowering BP,
18
19 reducing inflammation, reversing cardiovascular risk factors, and improving clinical
20
21 symptoms and quality of life (QOL).³⁵⁻³⁷ However, there has been no comprehensive
22
23 evaluation of clinical trials on the efficacy and adverse effects of JLD. This review
24
25 aims to systematically review the published and unpublished randomized controlled
26
27 trials (RCTs) to evaluate the current evidence for JLD in treating EH.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

METHODS

This study was conducted according to the Cochrane practice.³⁸

Search strategies

RCTs of JLD for the treatment of hypertensive patients were screened through the following electronic databases from their respective inceptions to March 2014: Cochrane Central Register of Controlled Trials (CENTRAL, 1996-2014), PubMed

1
2
3
4 (1959-2014), and EMBASE (1980-2014). In addition, as JLD is mainly prescribed in
5
6 China, four Chinese electronic databases including the Chinese National Knowledge
7
8 Infrastructure (CNKI, 1980-2014), Chinese Scientific Journal Database (VIP,
9
10 1989-2014), Chinese Biomedical Literature Database (CBM, 1978-2014), and
11
12 Wanfang Database (1998-2014) were searched to retrieve the maximum possible
13
14 number of trials. We also conducted a literature search of the website of the Chinese
15
16 clinical trial registry (available at <http://www.chictr.org/>) and international clinical
17
18 trial registry hosted by the US National Institutes of Health (available at
19
20 <http://clinicaltrials.gov/>) for all of the relevant ongoing registered clinical trials and
21
22 unpublished articles. The bibliographies of the studies identified in the systematic
23
24 search were reviewed for potentially relevant additional publications. No restriction
25
26 on publication status or language was imposed.
27
28
29
30
31
32

33
34 The keywords for databases searching were listed as follows: (“hypertension”
35
36 OR “essential hypertension” OR “primary hypertension” OR “high blood pressure”
37
38 OR “blood pressure”) AND (“*jian ling* decoction” OR “*jianling* decoction” OR “*jian*
39
40 *ling tang*” OR “*jianling tang*” OR “*jianlingtang*”) AND (“clinical trial” OR
41
42 “randomized controlled trial” OR “randomised controlled trial”).
43
44
45
46
47
48

49 **Study selection**

50 **Types of studies**

1
2
3
4 RCTs on the use of JLD for the treatment of EH were included.

5
6 Quasi-randomized trials and animal experiments were excluded.
7
8
9

10 11 **Types of participants** 12

13
14
15
16 Trials focused on the patients suffering from EH were included. All of the
17
18 participants who were enrolled in the trials were required to meet at least one of the
19
20 current or past definitions of EH.² Trials without a description of the detailed
21
22 diagnostic criteria but which reported patients with definite EH were also included .
23
24 Patients with secondary hypertension were excluded. There was no restriction on
25
26 gender, age, or ethnic origin of the participants.
27
28
29
30
31
32
33

34 **Types of interventions** 35

36
37
38 Only studies that tested JLD used alone versus antihypertensive drugs, or JLD
39
40 combined with antihypertensive drugs versus antihypertensive drugs were included.
41
42 However, trials assessing the combined effect of JLD with other interventions (*e.g.*,
43
44 another CHM, qigong, Tai Chi, acupuncture, moxibustion and massage) were
45
46 excluded given that the therapeutic effect of JLD could not be distinguished.
47
48
49 Interventions in the control group included antihypertensive drugs. Studies that used
50
51 non-conventional medicine or CAM as control groups were also excluded. The
52
53 duration of treatment was required to be at least two weeks.
54
55
56
57
58
59
60

1
2
3
4 According to the principle of similarity of the TCM formula,³⁹ modified JLD
5
6 should contain at least six out of eight herbs used in JLD, and only a few herbs could
7
8 be added into the JLD based on TCM syndrome theory. However, the resulting
9
10 prescription should contain the following four principal drugs: Achyranthes Root
11
12 (Niuxi, Achyranthis Bidentatae Radix), Hematite (Daizheshi, Haematitum), Fossilized
13
14 Mammal Bones (Longgu, Os Draconis), and Oyster Shell (Muli, Concha Ostreae).
15
16
17
18
19
20

21 **Types of outcome measures**

22
23
24
25

26 The primary outcome analyzed for this meta-analysis was categorical or
27
28 continuous BP, and secondary outcome was QOL.
29
30
31
32

33 **Data extraction**

34
35
36
37
38

39 All of the articles were read by two independent reviewers. Then, the eligible
40
41 studies were retrieved for further identification according to the above inclusion and
42
43 exclusion criteria. Duplicate papers were excluded. The data extraction form
44
45 comprised the authors, title, publication year, sample size, age, sex distribution,
46
47 diagnosis standard, study design, interventions in the treatment and control groups,
48
49 the composition of JLD or modified JLD, trial duration, outcome measures, and
50
51 adverse effects. If missing or unclear information regarding the original study was
52
53 found, we contacted the primary authors via email, telephone or fax whenever
54
55
56
57
58
59
60

possible. Any disagreement was resolved by discussion between the reviewers.

Methodological quality

The risk of bias of the included studies was independently evaluated by two reviewers according to the criteria in the Cochrane Handbook for Systematic Review of Interventions Version 5.1.0 (updated March 2011).³⁸ The following seven items were included: (a) sequence generation (selection bias); (b) allocation concealment (selection bias); (c) blinding of participants and personnel (performance bias); (d) blinding of outcome assessments (detection bias); (e) incomplete outcome data (attrition bias); (f) selective reporting (reporting bias); and (g) other sources of bias (from Chapter 8: assessing risk of bias in included studies).³⁸ Each domain was assessed as a “high”, “unclear”, or “low” risk of bias based on the above criteria. Then, the methodological quality of the trials was ranked into three levels: low risk of bias (all items with low risk of bias), high risk of bias (at least one item with high risk of bias), or unclear risk of bias (at least one item with an unclear domain).

Data synthesis

Review Manager, Version 5.1 (The Nordic Cochrane Centre, Copenhagen, Denmark) was used for data analysis. The values of the outcome measures after treatment were retrieved to assess differences between the JLD and control groups.

1
2
3
4 The weighted mean difference (WMD) was used for continuous data, while the risk
5
6 ratio (RR) was used for binary data. Subgroups analysis was conducted among
7
8 different types of comparisons (including JLD *versus* antihypertensive drugs and JLD
9
10 plus antihypertensive drugs *versus* antihypertensive drugs). If high quality trials could
11
12 be found, comparisons between all of the studies and studies with high quality would
13
14 be conducted. In a three-group design study that had two treatment groups of JLD and
15
16 JLD plus antihypertensive drugs, the two comparisons were split in the meta-analysis.
17
18 Heterogeneity was assessed by I^2 statistics.³⁸ Funnel plots were applied to detect for
19
20 publication bias when the number of included studies of any particular outcome was
21
22 more than ten. $P < 0.05$ was considered to be statistically significant.
23
24
25
26
27
28
29
30

31 RESULTS

32 33 34 35 36 Study characteristics

37
38
39
40
41 Figure 1 shows the process of study selection. Three hundred eight potentially
42
43 relevant articles were extracted in the initial screening of the seven databases. Ten
44
45 RCTs, with a total of 655 participants, met the eligibility criteria and were
46
47 included.⁴⁰⁻⁴⁹ The basic characteristics of included trials are summarized in Table 1.
48
49
50
51 Six diagnostic criteria of EH were specified: two trials^{40,41} used the Guidelines of
52
53 Clinical Research of New Drugs of Traditional Chinese Medicine (GCRNDTCM);
54
55
56 four trials^{42,44,46,47} used the WHO-ISH guidelines for the management of
57
58
59
60

1
2
3 hypertension-1999 (WHO -ISH GMH-1999); one trial⁴³ used the WHO-ISH
4
5 GMH-1985; one trial⁴⁵ used the Chinese Guidelines for the Management of
6
7 Hypertension-2005 (CGMH-2005); one trial⁴⁸ used the Seventh Report of the Joint
8
9 National Committee on Prevention, Detection, Evaluation, and Treatment of High
10
11 Blood Pressure (JNC 7); and one trial⁴⁹ used the Chinese Guidelines for the
12
13 Management of Hypertension-2010 (CGMH-2010). All of the studies were conducted
14
15 in China and published in Chinese language. One trial was a three-arm design (two
16
17 intervention groups versus one control group),⁴⁴ and the others used a two-arm study
18
19 design (one intervention group versus one control group). The clinical efficacy of JLD
20
21 was observed in all of the trials. However, the evaluation criteria on BP was different:
22
23 three trials used the categorical BP recommended by Chinese government in
24
25 GCRNDTCM,⁴⁰⁻⁴² and seven used continuous BP.⁴³⁻⁴⁹ QOL was only tested in one
26
27 trial.⁴²
28
29
30
31
32
33
34
35
36
37
38
39

40 **Treatment groups**

41
42
43 The types of intervention were classified as JLD (n = 4) or combination therapy
44
45 (JLD plus antihypertensive drugs, n = 7). The variable prescriptions based on JLD are
46
47 presented in Table 1. Different compositions of either JLD or modified JLD are
48
49 presented in Table 2.
50
51
52
53
54
55

56 **Control groups**

1
2
3
4
5
6 All of the patients in the control groups received antihypertensive drug treatment,
7
8 including felodipine,⁴⁰⁻⁴² nifedipine,^{43,47,49} enalapril,^{44,45,48} and benazepril
9
10 hydrochloride.⁴⁶
11
12

13 14 15 16 **Treatment duration**

17
18
19
20
21 The total treatment duration in the trials ranged from three to four weeks, with
22
23 most being four weeks (n = 8). The duration of follow-up was only mentioned in one
24
25 trial, being three months.⁴³
26
27
28
29
30

31 **Methodological quality**

32
33
34
35
36 As shown in Table 3, four trials reported the method used to generate the
37
38 allocation sequence (random number table).^{41,44,45,48} Information regarding allocation
39
40 concealment was provided in two trials.^{44,48} Blinding of participants and personnel
41
42 was reported in three trials;^{44,45,48} however, no trial used blinding of outcome
43
44 assessment. Drop-out and withdrawal data were provided for three trials.^{44,45,49} No
45
46
47 trial had a pre-trial estimation of sample size. Selective reporting could not be
48
49
50 evaluated as no preregistered protocols could be obtained from the primary authors.
51
52
53
54
55

56 **Outcome measures**

Primary outcome: BP

JLD *versus* antihypertensive drugs (4 studies)

The clinical efficacy of JLD as monotherapy for BP was assessed in four trials.^{40-42,44} Three trials⁴⁰⁻⁴² did not use continuous BP to evaluate the efficacy of JLD, but used categorical BP, the evaluation criteria of which has been authoritatively recommended by China Food and Drug Administration (available at <http://www.sda.gov.cn>). It was defined as follows: “significant improvement” (DBP decreased by 10 mmHg, reaching the normal range, or DBP not returning to normal but reduced by more than 20 mmHg), “improvement” (DBP decreased by less than 10 mmHg but reaching the normal range, DBP decreased by 10 to 19 mmHg but not reaching the normal range, or SBP decreased by more than 30 mmHg), and “no improvement” (not meeting the above standards).⁵⁰ These outcomes were converted into binary data for further overall analysis. Both “significant improvement” and “improvement” were classified as “effective”, and “no improvement” was classified as “ineffective”. The meta-analysis showed that JLD had no BP reduction effect compared with antihypertensive drugs (n = 170; RR: 0.99; 95% CI: 0.90 to 1.08; $P = 0.79$; Figure 2a), with no significant heterogeneity (chi-square = 0.22, $P = 0.90$; $I^2 = 0\%$). Another trial used continuous BP to evaluate the efficacy of modified JLD when compared with enalapril.⁴⁴ No significant difference was found for either SBP or DBP

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

($P > 0.05$).

JLD plus antihypertensive drugs *versus* antihypertensive drugs (7 studies)

Seven RCTs evaluated the effect of JLD combined with antihypertensive drugs versus antihypertensive drugs.⁴³⁻⁴⁹ Continuous BP was measured in all of these studies. SBP was significantly reduced in the JLD plus antihypertensive drugs group when compared with antihypertensive drugs (n = 485; WMD: -8.37 mmHg; 95% CI: -9.84 to -6.90; $P < 0.00001$; Figure 2b), with no significant heterogeneity (chi-square = 8.45, $P = 0.21$; $I^2 = 29\%$). For DBP, a significant beneficial effect was also found in the JLD plus antihypertensive drugs group (n = 485; WMD: -6.71 mmHg; 95% CI: -9.32, -4.10; $P < 0.00001$; Figure 2c), with significant heterogeneity (chi-square = 9.47, $P < 0.0001$; $I^2 = 80\%$).

Secondary outcome: QOL

Only one trial,⁴² conducted by Fan et al, used the Croog Scale⁵¹ to assess the effectiveness of JLD on QOL in aged hypertension patients. At the end of the trial, QOL was significantly improved by JLD when compared with the felodipine group ($P < 0.05$). The trial demonstrated that long-term use of JLD might improve QOL for hypertensive patients.

Adverse effects

Adverse effect monitoring was only reported in five studies [43-45, 48, 49] and was not mentioned in the other five trials. Among the former, no severe adverse effects were reported in two trials.^{43,49} Three trials reported dry cough caused by enalapril in both the JLD and antihypertensive drugs groups.^{44,45,48} Two trials reported severe dry cough in the antihypertensive drugs groups.^{44,45} None of the adverse effects were serious in the JLD groups.

Evaluation of publication bias

As the number of included trials was so small, it was not possible to conduct a sufficient additional analysis of publication bias.

DISCUSSION

Summary of evidence

Taking into account the gap between the lack of scientific evidence regarding the efficacy of JLD and the widespread application by TCM practitioners, the objective of this study was to systematically review the current English and Chinese literature to evaluate the efficacy and safety of JLD for EH. To our knowledge, this is the first SR

1
2
3
4 of JLD in English.

5
6 Ten claimed RCTs, with a total of 655 hypertensive patients, met the inclusion
7
8 criteria and were included in this review. The results suggested that both SBP and
9
10 DBP were significantly improved in patients receiving JLD plus antihypertensive
11
12 drugs therapy, although the effect was not significant in the JLD alone group.
13
14 Moreover, JLD was found to be effective in terms of improving QOL when compared
15
16 with antihypertensive drugs. However, the evidence for JLD as an effective modality
17
18 for treating EH was restricted by a limited number of trials, small sample sizes, poor
19
20 methodological quality, and a high risk of bias in primary studies.
21
22
23
24
25
26
27

28 **Limitations**

29
30
31
32
33
34 The following limitations should be considered before accepting the findings of
35
36 this review.

37
38
39 (1) Although there were two randomized, single-blind, controlled trials, the
40
41 methodology of most of the included trials was assessed to be generally poor. The
42
43 main reasons are analyzed as follows:
44
45

46
47 Firstly, although all studies claimed randomization, only four trials demonstrated
48
49 the random sequence generation, and two trials reported allocation concealment;
50
51 therefore, selection bias may exist. Secondly, only three trials described the blinding
52
53 of the participants and personnel; however, no trials reported the blinding of outcome
54
55 assessment. Therefore, both selection bias and detection bias might have occurred.
56
57
58
59
60

1
2
3
4 Thirdly, only three trials reported drop-out or withdraw statistics, suggesting a high
5
6 risk of attrition bias. Fourthly, most of the included studies did not mention intention
7
8 to treat analysis, which may lead to some other bias. Fifthly, no trials had a
9
10 pre-estimation of sample size. Sixthly, no trial had a placebo control, which might
11
12 decrease the quality of positive conclusions.
13

14
15
16 (2) As shown in Figure 2c, heterogeneity is another critical issue that should be
17
18 considered, which may be associated with variations in study quality, participants,
19
20 JLD compositions, and antihypertensive drugs.
21

22
23
24 (3) Limited number of included trials and different interventions in both the JLD
25
26 and antihypertensive drugs groups restricted us from conducting meaningful subgroup
27
28 analyses to explore effect modifiers such as duration of intervention and types of
29
30 antihypertensive drug therapies.
31

32
33
34 (4) Publication bias should also be considered. In this review, all of the included
35
36 trials were conducted in China and published in Chinese. Almost all studies claimed a
37
38 similar beneficial effect or a better effect when compared with antihypertensive drugs
39
40 alone. No negative conclusions were found. What is more, a funnel plot checking for
41
42 possible publication bias for BP could not be conducted due to the small number of
43
44 included studies.
45
46
47

48
49 (5) Although one trial had a short-term follow up, most of the studies had no
50
51 follow up, indicating a lack of knowledge for some critical outcomes, such as
52
53 all-cause mortality and progression to severe complications due to high BP, which is
54
55 the most common problem for TCM studies in general.
56
57
58

1
2
3
4 (6) As the use of natural products is very common among patients in a variety of
5
6 health care settings, the safety of CHM and potential herb-drug interactions has hence
7
8 become a concern. This review suggested that JLD may be safe for the management
9
10 of EH. In fact, no parallel double blind randomized placebo-controlled trials
11
12 indicating the adverse effects of JLD for EH could be found. Due to the insufficient
13
14 clinical data, it is difficult to draw a definitive conclusion regarding the safety of JLD
15
16 for EH at present. We therefore suggest that the adverse effects of JLD need to be
17
18 monitored rigorously in future studies.
19
20
21
22
23
24
25

26 **CONCLUSION**

27
28
29
30
31 Due to the insufficient clinical data, poor methodological design, and high risk of
32
33 bias, it is difficult to draw a definite conclusion regarding the effectiveness and safety
34
35 of JLD for EH. More rigorously designed trials according to the CONSORT
36
37 Statement are needed.⁵²⁻⁵⁴
38
39
40
41
42
43

44 **Funding**

45
46 XJX was supported by the National Natural Science Foundation Project of China (No.
47
48 81403375). The funders had no role in study design, data collection and analysis,
49
50 decision to publish, or preparation of the manuscript.
51
52
53
54

55 **Competing interests**

1
2
3
4 None.
5
6
7

8 **Contributors**

9
10 XX conceived the idea for the study and designed the method of this systematic
11
12 review and meta-analysis including the inclusion and exclusion criteria. XX also
13
14 performed data collection and extraction, conducted the statistical analysis, and wrote
15
16 the first draft of the article. PW, XL, and YZ searched the articles and assessed their
17
18 methodological quality. Disagreement was resolved by discussion between XX, PW,
19
20 XL, and YZ. PW performed the major revision, interpreted the results, and made
21
22 comments. All of the authors approved the final version of the manuscript.
23
24
25
26
27
28
29

30 **Provenance and peer review**

31
32 Not commissioned; externally peer reviewed.
33
34
35
36
37

38 **Data sharing statement**

39
40 No additional data available.
41
42
43
44

45 **REFERENCES**

- 46
47 1. Lawes CM, Hoorn SV, Rodgers A, and for the International Society of
48
49 Hypertension. Global burden of blood-pressure-related disease 2001. *Lancet* 2008;
50
51 371: 1513-1518.
52
53
54
55 2. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the
56
57 management of high blood pressure in adults report from the panel members
58
59
60

- 1
2
3
4 appointed to the Eighth Joint National Committee (JNC 8). *J Am Med Assoc* 2014;
5
6 311: 507-520.
7
8
9 3. Ezzati M, Lopez AD, Rodgers A, et al. Comparative risk assessment
10 collaborative group: selected major risk factors and global and regional burden of
11 disease. *Lancet* 2002; 360: 1347-1360.
12
13
14
15
16 4. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension:
17 analysis of worldwide data. *Lancet* 2005; 365: 217-223.
18
19
20
21 5. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease
22 and risk factors 2001: systematic analysis of population health data. *Lancet* 2006;
23 367: 1747-1757.
24
25
26
27
28
29 6. Fisher JW. The diagnostic value of the sphygmomanometer in examinations for
30 life insurance. *J Am Med Assoc* 1914; 63: 1752-1754.
31
32
33
34 7. Lewington S, Clarke R, Qizilbash N, et al. Prospective Studies Collaboration.
35 Age-specific relevance of usual blood pressure to vascular mortality: a
36 meta-analysis of individual data for one million adults in 61 prospective studies.
37
38
39
40
41
42
43
44
45 8. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the
46 prevention of cardiovascular disease: meta-analysis of 147 randomised trials in
47 the context of expectations from prospective epidemiological studies. *Brit Med J*
48 2009; 338: b1665, 1-19.
49
50
51
52
53
54 9. Xiong XJ, Yang XC, Liu YM, et al. Chinese herbal formulas for treating
55 hypertension in traditional Chinese medicine: perspective of modern science.
56
57
58
59
60

- 1
2
3
4 *Hypertens Res* 2013; 36: 570-579.
- 5
6 10. Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and
7
8 control of hypertension in rural and urban communities in high-, middle-, and
9
10 low-income countries. *J Am Med Assoc* 2013; 310: 1-10.
- 11
12
13 11. Brook RD, Appel LJ, Rubenfire M, et al. Beyond medications and diet:
14
15 alternative approaches to lowering blood pressure. *Hypertension* 2013; 61:
16
17 1360-1383.
- 18
19
20
21 12. Mansoor GA. Herbs and alternative therapies in the hypertension clinic. *Am J*
22
23 *Hypertens* 2001; 14: 971-975.
- 24
25
26 13. Xiong XJ, Borrelli F, Ferreira AS, et al. Herbal medicines for cardiovascular
27
28 diseases. *Evid Based Complement Alternat Med* 2014; 2014: e809741, 1-3.
- 29
30
31 14. Wang J, Xiong XJ. Current situation and perspectives of clinical study in
32
33 integrative medicine in China. *Evid Based Complement Alternat Med* 2012; 2012:
34
35 e268542, 1-11.
- 36
37
38 15. Wang J, Feng B, Yang XC, et al. Chinese herbal medicine for the treatment of
39
40 prehypertension. *Evid Based Complement Alternat Med* 2013; 2013: e493521,
41
42 1-9.
- 43
44
45 16. Tachjian A, Maria V, Jahangir A. Use of herbal products and potential
46
47 interactions in patients with cardiovascular diseases. *J Am Coll Cardiol* 2010; 55:
48
49 515-525.
- 50
51
52
53 17. Xiong XJ, Yang XC, Liu W, et al. Trends in the treatment of hypertension from
54
55 the perspective of traditional Chinese medicine. *Evid Based Complement Alternat*
56
57
58
59
60

- 1
2
3
4 *Med* 2013; 2013: e275279, 1-13.
- 5
6 18. Wang J, Xiong XJ. Control strategy on hypertension in Chinese medicine. *Evid*
7
8 *Based Complement Alternat Med* 2012; 2012: e284847, 1-6.
- 9
10
11 19. Wang J, Xiong XJ. Evidence-based Chinese Medicine for Hypertension. *Evid*
12
13 *Based Complement Alternat Med* 2013; 2013: e978398, 1-12.
- 14
15
16 20. Wang J, Xiong XJ. Outcome measures of Chinese herbal medicine for
17
18 hypertension: an overview of systematic reviews. *Evid Based Complement*
19
20 *Alternat Med* 2012; 2012: e697237, 1-10.
- 21
22
23 21. Wang J, Feng B, Yang XC, et al. Tianma gouteng yin as adjunctive treatment for
24
25 essential hypertension: a systematic review of randomized controlled trials. *Evid*
26
27 *Based Complement Alternat Med* 2013; 2013: e706125, 1-18.
- 28
29
30 22. Xiong XJ, Yang XC, Feng B, et al. Zhen gan xi feng decoction, a traditional
31
32 Chinese herbal formula, for the treatment of essential hypertension: a systematic
33
34 review of randomized controlled trials. *Evid Based Complement Alternat Med*
35
36 2013; 2013: e982380, 1-9.
- 37
38
39 23. Wang J, Yang XC, Feng B, et al. Is Yangxue Qingnao Granule combined with
40
41 antihypertensive drugs, a new integrative medicine therapy, more effective than
42
43 antihypertensive therapy alone in treating essential hypertension?. *Evid Based*
44
45 *Complement Alternat Med* 2013; 2013: e540613, 1-8.
- 46
47
48
49
50
51 24. Xiong XJ, Liu W, Yang XC, et al. Ginkgo biloba extract for essential
52
53 hypertension: a systemic review. *Phytomedicine* 2014; 21: 1131-1136.
- 54
55
56 25. Wang J, Yao KW, Yang XC, et al. Chinese patent medicine liu wei di huang wan
57
58
59
60

- 1
2
3
4 combined with antihypertensive drugs, a new integrative medicine therapy, for
5
6 the treatment of essential hypertension: a systematic review of randomized
7
8 controlled trials. *Evid Based Complement Alternat Med* 2012; 2012: e714805,
9
10 1-7.
- 11
12
13
14 26. Wang J, Feng B, Xiong XJ. Chinese herbal medicine for the treatment of
15
16 obesity-related hypertension. *Evid Based Complement Alternat Med* 2013; 2013:
17
18 e757540, 1-11.
- 19
20
21
22 27. Lu AP, Jia HW, Xiao C, et al. Theory of traditional Chinese medicine and
23
24 therapeutic method of diseases. *World J Gastroenterol* 2004; 10: 1854-1856.
- 25
26
27 28. Jiang WY. Therapeutic wisdom in traditional Chinese medicine: a perspective
28
29 from modern science. *Trends Pharmacol Sci* 2005; 26: 558-563.
- 30
31
32 29. Ge HX, Dai XM, Zhang ZX, et al. Modern application and experimental research
33
34 progress of jian ling decoction. *Zhong Yi Yao Xue Bao* 2002; 30: 21-23.
- 35
36
37 30. Yu HW. Effect of modified jian ling decoction on insulin resistance and serum
38
39 levels of TNF- α in patients with essential hypertension. *Haerbin: Heilongjiang*
40
41 *Zhong Yi Yao Da Xue* 2008; 1-56.
- 42
43
44 31. Cao JM. Effect of modified jian ling decoction on serum leptin and angiotensin II
45
46 in hypertension with insulin resistance. *Haerbin: Heilongjiang Zhong Yi Yao Da*
47
48 *Xue* 2012; 1-51.
- 49
50
51
52 32. Jiang CX. Effect of modified jian ling decoction on blood pressure and
53
54 angiotensin II in elderly hypertensive patients. *Haerbin: Heilongjiang Zhong Yi*
55
56 *Yao Da Xue* 2012; 1-51.
- 57
58
59
60

- 1
2
3
4 33. Zhang N, Sun JL, Dong ZZ, et al. Effect of modified jian ling decoction on
5
6 insulin resistance and serum interleukin-6 of essential hypertension patients.
7
8 *Zhongguo Zhong Yi Yao Xin Xi Za Zhi* 2011; 18: 19-21.
9
10
11 34. Feng DR, Wei B. Effects of jian ling decoction on the blood lipid and lipid
12
13 peroxidation in experimental hyperlipidemia rats with yin deficiency of liver
14
15 and kidney. *Guangxi Zhong Yi Yao* 2009; 32: 51-54.
16
17
18 35. Huang YT, Wu CB, Zeng QM. Effect of jian ling decoction on 120 patients of
19
20 essential hypertension. *Zhongguo Zhong Xi Yi Jie He Za Zhi* 1996; 16: 561.
21
22
23 36. Hao HY, Wang QH, Sun CJ, et al. Effect of modified jian ling decoction on 30
24
25 patients of essential hypertension. *Shanxi Zhong Yi* 1998; 19: 541.
26
27
28 37. Guan DM, Du SQ. Clinical observation on the effect of jian ling decoction
29
30 combined with urapidil on stage III hypertension with high-risk. *Zhongguo She*
31
32 *Qu Yi Shi* 2013; 15: 214-215.
33
34
35 38. Higgins JPT, Green S. *Cochrane Handbook for Systematic Reviews of*
36
37 *Interventions, Version 5.1.0.* The Cochrane Collaboration.
38
39 <http://handbook.cochrane.org/>. 2011.
40
41
42 39. Li YB, Cui M, Yang Y, et al. Similarity of traditional Chinese medicine formula.
43
44 *Zhong Hua Zhong Yi Yao Xue Kan* 2012; 30: 1096-1097.
45
46
47 40. Tong WH. Analysis on clinical therapeutic effect of jian ling decoction on
48
49 essential hypertension with yin deficiency and yang hyperactivity syndrome.
50
51 *Zhongguo Yi Yao Zhi Nan* 2013; 11: 258-259.
52
53
54 41. He T, Zhu YQ, Xu SX. Effect of jian ling decoction on 30 hypertensive patients
55
56
57
58
59
60

- 1
2
3
4 with yin deficiency and yang hyperactivity syndrome. *Zhong Yi Yao Dao Bao*
5
6 2012; 18: 50-51.
7
8
9 42. Fan R, Zhou H, Tan HY. Effect of jian ling decoction on aged hypertension
10
11 patient's life mass and CAT. *Zhongguo Xian Dai Yi Xue Za Zhi* 2005; 15:
12
13 1706-1708.
14
15 43. Cai XP. Combined traditional Chinese and western medicine in the treatment of
16
17 50 patients with essential hypertension. *Guagndong Yi Xue* 1995; 16: 400-402.
18
19
20 44. Zhang N. Effect of modified jian ling decoction on essential hypertension.
21
22 *Haerbin: Heilongjiang Zhong Yi Yao Da Xue* 2004; 1-34.
23
24
25 45. Zhang N. Effect of modified jian ling decoction on insulin resistance and serum
26
27 levels of IL-6 in essential hypertension. *Haerbin: Heilongjiang Zhong Yi Yao Da*
28
29 *Xue* 2009; 1-51.
30
31
32 46. Jiang CX, Cao JM. Effect of modified jian ling decoction on renin-angiotensin II
33
34 in patients with senile hypertension. *Zhongguo Zhong Yi Yao Ke Ji* 2012; 19: 145.
35
36
37 47. Chu GM, Xu JY. Effect of modified jian ling decoction on high-sensitivity
38
39 C-reactive protein on 67 cases of hypertensive patients. *Zhong Yi Yao Xin Xi* 2013;
40
41 30: 66-67.
42
43
44 48. Liu L, Jin J, Yu HW. Effect of modified jian ling decoction on insulin resistance
45
46 and TNF- α level in patients of EH. *Zhong Yi Yao Xin Xi* 2008; 25: 68-70, 80.
47
48
49 49. Li CM. Effect of modified jian ling decoction on senile primary hypertension.
50
51 *Jinan: Shandong Zhong Yi Yao Da Xue* 2013; 1-30.
52
53
54 50. Xiong XJ, Liu W, Yang XC, et al. Moxibustion for essential hypertension.
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Complement Ther Med 2014; 22: 187-195.

51. Croog SH, Levine S, Testa MA, et al. The effect of antihypertensive therapy on the quality of life. *N Engl J Med* 1986; 314: 1657-1659.
52. Liu JP, Han M, Li XX, et al. Prospective registration, bias risk and outcome-reporting bias in randomised clinical trials of traditional Chinese medicine: An empirical methodological study. *BMJ Open* 2013; 3: e002968, 1-7.
53. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. *Ann Intern Med* 2012; 152: 726-732.
54. Gagnier JJ, Boon H, Rochon P, et al. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. *Ann Intern Med* 2006; 144: 364-367.

1
2
3
4 **Table 1. Basic characteristics of the included studies.**
5
6
7

8
9 **Table 2. Herbal medicines in the included studies.**
10
11

12
13
14 **Table 3. Methodological quality of included studies based on the Cochrane**
15 **handbook.**
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FIGURE LEGENDS**Figure 1.**

Flow diagram of study selection and identification.

Figure 2.

Effect of JLD on BP. (a) JLD *versus* AD and (b) JPAD *versus* AD.

AD: antihypertensive drugs; BP: blood pressure; DBP: diastolic blood pressure; JLD:

Jian Ling Decoction; JPAD: Jian Ling Decoction plus antihypertensive drugs; SBP:

systolic blood pressure.

Table 1. Basic characteristics of the included studies.

Study ID	Sample size (randomized /analyzed) M/F	Age(yrs)	Diagnosis standard	Intervention	Control	Course (week)	Outcome measures
Tong 2013 [40]	60/60 T: 30 C: 30 F/M: NR	40-60 (T/C: NR)	GCRNDTC M	JLD (1 dose/d)	felodipine (5 mg, qd)	4	BP
He et al. 2012 [41]	60/60 T: 15/15 C: 17/13	T: 54.89 ± 5.34 C: 57.36 ± 6.47	GCRNDTC M	JLD (1 dose/d)	felodipine (5 mg, qd)	4	BP
Fan 2005 [42]	50/50 T: 14/11 C: 13/12	T: 64.80 ± 7.40 C: 63.70 ± 6.90	WHO -ISH GMH-1999	JLD (1 dose/d)	felodipine (2.5 mg, qd)	4	BP; QOL
Cai 1995 [43]	100/100 T: 35/15 C: 34/16	T: 50-81 C: 47-84	WHO -ISH GMH-1985	modified JLD (1 dose/d) + control	nifedipine (10 mg, tid)	4	BP; adverse effect
Zhang 2004 [44]	90/89 T1: 16/14 T2: 17/13 C: 15/14	T1: 58.23 ± 8.26 T2: 58.45 ± 6.87 C: 59.16 ± 9.28	WHO -ISH GMH-1999	T1: modified JLD (1 dose/d) T2: modified JLD (1 dose/d) + control	enalapril (10 mg, bid)	4	BP; adverse effect
Zhang 2009 [45]	60/57 T: 15/14 C: 12/16	T: 56.41 ± 10.98 C: 58.57 ± 8.21	CGMH-200 5	modified JLD (1 dose/d) + control	enalapril (10 mg, bid)	3	BP; adverse effect
Jiang and Cao 2012 [46]	82/82 T: 26/16 C: 23/17	T: 60-75 C: 62-75	WHO -ISH GMH-1999	modified JLD (100 ml/d) + control	benazepril hydrochloride (10 mg, tid)	4	BP
Chu and Xu 2013 [47]	67/67 T: 19/15 C: 17/16	T: 67.00 ± 7.20 C: 68.00 ± 5.90	WHO -ISH GMH-1999	modified JLD (100 ml/d) + control	nifedipine controlled release tablet (30 mg, qd)	4	BP
Liu et al. 2008 [48]	60/60 T: 30 C: 30 F/M: NR	18-70 (T/C: NR)	JNC 7	modified JLD (100 ml/d) + control	enalapril (10 mg, bid)	3	BP; adverse effect
Li 2013 [49]	60/60 T: 16/14 C: 17/13	T: 64.33 ± 7.96 C: 61.20 ± 10.23	CGMH-201 0	modified JLD (400 ml/d) + control	nifedipine controlled release tablet (30 mg, qd) and irbesartan (150 mg, qd)	4	BP; adverse effect

Abbreviations: BP: blood pressure; C: control group; CGMH: Chinese Guidelines for the Management of Hypertension; F: female; GCRNDTCM: Guidelines of Clinical Research of New Drugs of Traditional Chinese Medicine; JLD: Jian Ling Decoction; JNC 7: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; M: male; NR: not reported; QOL: quality of life; T: treatment group; WHO-ISH GMH: WHO-ISH guidelines for the management of hypertension.

Table 2. Herbal medicines in the included studies.

Study ID	Formula	Composition of formula
Tong 2013 [40]	JLD	Arbor Vitae Seed (Baiziren, Semen Platycladi) 10 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 10 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 15 g, Oyster Shell (Muli, Concha Ostreae) 10 g, Fossilized Mammal Bones (Longgu, Os Draconis) 10 g, Hematite (Daizheshi, Haematitum) 10 g, Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 15 g, and Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 20 g.
He et al. 2012 [41]	JLD	Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 15 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 20 g, Hematite (Daizheshi, Haematitum) 10 g, Oyster Shell (Muli, Concha Ostreae) 10 g, Fossilized Mammal Bones (Longgu, Os Draconis) 10 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 15 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 10 g, and Arbor Vitae Seed (Baiziren, Semen Platycladi) 10 g.
Fan 2005 [42]	JLD	Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 30 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 30 g, Hematite (Daizheshi, Haematitum) 24 g, Oyster Shell (Muli, Concha Ostreae) 18 g, Fossilized Mammal Bones (Longgu, Os Draconis) 18 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 18 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 12 g, and Arbor Vitae Seed (Baiziren, Semen Platycladi) 12 g.
Cai 1995 [43]	modified JLD	Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 30 g, Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 30 g, Abalone Shell (Shijueming, Haliotidis Concha) 30 g, Hematite (Daizheshi, Haematitum) 24 g, Oyster Shell (Muli, Concha Ostreae) 18 g, Fossilized Mammal Bones (Longgu, Os Draconis) 18 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 18 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 12 g, and Arbor Vitae Seed (Baiziren, Semen Platycladi) 12 g. Headache plus Puncturevine Caltrop Fruit (Cijili, Tribulus terrestris Linn) 10 g; constipation plus Rhubarb Root and Rhizome (Daihuang, Radix Et Rhizoma Rhei) 5 g.
Zhang 2004 [44]	modified JLD	Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 30 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 30 g, Hematite (Daizheshi, Haematitum) 24 g, Oyster Shell (Muli, Concha Ostreae) 18 g, Fossilized Mammal Bones (Longgu, Os Draconis) 18 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 18 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 12 g, and Arbor Vitae Seed (Baiziren, Semen Platycladi) 12 g. Headache, dizziness, and irritability plus Gastrodia (Tianma, Gastrodiae Rhizoma) 15 g and Abalone Shell (Shijueming, Haliotidis Concha) 30 g; irritability, bitty mouth and red face plus Coptis Rhizome (Huanglian, Rhizoma Coptidis) 10 g and Gardenia (Zhizi, Fructus Gardeniae Jasminoidis) 10 g; and constipation plus Rhubarb Root and Rhizome (Daihuang, Radix Et Rhizoma Rhei) 5 g.
Zhang 2009 [45]	modified JLD	Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 30 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 30 g, Hematite (Daizheshi, Haematitum) 24 g, Oyster Shell (Muli, Concha Ostreae) 18 g, Fossilized Mammal Bones (Longgu, Os Draconis) 18 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 18 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 12 g, and Arbor Vitae Seed (Baiziren, Semen Platycladi) 12 g. Excessive accumulation of phlegm-dampness plus Pinellia Rhizome (Banxia, Rhizoma Pinelliae Tematae) 15 g, Sclerotium of Tuckahoe (Fuling, Scierotium Poriae Cocos) 15 g, Tangerine Peel (Chenpi, Pericarpium Citri Reticulatae) 10 g, Bamboo Shavings (Zhuru, Bambusae Caulis in Taeniam) 10 g, and Liquoric Root (Gancao, Radix Glycyrrhizae) 3 g.
Jiang and Cao	modified	Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 30 g, Fresh Water Turtle Shell (Guijia, Plastrum

2012 [46]	JLD	Testudinis) 30 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 30 g, Hematite (Daizheshi, Haematitum) 20 g, Oyster Shell (Muli, Concha Ostreae) 20 g, Fossilized Mammal Bones (Longgu, Os Draconis) 20 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 20 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 15 g, and Arbor Vitae Seed (Baiziren, Semen Platycladi) 15 g.
Chu and Xu 2013 [47]	modified JLD	Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 25 g, Fresh Water Turtle Shell (Guijia, Plastrum Testudinis) 25 g, Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 30 g, Hematite (Daizheshi, Haematitum) 15 g, Oyster Shell (Muli, Concha Ostreae) 25 g, Fossilized Mammal Bones (Longgu, Os Draconis) 25 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 25 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 20 g, and Arbor Vitae Seed (Baiziren, Semen Platycladi) 20 g.
Liu et al. 2008 [48]	modified JLD	Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 30 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 18 g, Hematite (Daizheshi, Haematitum) 24 g, Oyster Shell (Muli, Concha Ostreae) 18 g, Fossilized Mammal Bones (Longgu, Os Draconis) 18 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 30 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 20 g, and Arbor Vitae Seed (Baiziren, Semen Platycladi) 20 g. Excessive accumulation of phlegm-dampness plus Pinellia Rhizome (Banxia, Rhizoma Pinelliae Tematae) 15 g, Sclerotium of Tuckahoe (Fuling, Scierotium Poriae Cocos) 15 g, Tangerine Peel (Chenpi, Pericarpium Citri Reticulatae) 10 g, Bamboo Shavings (Zhuru, Bambusae Caulis in Taeniam) 10 g, and Liquoric Root (Gancao, Radix Glycyrrhizae) 3 g.
Li 2013 [49]	modified JLD	Fossilized Mammal Bones (Longgu, Os Draconis) 30 g, Oyster Shell (Muli, Concha Ostreae) 30 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 20 g, Hematite (Daizheshi, Haematitum) 20 g, Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 30 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 30 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 20 g, Arbor Vitae Seed (Baiziren, Semen Platycladi) 15 g, Gambir Vine Stems and Thorns (Gouteng, Ramulus Uncariae Cum Uncis) 30 g, Pueraria (Gegen, Radix Puerariae) 30 g, Gastrodia (Tianma, Gastrodiae Rhizoma) 15 g, Chinese Taxillus Twig (Sangjisheng, Herba Taxilli) 30 g, Eucommia Bark (Duzhong, Cortex Eucommiae Ulmoidis) 15 g, and Coptis Rhizome (Huanglian, Rhizoma Coptidis) 9 g.

Abbreviations: JLD: Jian Ling Decoction.

Table 3. Methodological quality of included studies based on the Cochrane handbook.

Included trials	A	B	C	D	E	F	G
Tong 2013 [40]	?	?	?	?	+	?	?
He et al. 2012 [41]	+	?	?	?	+	?	?
Fan 2005 [42]	?	?	?	?	+	?	?
Cai 1995 [43]	?	+	?	?	+	?	?
Zhang 2004 [44]	+	+	+	?	+	?	?
Zhang 2009 [45]	+	?	+	?	+	?	?
Jiang and Cao 2012 [46]	?	?	?	?	+	?	?
Chu and Xu 2013 [47]	?	?	?	?	+	?	?
Liu et al. 2008 [48]	+	+	+	?	+	?	?
Li 2013 [49]	?	?	?	?	+	?	?

Abbreviations: A: Adequate sequence generation; B: Concealment of allocation; C: Blinding (participants and personnel); D: Blinding (assessor); E: Incomplete outcome data addressed (ITT analysis); F: Free of selective reporting; G: other potential threat to validity; +: low risk; -: high risk; ?: unclear.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends

Figure 1. Flow diagram of study selection and identification.

Figure 2. Effect of JLD on BP. (a) JLD *versus* AD and (b) JPAD *versus* AD.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

Chinese herbal medicine Jian Ling Decoction for essential hypertension: A systematic review and meta-analysis of randomized controlled trials

Xingjiang Xiong^{1*}, Pengqian Wang², Xiaoke Li³, and Yuqing Zhang⁴

¹ Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China

² Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China

³ Bio-organic and Natural Products Laboratory, McLean Hospital, Harvard Medical School, Belmont, CA, USA

⁴ Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada

Total word count: 3201.

Number of tables and figures: 3 tables and 2 figures.

Running head: Jian Ling Decoction for essential hypertension.

53
54
55
56
57
58
59
60

* *BMJ Open* 2014

Correspondence to: Xingjiang Xiong, MD, Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beixiange 5#, Xicheng District, Beijing 100053, China. Tel: +10 88001817. Fax: +10 88001229. E-mail: xiongxingjiangtcm@163.com or 5administration@163.com.

ABSTRACT

Objectives: Jian Ling Decoction (JLD) is often prescribed to improve hypertension-related symptoms in China. However, this treatment has not been systematically reviewed for its efficacy against essential hypertension (EH). This review aims to assess the current clinical evidence of JLD in the treatment of EH.

Design: Seven electronic databases including the Cochrane Central Register of Controlled Trials, PubMed, EMBASE, the Chinese National Knowledge Infrastructure (CNKI), the Chinese Scientific Journal Database (VIP), the Chinese Biomedical Literature Database (CBM), and the Wanfang Database were searched up to March 2014. Randomized control trials (RCTs) comparing JLD or combined with antihypertensive drugs versus antihypertensive drugs were included. We assessed the methodological quality, extracted the valid data, and conducted the meta-analysis according to criteria from the Cochrane group. The primary outcome was categorical or continuous blood pressure (BP), and the secondary outcome was quality of life (QOL).

Results: Ten trials (655 patients) with unclear-to-high risk of bias were identified. Meta-analysis showed that JLD used alone showed no BP reduction effect; however, improvement on QOL was found when compared to antihypertensive drugs. A significant reduction on systolic BP and diastolic BP were observed for JLD plus antihypertensive drugs when compared to antihypertensive drugs alone. No serious adverse effects were reported.

Conclusion: Due to insufficient clinical data, it is difficult to draw a definite

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

conclusion regarding the effectiveness and safety of JLD for EH, and better trials are needed.

For peer review only

KEY WORDS

essential hypertension; **blood pressure**; Chinese herbal medicine; Jian Ling Decoction;
systematic review

For peer review only

ARTICLE SUMMARY

Article focus

- Jian Ling Decoction (JLD), a traditional Chinese herbal formula, is often prescribed for patients with essential hypertension (EH).

Key messages

- No definitive conclusion regarding the efficacy and safety of JLD for EH could be drawn based on the insufficient clinical data

Strengths and limitations of this study

- The strength of this article is its use of a comprehensive and unbiased literature searching of seven electronic databases without language and publication restrictions.
- The included trials were of small sample size, with poor methodological quality and significant heterogeneity.

INTRODUCTION

Hypertension is one of the most important preventable causes of death and one of the most common conditions treated in primary health care. In addition, hypertension represents an important public health challenge because of its high prevalence and the concomitant increase in the risk of cardiovascular, cerebrovascular and renal diseases.^{1,2} This condition has been ranked as the leading global risk factor for mortality and is the third leading risk factor for disease burden according to the comparative Risk Assessment Collaborating Group.^{3,4} Currently, about one billion patients have been affected.⁵ The association between blood pressure (BP) and mortality was discovered approximately 100 years ago.⁶ Recent studies also confirmed that BP is closely related to vascular outcomes, and even a minor reduction in BP could reduce cardiovascular events, especially stroke.^{7,8} Therefore, early diagnosis and effective treatment is of great importance for patients with essential hypertension (EH). Nevertheless, despite remarkable achievements in the research and development of antihypertensive drugs, the current awareness, curative and control rates of hypertension among different age groups is still far from satisfactory.^{9,10} Additionally, in the light of the adverse effects of antihypertensive drugs and hoping for an adjunctive approach with few adverse effects, patients in Western countries with EH and other cardiovascular diseases increasingly use complementary and alternative medicine (CAM),¹¹⁻¹³ including traditional Chinese medicine (TCM).¹⁴⁻¹⁶

Chinese herbal medicine (CHM), one of the commonly used TCM therapies, has played an important role in relieving hypertension-related signs and symptoms for centuries in East Asia.^{17,18} Recently, more robust evidence from systematic reviews (SRs) has suggested the efficacy and safety of CHM for EH.¹⁹⁻²⁶ In TCM theory, liver yang hyperactivity syndrome (LYHS) and liver-kidney yin deficiency syndrome (LKYDS) are the two most important patterns of EH, which often appear at the same time.¹⁷ These patterns manifest as headache, vertigo, tinnitus, irritability, insomnia, lassitude in the waist and legs, dysphoria with feverish sensation, dry mouth, bright red tongue with less fur, and a wiry pulse.^{14,17,21,27,28} Jian Ling Decoction (JLD) is a traditional CHM invented by Zhang Xichun in *Yixue Zhongzhong Canxilu (Records of Traditional Chinese in Combination with Western Medicine)* in the 1920s. It contains the following eight commonly used herbs: Dioscorea Root (Shanyao, *Dioscoreae Rhizoma*), Achyranthes Root (Niuxi, *Achyranthis Bidentatae Radix*), Hematite (Daizheshi, *Haematitum*), Fossilized Mammal Bones (Longgu, *Os Draconis*), Oyster Shell (Muli, *Concha Ostreae*), Rehmannia (Dihuang, *Radix Rehmanniae Glutinosae*), White Peony Root (Baishao, *Radix Albus Paeoniae Lactiflorae*), and Arbor Vitae Seed (Baiziren, *Semen Platycladi*). All of these herbs have been recorded in the Pharmacopoeia of the People's Republic of China (2010 edition). Both LYHS and LKYDS can be effectively treated with JLD.¹⁹ Currently, JLD is often prescribed for the management of EH by TCM practitioners in China. It is worth noting that in the context of CAM therapies, add-on designs are very popular for the treatment of hypertension.^{14,20-25} JLD is usually used in combination with antihypertensive drugs

1
2
3
4 to achieve greater improvement in the signs and symptoms of hypertension and to
5
6 enhance the antihypertensive effect of conventional drugs with less adverse effects.
7
8 The pharmacological mechanisms of these effects may be related to the reduction in
9
10 levels of angiotensin II, IL-6, tumor necrosis factor- α (TNF- α), and leptin, as well as
11
12 insulin resistance and decreased blood lipids.²⁹⁻³⁴ Regarding the clinical use of JLD, a
13
14 large number of studies (including case reports, case series, controlled observational
15
16 studies, and randomized trials) have reported its effects on EH, including lowering BP,
17
18 reducing inflammation, reversing cardiovascular risk factors, and improving clinical
19
20 symptoms and quality of life (QOL).³⁵⁻³⁷ However, there has been no comprehensive
21
22 evaluation of clinical trials on the efficacy and adverse effects of JLD. This review
23
24 aims to systematically review the published and unpublished randomized controlled
25
26 trials (RCTs) to evaluate the current evidence for JLD in treating EH.
27
28
29
30
31
32
33
34
35
36

37 METHODS

38
39
40
41 This study was conducted according to the Cochrane practice.³⁸
42
43
44
45

46 Search strategies

47
48
49
50
51 RCTs of JLD for the treatment of hypertensive patients were screened through
52
53 the following electronic databases from their respective inceptions to March 2014:

54
55
56 Cochrane Central Register of Controlled Trials (CENTRAL, 1996-2014), PubMed
57
58
59
60

1
2
3
4 (1959-2014), and EMBASE (1980-2014). In addition, as JLD is mainly prescribed in
5
6 China, **four** Chinese electronic databases including **the** Chinese National Knowledge
7
8 Infrastructure (CNKI, 1980-2014), Chinese Scientific Journal Database (VIP,
9
10 1989-2014), Chinese Biomedical Literature Database (CBM, 1978-2014), and
11
12 Wanfang Database (1998-2014) were searched to retrieve the maximum possible
13
14 number of trials. **We also conducted a literature search of the website of the Chinese**
15
16 **clinical trial registry (available at <http://www.chictr.org/>) and international clinical**
17
18 **trial registry hosted by the US National Institutes of Health (available at**
19
20 **<http://clinicaltrials.gov/>) for all of the relevant ongoing registered clinical trials and**
21
22 **unpublished articles. The bibliographies of the studies identified in the systematic**
23
24 **search were reviewed for potentially relevant additional publications. No restriction**
25
26 **on publication status or language was imposed.**

27
28
29
30
31
32
33
34 The keywords for databases searching were listed as follows: (“hypertension”
35
36 OR “essential hypertension” OR “primary hypertension” OR “high blood pressure”
37
38 OR “blood pressure”) AND (“*jian ling* decoction” OR “*jianling* decoction” OR “*jian*
39
40 *ling tang*” OR “*jianling tang*” OR “*jianlingtang*”) AND (“clinical trial” OR
41
42 “randomized controlled trial” OR “randomised controlled trial”).
43
44
45
46
47
48

49 **Study selection**

50 51 52 53 54 **Types of studies**

1
2
3
4 RCTs on the use of JLD for the treatment of EH were included.
5

6 Quasi-randomized trials and animal experiments were excluded.
7
8
9

10 11 **Types of participants** 12

13
14
15
16 Trials focused on the patients suffering from EH were included. All of the
17
18 participants who were enrolled in the trials were required to meet at least one of the
19
20 current or past definitions of EH.² Trials without a description of the detailed
21
22 diagnostic criteria but which reported patients with definite EH were also included .
23
24 Patients with secondary hypertension were excluded. There was no restriction on
25
26 gender, age, or ethnic origin of the participants.
27
28
29
30
31
32
33

34 **Types of interventions** 35

36
37
38
39 Only studies that tested JLD used alone versus antihypertensive drugs, or JLD
40
41 combined with antihypertensive drugs versus antihypertensive drugs were included.
42
43 However, trials assessing the combined effect of JLD with other interventions (*e.g.*,
44
45 another CHM, qigong, Tai Chi, acupuncture, moxibustion and massage) were
46
47 excluded given that the therapeutic effect of JLD could not be distinguished.
48
49 Interventions in the control group included antihypertensive drugs. Studies that used
50
51 non-conventional medicine or CAM as control groups were also excluded. The
52
53 duration of treatment was required to be at least two weeks.
54
55
56
57
58
59
60

1
2
3
4 According to the principle of similarity of the TCM formula,³⁹ modified JLD
5
6 should contain at least six out of eight herbs used in JLD, and only a few herbs could
7
8 be added into the JLD based on TCM syndrome theory. However, the resulting
9
10 prescription should contain the following four principal drugs: Achyranthes Root
11
12 (Niuxi, Achyranthis Bidentatae Radix), Hematite (Daizheshi, Haematitum), Fossilized
13
14 Mammal Bones (Longgu, Os Draconis), and Oyster Shell (Muli, Concha Ostreae).
15
16
17
18
19
20

21 **Types of outcome measures**

22
23
24
25

26 The primary outcome analyzed for this meta-analysis was categorical or
27
28 continuous BP, and secondary outcome was QOL.
29
30
31
32

33 **Data extraction**

34
35
36
37
38

39 All of the articles were read by two independent reviewers. Then, the eligible
40
41 studies were retrieved for further identification according to the above inclusion and
42
43 exclusion criteria. Duplicate papers were excluded. The data extraction form
44
45 comprised the authors, title, publication year, sample size, age, sex distribution,
46
47 diagnosis standard, study design, interventions in the treatment and control groups,
48
49 the composition of JLD or modified JLD, trial duration, outcome measures, and
50
51 adverse effects. If missing or unclear information regarding the original study was
52
53
54 found, we contacted the primary authors via email, telephone or fax whenever
55
56
57
58
59
60

possible. Any disagreement was resolved by discussion between the reviewers.

Methodological quality

The risk of bias of the included studies was independently evaluated by two reviewers according to the criteria in the Cochrane Handbook for Systematic Review of Interventions Version 5.1.0 (updated March 2011).³⁸ The following seven items were included: (a) sequence generation (selection bias); (b) allocation concealment (selection bias); (c) blinding of participants and personnel (performance bias); (d) blinding of outcome assessments (detection bias); (e) incomplete outcome data (attrition bias); (f) selective reporting (reporting bias); and (g) other sources of bias (from Chapter 8: assessing risk of bias in included studies).³⁸ Each domain was assessed as a “high”, “unclear”, or “low” risk of bias based on the above criteria. Then, the methodological quality of the trials was ranked into three levels: low risk of bias (all items with low risk of bias), high risk of bias (at least one item with high risk of bias), or unclear risk of bias (at least one item with an unclear domain).

Data synthesis

Review Manager, Version 5.1 (The Nordic Cochrane Centre, Copenhagen, Denmark) was used for data analysis. The values of the outcome measures after treatment were retrieved to assess differences between the JLD and control groups.

1
2
3
4 The weighted mean difference (WMD) was used for continuous data, while the risk
5
6 ratio (RR) was used for binary data. Subgroups analysis was conducted among
7
8 different types of comparisons (including JLD *versus* antihypertensive drugs and JLD
9
10 plus antihypertensive drugs *versus* antihypertensive drugs). If high quality trials could
11
12 be found, comparisons between all of the studies and studies with high quality would
13
14 be conducted. In a three-group design study that had two treatment groups of JLD and
15
16 JLD plus antihypertensive drugs, the two comparisons were split in the meta-analysis.
17
18 Heterogeneity was assessed by I^2 statistics.³⁸ Funnel plots were applied to detect for
19
20 publication bias when the number of included studies of any particular outcome was
21
22 more than ten. $P < 0.05$ was considered to be statistically significant.
23
24
25
26
27
28
29
30
31

32 RESULTS

33 34 35 36 Study characteristics

37
38
39
40
41 Figure 1 shows the process of study selection. Three hundred eight potentially
42
43 relevant articles were extracted in the initial screening of the seven databases. Ten
44
45 RCTs, with a total of 655 participants, met the eligibility criteria and were
46
47 included.⁴⁰⁻⁴⁹ The basic characteristics of included trials are summarized in Table 1.
48
49
50
51 Six diagnostic criteria of EH were specified: two trials^{40,41} used the Guidelines of
52
53 Clinical Research of New Drugs of Traditional Chinese Medicine (GCRNDTCM);
54
55
56 four trials^{42,44,46,47} used the WHO-ISH guidelines for the management of
57
58
59
60

1
2
3 hypertension-1999 (WHO -ISH GMH-1999); one trial⁴³ used the WHO-ISH
4
5
6 GMH-1985; one trial⁴⁵ used the Chinese Guidelines for the Management of
7
8
9 Hypertension-2005 (CGMH-2005); one trial⁴⁸ used the Seventh Report of the Joint
10
11
12 National Committee on Prevention, Detection, Evaluation, and Treatment of High
13
14
15 Blood Pressure (JNC 7); and one trial⁴⁹ used the Chinese Guidelines for the
16
17
18 Management of Hypertension-2010 (CGMH-2010). All of the studies were conducted
19
20
21 in China and published in Chinese language. One trial was a three-arm design (two
22
23
24 intervention groups versus one control group),⁴⁴ and the others used a two-arm study
25
26
27 design (one intervention group versus one control group). The clinical efficacy of JLD
28
29
30 was observed in all of the trials. However, the evaluation criteria on BP was different:
31
32
33 three trials used the categorical BP recommended by Chinese government in
34
35
36 GCRNDTCM,⁴⁰⁻⁴² and seven used continuous BP.⁴³⁻⁴⁹ QOL was only tested in one
37
38
39 trial.⁴²

40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Treatment groups

The types of intervention were classified as JLD (n = 4) or combination therapy (JLD plus antihypertensive drugs, n = 7). The variable prescriptions based on JLD are presented in Table 1. Different compositions of either JLD or modified JLD are presented in Table 2.

Control groups

1
2
3
4
5
6 All of the patients in the control groups received antihypertensive drug treatment,
7
8 including felodipine,⁴⁰⁻⁴² nifedipine,^{43,47,49} enalapril,^{44,45,48} and benazepril
9
10 hydrochloride.⁴⁶
11
12

13 14 15 16 **Treatment duration** 17

18
19
20
21 The total treatment duration in the trials ranged from three to four weeks, with
22
23 most being four weeks (n = 8). The duration of follow-up was only mentioned in one
24
25 trial, being three months.⁴³
26
27
28
29
30

31 **Methodological quality** 32

33
34
35
36 As shown in Table 3, four trials reported the method used to generate the
37
38 allocation sequence (random number table).^{41,44,45,48} Information regarding allocation
39
40 concealment was provided in two trials.^{44,48} Blinding of participants and personnel
41
42 was reported in three trials;^{44,45,48} however, no trial used blinding of outcome
43
44 assessment. Drop-out and withdrawal data were provided for three trials.^{44,45,49} No
45
46
47 trial had a pre-trial estimation of sample size. Selective reporting could not be
48
49
50 evaluated as no preregistered protocols could be obtained from the primary authors.
51
52
53
54
55

56 **Outcome measures** 57 58 59 60

Primary outcome: BP

JLD *versus* antihypertensive drugs (4 studies)

The clinical efficacy of JLD as monotherapy for BP was assessed in four trials.^{40-42,44} Three trials⁴⁰⁻⁴² did not use continuous BP to evaluate the efficacy of JLD, but used categorical BP, the evaluation criteria of which has been authoritatively recommended by China Food and Drug Administration (available at <http://www.sda.gov.cn>). It was defined as follows: “significant improvement” (DBP decreased by 10 mmHg, reaching the normal range, or DBP not returning to normal but reduced by more than 20 mmHg), “improvement” (DBP decreased by less than 10 mmHg but reaching the normal range, DBP decreased by 10 to 19 mmHg but not reaching the normal range, or SBP decreased by more than 30 mmHg), and “no improvement” (not meeting the above standards).⁵⁰ These outcomes were converted into binary data for further overall analysis. Both “significant improvement” and “improvement” were classified as “effective”, and “no improvement” was classified as “ineffective”. The meta-analysis showed that JLD had no BP reduction effect compared with antihypertensive drugs (n = 170; RR: 0.99; 95% CI: 0.90 to 1.08; *P* = 0.79; Figure 2a), with no significant heterogeneity (chi-square = 0.22, *P* = 0.90; *I*² = 0%). Another trial used continuous BP to evaluate the efficacy of modified JLD when compared with enalapril.⁴⁴ No significant difference was found for either SBP or DBP

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

($P > 0.05$).

JLD plus antihypertensive drugs *versus* antihypertensive drugs (7 studies)

Seven RCTs evaluated the effect of JLD combined with antihypertensive drugs versus antihypertensive drugs.⁴³⁻⁴⁹ Continuous BP was measured in all of these studies. SBP was significantly reduced in the JLD plus antihypertensive drugs group when compared with antihypertensive drugs (n = 485; WMD: -8.37 mmHg; 95% CI: -9.84 to -6.90; $P < 0.00001$; Figure 2b), with no significant heterogeneity (chi-square = 8.45, $P = 0.21$; $I^2 = 29\%$). For DBP, a significant beneficial effect was also found in the JLD plus antihypertensive drugs group (n = 485; WMD: -6.71 mmHg; 95% CI: -9.32, -4.10; $P < 0.00001$; Figure 2c), with significant heterogeneity (chi-square = 9.47, $P < 0.0001$; $I^2 = 80\%$).

Secondary outcome: QOL

Only one trial,⁴² conducted by Fan et al, used the Croog Scale⁵¹ to assess the effectiveness of JLD on QOL in aged hypertension patients. At the end of the trial, QOL was significantly improved by JLD when compared with the felodipine group ($P < 0.05$). The trial demonstrated that long-term use of JLD might improve QOL for hypertensive patients.

Adverse effects

Adverse effect monitoring was only reported in five studies [43-45, 48, 49] and was not mentioned in the other five trials. Among the former, no severe adverse effects were reported in two trials.^{43,49} Three trials reported dry cough caused by enalapril in both the JLD and antihypertensive drugs groups.^{44,45,48} Two trials reported severe dry cough in the antihypertensive drugs groups.^{44,45} None of the adverse effects were serious in the JLD groups.

Evaluation of publication bias

As the number of included trials was so small, it was not possible to conduct a sufficient additional analysis of publication bias.

DISCUSSION

Summary of evidence

Taking into account the gap between the lack of scientific evidence regarding the efficacy of JLD and the widespread application by TCM practitioners, the objective of this study was to systematically review the current English and Chinese literature to evaluate the efficacy and safety of JLD for EH. To our knowledge, this is the first SR

1
2
3
4 of JLD in English.

5
6 Ten claimed RCTs, with a total of 655 hypertensive patients, met the inclusion
7
8 criteria and were included in this review. The results suggested that both SBP and
9
10 DBP were significantly improved in patients receiving JLD plus antihypertensive
11
12 drugs therapy, although the effect was not significant in the JLD alone group.
13
14 Moreover, JLD was found to be effective in terms of improving QOL when compared
15
16 with antihypertensive drugs. However, the evidence for JLD as an effective modality
17
18 for treating EH was restricted by a limited number of trials, small sample sizes, poor
19
20 methodological quality, and a high risk of bias in primary studies.
21
22
23
24
25
26
27

28 29 **Limitations**

30
31
32
33
34 The following limitations should be considered before accepting the findings of
35
36 this review.

37
38
39 (1) Although there were two randomized, single-blind, controlled trials, the
40
41 methodology of most of the included trials was assessed to be generally poor. The
42
43 main reasons are analyzed as follows:
44

45
46 Firstly, although all studies claimed randomization, only four trials demonstrated
47
48 the random sequence generation, and two trials reported allocation concealment;
49
50 therefore, selection bias may exist. Secondly, only three trials described the blinding
51
52 of the participants and personnel; however, no trials reported the blinding of outcome
53
54 assessment. Therefore, both selection bias and detection bias might have occurred.
55
56
57
58
59
60

1
2
3
4 Thirdly, only three trials reported drop-out or withdraw statistics, suggesting a high
5
6 risk of attrition bias. Fourthly, most of the included studies did not mention intention
7
8 to treat analysis, which may lead to some other bias. Fifthly, no trials had a
9
10 pre-estimation of sample size. Sixthly, no trial had a placebo control, which might
11
12 decrease the quality of positive conclusions.
13
14

15
16 (2) As shown in Figure 2c, heterogeneity is another critical issue that should be
17
18 considered, which may be associated with variations in study quality, participants,
19
20 JLD compositions, and antihypertensive drugs.
21
22

23
24 (3) Limited number of included trials and different interventions in both the JLD
25
26 and antihypertensive drugs groups restricted us from conducting meaningful subgroup
27
28 analyses to explore effect modifiers such as duration of intervention and types of
29
30 antihypertensive drug therapies.
31
32

33
34 (4) Publication bias should also be considered. In this review, all of the included
35
36 trials were conducted in China and published in Chinese. Almost all studies claimed a
37
38 similar beneficial effect or a better effect when compared with antihypertensive drugs
39
40 alone. No negative conclusions were found. What is more, a funnel plot checking for
41
42 possible publication bias for BP could not be conducted due to the small number of
43
44 included studies.
45
46
47

48
49 (5) Although one trial had a short-term follow up, most of the studies had no
50
51 follow up, indicating a lack of knowledge for some critical outcomes, such as
52
53 all-cause mortality and progression to severe complications due to high BP, which is
54
55 the most common problem for TCM studies in general.
56
57
58
59
60

1
2
3
4 (6) As the use of natural products is very common among patients in a variety of
5
6 health care settings, the safety of CHM and potential herb-drug interactions has hence
7
8 become a concern. This review suggested that JLD may be safe for the management
9
10 of EH. In fact, no parallel double blind randomized placebo-controlled trials
11
12 indicating the adverse effects of JLD for EH could be found. Due to the insufficient
13
14 clinical data, it is difficult to draw a definitive conclusion regarding the safety of JLD
15
16 for EH at present. We therefore suggest that the adverse effects of JLD need to be
17
18 monitored rigorously in future studies.
19
20
21
22
23
24
25

26 CONCLUSION

27
28
29
30
31 Due to the insufficient clinical data, poor methodological design, and high risk of
32
33 bias, it is difficult to draw a definite conclusion regarding the effectiveness and safety
34
35 of JLD for EH. More rigorously designed trials according to the CONSORT
36
37 Statement are needed.⁵²⁻⁵⁴
38
39
40
41
42
43

44 Funding

45
46 XJX was supported by the National Natural Science Foundation Project of China (No.
47
48 81403375). The funders had no role in study design, data collection and analysis,
49
50 decision to publish, or preparation of the manuscript.
51
52
53
54

56 Competing interests

1
2
3
4 None.
5
6
7

8 **Contributors**

9
10 XX conceived the idea for the study and designed the method of this systematic
11
12 review and meta-analysis including the inclusion and exclusion criteria. XX also
13
14 performed data collection and extraction, conducted the statistical analysis, and wrote
15
16 the first draft of the article. PW, XL, and YZ searched the articles and assessed their
17
18 methodological quality. Disagreement was resolved by discussion between XX, PW,
19
20 XL, and YZ. PW performed the major revision, interpreted the results, and made
21
22 comments. All of the authors approved the final version of the manuscript.
23
24
25
26
27
28
29

30 **Provenance and peer review**

31
32 Not commissioned; externally peer reviewed.
33
34
35
36
37
38
39

40 **Data sharing statement**

41
42 No additional data available.
43
44

45 **REFERENCES**

- 46
47 1. Lawes CM, Hoorn SV, Rodgers A, and for the International Society of
48
49 Hypertension. Global burden of blood-pressure-related disease 2001. *Lancet* 2008;
50
51 371: 1513-1518.
52
53
54
55 2. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the
56
57 management of high blood pressure in adults report from the panel members
58
59
60

- 1
2
3
4 appointed to the Eighth Joint National Committee (JNC 8). *J Am Med Assoc* 2014;
5
6 311: 507-520.
7
8
9 3. Ezzati M, Lopez AD, Rodgers A, et al. Comparative risk assessment
10 collaborative group: selected major risk factors and global and regional burden of
11 disease. *Lancet* 2002; 360: 1347-1360.
12
13
14
15
16 4. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension:
17 analysis of worldwide data. *Lancet* 2005; 365: 217-223.
18
19
20
21 5. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease
22 and risk factors 2001: systematic analysis of population health data. *Lancet* 2006;
23 367: 1747-1757.
24
25
26
27
28
29 6. Fisher JW. The diagnostic value of the sphygmomanometer in examinations for
30 life insurance. *J Am Med Assoc* 1914; 63: 1752-1754.
31
32
33
34 7. Lewington S, Clarke R, Qizilbash N, et al. Prospective Studies Collaboration.
35 Age-specific relevance of usual blood pressure to vascular mortality: a
36 meta-analysis of individual data for one million adults in 61 prospective studies.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54 8. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the
55 prevention of cardiovascular disease: meta-analysis of 147 randomised trials in
56 the context of expectations from prospective epidemiological studies. *Brit Med J*
57 2009; 338: b1665, 1-19.
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
9. Xiong XJ, Yang XC, Liu YM, et al. Chinese herbal formulas for treating
hypertension in traditional Chinese medicine: perspective of modern science.

- 1
2
3
4 *Hypertens Res* 2013; 36: 570-579.
- 5
6 10. Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and
7
8 control of hypertension in rural and urban communities in high-, middle-, and
9
10 low-income countries. *J Am Med Assoc* 2013; 310: 1-10.
- 11
12
13 11. Brook RD, Appel LJ, Rubenfire M, et al. Beyond medications and diet:
14
15 alternative approaches to lowering blood pressure. *Hypertension* 2013; 61:
16
17 1360-1383.
- 18
19
20
21 12. Mansoor GA. Herbs and alternative therapies in the hypertension clinic. *Am J*
22
23 *Hypertens* 2001; 14: 971-975.
- 24
25
26 13. Xiong XJ, Borrelli F, Ferreira AS, et al. Herbal medicines for cardiovascular
27
28 diseases. *Evid Based Complement Alternat Med* 2014; 2014: e809741, 1-3.
- 29
30
31 14. Wang J, Xiong XJ. Current situation and perspectives of clinical study in
32
33 integrative medicine in China. *Evid Based Complement Alternat Med* 2012; 2012:
34
35 e268542, 1-11.
- 36
37
38 15. Wang J, Feng B, Yang XC, et al. Chinese herbal medicine for the treatment of
39
40 prehypertension. *Evid Based Complement Alternat Med* 2013; 2013: e493521,
41
42 1-9.
- 43
44
45 16. Tachjian A, Maria V, Jahangir A. Use of herbal products and potential
46
47 interactions in patients with cardiovascular diseases. *J Am Coll Cardiol* 2010; 55:
48
49 515-525.
- 50
51
52
53 17. Xiong XJ, Yang XC, Liu W, et al. Trends in the treatment of hypertension from
54
55 the perspective of traditional Chinese medicine. *Evid Based Complement Alternat*
56
57
58
59
60

- 1
2
3
4 *Med* 2013; 2013: e275279, 1-13.
- 5
6 18. Wang J, Xiong XJ. Control strategy on hypertension in Chinese medicine. *Evid*
7
8 *Based Complement Alternat Med* 2012; 2012: e284847, 1-6.
- 9
10
11 19. Wang J, Xiong XJ. Evidence-based Chinese Medicine for Hypertension. *Evid*
12
13 *Based Complement Alternat Med* 2013; 2013: e978398, 1-12.
- 14
15
16 20. Wang J, Xiong XJ. Outcome measures of Chinese herbal medicine for
17
18 hypertension: an overview of systematic reviews. *Evid Based Complement*
19
20 *Alternat Med* 2012; 2012: e697237, 1-10.
- 21
22
23 21. Wang J, Feng B, Yang XC, et al. Tianma gouteng yin as adjunctive treatment for
24
25 essential hypertension: a systematic review of randomized controlled trials. *Evid*
26
27 *Based Complement Alternat Med* 2013; 2013: e706125, 1-18.
- 28
29
30 22. Xiong XJ, Yang XC, Feng B, et al. Zhen gan xi feng decoction, a traditional
31
32 Chinese herbal formula, for the treatment of essential hypertension: a systematic
33
34 review of randomized controlled trials. *Evid Based Complement Alternat Med*
35
36 2013; 2013: e982380, 1-9.
- 37
38
39 23. Wang J, Yang XC, Feng B, et al. Is Yangxue Qingnao Granule combined with
40
41 antihypertensive drugs, a new integrative medicine therapy, more effective than
42
43 antihypertensive therapy alone in treating essential hypertension?. *Evid Based*
44
45 *Complement Alternat Med* 2013; 2013: e540613, 1-8.
- 46
47
48 24. Xiong XJ, Liu W, Yang XC, et al. Ginkgo biloba extract for essential
49
50 hypertension: a systemic review. *Phytomedicine* 2014; 21: 1131-1136.
- 51
52
53
54
55
56 25. Wang J, Yao KW, Yang XC, et al. Chinese patent medicine liu wei di huang wan
57
58
59
60

- 1
2
3
4 combined with antihypertensive drugs, a new integrative medicine therapy, for
5
6 the treatment of essential hypertension: a systematic review of randomized
7
8 controlled trials. *Evid Based Complement Alternat Med* 2012; 2012: e714805,
9
10
11 1-7.
- 12
13
14 26. Wang J, Feng B, Xiong XJ. Chinese herbal medicine for the treatment of
15
16 obesity-related hypertension. *Evid Based Complement Alternat Med* 2013; 2013:
17
18 e757540, 1-11.
- 19
20
21 27. Lu AP, Jia HW, Xiao C, et al. Theory of traditional Chinese medicine and
22
23 therapeutic method of diseases. *World J Gastroenterol* 2004; 10: 1854-1856.
- 24
25
26 28. Jiang WY. Therapeutic wisdom in traditional Chinese medicine: a perspective
27
28 from modern science. *Trends Pharmacol Sci* 2005; 26: 558-563.
- 29
30
31 29. Ge HX, Dai XM, Zhang ZX, et al. Modern application and experimental research
32
33 progress of jian ling decoction. *Zhong Yi Yao Xue Bao* 2002; 30: 21-23.
- 34
35
36 30. Yu HW. Effect of modified jian ling decoction on insulin resistance and serum
37
38 levels of TNF- α in patients with essential hypertension. *Haerbin: Heilongjiang*
39
40 *Zhong Yi Yao Da Xue* 2008; 1-56.
- 41
42
43 31. Cao JM. Effect of modified jian ling decoction on serum leptin and angiotensin II
44
45 in hypertension with insulin resistance. *Haerbin: Heilongjiang Zhong Yi Yao Da*
46
47 *Xue* 2012; 1-51.
- 48
49
50
51 32. Jiang CX. Effect of modified jian ling decoction on blood pressure and
52
53 angiotensin II in elderly hypertensive patients. *Haerbin: Heilongjiang Zhong Yi*
54
55 *Yao Da Xue* 2012; 1-51.
- 56
57
58
59
60

- 1
2
3
4 33. Zhang N, Sun JL, Dong ZZ, *et al.* Effect of modified jian ling decoction on
5
6 insulin resistance and serum interleukin-6 of essential hypertension patients.
7
8 *Zhongguo Zhong Yi Yao Xin Xi Za Zhi* 2011; 18: 19-21.
9
10
11 34. Feng DR, Wei B. Effects of jian ling decoction on the blood lipid and lipid
12
13 peroxidation in experimental hyperlipidemia rats with yin deficiency of liver
14
15 and kidney. *Guangxi Zhong Yi Yao* 2009; 32: 51-54.
16
17
18 35. Huang YT, Wu CB, Zeng QM. Effect of jian ling decoction on 120 patients of
19
20 essential hypertension. *Zhongguo Zhong Xi Yi Jie He Za Zhi* 1996; 16: 561.
21
22
23 36. Hao HY, Wang QH, Sun CJ, *et al.* Effect of modified jian ling decoction on 30
24
25 patients of essential hypertension. *Shanxi Zhong Yi* 1998; 19: 541.
26
27
28 37. Guan DM, Du SQ. Clinical observation on the effect of jian ling decoction
29
30 combined with urapidil on stage III hypertension with high-risk. *Zhongguo She*
31
32 *Qu Yi Shi* 2013; 15: 214-215.
33
34
35 38. Higgins JPT, Green S. *Cochrane Handbook for Systematic Reviews of*
36
37 *Interventions, Version 5.1.0.* The Cochrane Collaboration.
38
39 <http://handbook.cochrane.org/>. 2011.
40
41
42 39. Li YB, Cui M, Yang Y, *et al.* Similarity of traditional Chinese medicine formula.
43
44 *Zhong Hua Zhong Yi Yao Xue Kan* 2012; 30: 1096-1097.
45
46
47 40. Tong WH. Analysis on clinical therapeutic effect of jian ling decoction on
48
49 essential hypertension with yin deficiency and yang hyperactivity syndrome.
50
51 *Zhongguo Yi Yao Zhi Nan* 2013; 11: 258-259.
52
53
54 41. He T, Zhu YQ, Xu SX. Effect of jian ling decoction on 30 hypertensive patients
55
56
57
58
59
60

- with yin deficiency and yang hyperactivity syndrome. *Zhong Yi Yao Dao Bao* 2012; 18: 50-51.
42. Fan R, Zhou H, Tan HY. Effect of jian ling decoction on aged hypertension patient's life mass and CAT. *Zhongguo Xian Dai Yi Xue Za Zhi* 2005; 15: 1706-1708.
43. Cai XP. Combined traditional Chinese and western medicine in the treatment of 50 patients with essential hypertension. *Guagndong Yi Xue* 1995; 16: 400-402.
44. Zhang N. Effect of modified jian ling decoction on essential hypertension. *Haerbin: Heilongjiang Zhong Yi Yao Da Xue* 2004; 1-34.
45. Zhang N. Effect of modified jian ling decoction on insulin resistance and serum levels of IL-6 in essential hypertension. *Haerbin: Heilongjiang Zhong Yi Yao Da Xue* 2009; 1-51.
46. Jiang CX, Cao JM. Effect of modified jian ling decoction on renin-angiotensin II in patients with senile hypertension. *Zhongguo Zhong Yi Yao Ke Ji* 2012; 19: 145.
47. Chu GM, Xu JY. Effect of modified jian ling decoction on high-sensitivity C-reactive protein on 67 cases of hypertensive patients. *Zhong Yi Yao Xin Xi* 2013; 30: 66-67.
48. Liu L, Jin J, Yu HW. Effect of modified jian ling decoction on insulin resistance and TNF- α level in patients of EH. *Zhong Yi Yao Xin Xi* 2008; 25: 68-70, 80.
49. Li CM. Effect of modified jian ling decoction on senile primary hypertension. *Jinan: Shandong Zhong Yi Yao Da Xue* 2013; 1-30.
50. Xiong XJ, Liu W, Yang XC, et al. Moxibustion for essential hypertension.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Complement Ther Med 2014; 22: 187-195.

51. Croog SH, Levine S, Testa MA, et al. The effect of antihypertensive therapy on the quality of life. *N Engl J Med* 1986; 314: 1657-1659.

52. Liu JP, Han M, Li XX, et al. Prospective registration, bias risk and outcome-reporting bias in randomised clinical trials of traditional Chinese medicine: An empirical methodological study. *BMJ Open* 2013; 3: e002968, 1-7.

53. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. *Ann Intern Med* 2012; 152: 726-732.

54. Gagnier JJ, Boon H, Rochon P, et al. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. *Ann Intern Med* 2006; 144: 364-367.

1
2
3
4 **Table 1. Basic characteristics of the included studies.**
5
6
7

8
9 **Table 2. Herbal medicines in the included studies.**
10
11

12
13
14 **Table 3. Methodological quality of included studies based on the Cochrane**
15 **handbook.**
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FIGURE LEGENDS**Figure 1.****Flow diagram of study selection and identification.****Figure 2.****Effect of JLD on BP. (a) JLD *versus* AD and (b) JPAD *versus* AD.**

AD: antihypertensive drugs; BP: blood pressure; DBP: diastolic blood pressure; JLD:

Jian Ling Decoction; JPAD: Jian Ling Decoction plus antihypertensive drugs; SBP:

systolic blood pressure.

Table 1. Basic characteristics of the included studies.

Study ID	Sample size (randomized /analyzed) M/F	Age(yrs)	Diagnosis standard	Intervention	Control	Course (week)	Outcome measures
Tong 2013 [40]	60/60 T: 30 C: 30 F/M: NR	40-60 (T/C: NR)	GCRNDTC M	JLD (1 dose/d)	felodipine (5 mg, qd)	4	BP
He et al. 2012 [41]	60/60 T: 15/15 C: 17/13	T: 54.89 ± 5.34 C: 57.36 ± 6.47	GCRNDTC M	JLD (1 dose/d)	felodipine (5 mg, qd)	4	BP
Fan 2005 [42]	50/50 T: 14/11 C: 13/12	T: 64.80 ± 7.40 C: 63.70 ± 6.90	WHO -ISH GMH-1999	JLD (1 dose/d)	felodipine (2.5 mg, qd)	4	BP; QOL
Cai 1995 [43]	100/100 T: 35/15 C: 34/16	T: 50-81 C: 47-84	WHO -ISH GMH-1985	modified JLD (1 dose/d) + control	nifedipine (10 mg, tid)	4	BP; adverse effect
Zhang 2004 [44]	90/89 T1: 16/14 T2: 17/13 C: 15/14	T1: 58.23 ± 8.26 T2: 58.45 ± 6.87 C: 59.16 ± 9.28	WHO -ISH GMH-1999	T1: modified JLD (1 dose/d) T2: modified JLD (1 dose/d) + control	enalapril (10 mg, bid)	4	BP; adverse effect
Zhang 2009 [45]	60/57 T: 15/14 C: 12/16	T: 56.41 ± 10.98 C: 58.57 ± 8.21	CGMH-200 5	modified JLD (1 dose/d) + control	enalapril (10 mg, bid)	3	BP; adverse effect
Jiang and Cao 2012 [46]	82/82 T: 26/16 C: 23/17	T: 60-75 C: 62-75	WHO -ISH GMH-1999	modified JLD (100 ml/d) + control	benazepril hydrochloride (10 mg, tid)	4	BP
Chu and Xu 2013 [47]	67/67 T: 19/15 C: 17/16	T: 67.00 ± 7.20 C: 68.00 ± 5.90	WHO -ISH GMH-1999	modified JLD (100 ml/d) + control	nifedipine controlled release tablet (30 mg, qd)	4	BP
Liu et al. 2008 [48]	60/60 T: 30 C: 30 F/M: NR	18-70 (T/C: NR)	JNC 7	modified JLD (100 ml/d) + control	enalapril (10 mg, bid)	3	BP; adverse effect
Li 2013 [49]	60/60 T: 16/14 C: 17/13	T: 64.33 ± 7.96 C: 61.20 ± 10.23	CGMH-201 0	modified JLD (400 ml/d) + control	nifedipine controlled release tablet (30 mg, qd) and irbesartan (150 mg, qd)	4	BP; adverse effect

Abbreviations: BP: blood pressure; C: control group; CGMH: Chinese Guidelines for the Management of Hypertension; F: female; GCRNDTCM: Guidelines of Clinical Research of New Drugs of Traditional Chinese Medicine; JLD: Jian Ling Decoction; JNC 7: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; M: male; NR: not reported; QOL: quality of life; T: treatment group; WHO-ISH GMH: WHO-ISH guidelines for the management of hypertension.

Table 2. Herbal medicines in the included studies.

Study ID	Formula	Composition of formula
Tong 2013 [40]	JLD	Arbor Vitae Seed (Baiziren, Semen Platycladi) 10 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 10 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 15 g, Oyster Shell (Muli, Concha Ostreae) 10 g, Fossilized Mammal Bones (Longgu, Os Draconis) 10 g, Hematite (Daizheshi, Haematitum) 10 g, Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 15 g, and Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 20 g.
He et al. 2012 [41]	JLD	Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 15 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 20 g, Hematite (Daizheshi, Haematitum) 10 g, Oyster Shell (Muli, Concha Ostreae) 10 g, Fossilized Mammal Bones (Longgu, Os Draconis) 10 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 15 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 10 g, and Arbor Vitae Seed (Baiziren, Semen Platycladi) 10 g.
Fan 2005 [42]	JLD	Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 30 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 30 g, Hematite (Daizheshi, Haematitum) 24 g, Oyster Shell (Muli, Concha Ostreae) 18 g, Fossilized Mammal Bones (Longgu, Os Draconis) 18 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 18 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 12 g, and Arbor Vitae Seed (Baiziren, Semen Platycladi) 12 g.
Cai 1995 [43]	modified JLD	Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 30 g, Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 30 g, Abalone Shell (Shijueming, Haliotidis Concha) 30 g, Hematite (Daizheshi, Haematitum) 24 g, Oyster Shell (Muli, Concha Ostreae) 18 g, Fossilized Mammal Bones (Longgu, Os Draconis) 18 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 18 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 12 g, and Arbor Vitae Seed (Baiziren, Semen Platycladi) 12 g. Headache plus Puncturevine Caltrop Fruit (Cijili, Tribulus terrestris Linn) 10 g; constipation plus Rhubarb Root and Rhizome (Daihuang, Radix Et Rhizoma Rhei) 5 g.
Zhang 2004 [44]	modified JLD	Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 30 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 30 g, Hematite (Daizheshi, Haematitum) 24 g, Oyster Shell (Muli, Concha Ostreae) 18 g, Fossilized Mammal Bones (Longgu, Os Draconis) 18 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 18 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 12 g, and Arbor Vitae Seed (Baiziren, Semen Platycladi) 12 g. Headache, dizziness, and irritability plus Gastrodia (Tianma, Gastrodiae Rhizoma) 15 g and Abalone Shell (Shijueming, Haliotidis Concha) 30 g; irritability, bitty mouth and red face plus Coptis Rhizome (Huanglian, Rhizoma Coptidis) 10 g and Gardenia (Zhizi, Fructus Gardeniae Jasminoidis) 10 g; and constipation plus Rhubarb Root and Rhizome (Daihuang, Radix Et Rhizoma Rhei) 5 g.
Zhang 2009 [45]	modified JLD	Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 30 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 30 g, Hematite (Daizheshi, Haematitum) 24 g, Oyster Shell (Muli, Concha Ostreae) 18 g, Fossilized Mammal Bones (Longgu, Os Draconis) 18 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 18 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 12 g, and Arbor Vitae Seed (Baiziren, Semen Platycladi) 12 g. Excessive accumulation of phlegm-dampness plus Pinellia Rhizome (Banxia, Rhizoma Pinelliae Tematae) 15 g, Sclerotium of Tuckahoe (Fuling, Scierotium Poriae Cocos) 15 g, Tangerine Peel (Chenpi, Pericarpium Citri Reticulatae) 10 g, Bamboo Shavings (Zhuru, Bambusae Caulis in Taeniam) 10 g, and Liquoric Root (Gancao, Radix Glycyrrhizae) 3 g.
Jiang and Cao	modified	Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 30 g, Fresh Water Turtle Shell (Guijia, Plastrum

2012 [46]	JLD	Testudinis) 30 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 30 g, Hematite (Daizheshi, Haematitum) 20 g, Oyster Shell (Muli, Concha Ostreae) 20 g, Fossilized Mammal Bones (Longgu, Os Draconis) 20 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 20 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 15 g, and Arbor Vitae Seed (Baiziren, Semen Platycladi) 15 g.
Chu and Xu 2013 [47]	modified JLD	Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 25 g, Fresh Water Turtle Shell (Guijia, Plastrum Testudinis) 25 g, Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 30 g, Hematite (Daizheshi, Haematitum) 15 g, Oyster Shell (Muli, Concha Ostreae) 25 g, Fossilized Mammal Bones (Longgu, Os Draconis) 25 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 25 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 20 g, and Arbor Vitae Seed (Baiziren, Semen Platycladi) 20 g.
Liu et al. 2008 [48]	modified JLD	Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 30 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 18 g, Hematite (Daizheshi, Haematitum) 24 g, Oyster Shell (Muli, Concha Ostreae) 18 g, Fossilized Mammal Bones (Longgu, Os Draconis) 18 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 30 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 20 g, and Arbor Vitae Seed (Baiziren, Semen Platycladi) 20 g. Excessive accumulation of phlegm-dampness plus Pinellia Rhizome (Banxia, Rhizoma Pinelliae Tematae) 15 g, Sclerotium of Tuckahoe (Fuling, Scierotium Poriae Cocos) 15 g, Tangerine Peel (Chenpi, Pericarpium Citri Reticulatae) 10 g, Bamboo Shavings (Zhuru, Bambusae Caulis in Taeniam) 10 g, and Liquoric Root (Gancao, Radix Glycyrrhizae) 3 g.
Li 2013 [49]	modified JLD	Fossilized Mammal Bones (Longgu, Os Draconis) 30 g, Oyster Shell (Muli, Concha Ostreae) 30 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 20 g, Hematite (Daizheshi, Haematitum) 20 g, Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 30 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 30 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 20 g, Arbor Vitae Seed (Baiziren, Semen Platycladi) 15 g, Gambir Vine Stems and Thorns (Gouteng, Ramulus Uncariae Cum Uncis) 30 g, Pueraria (Gegen, Radix Puerariae) 30 g, Gastrodia (Tianma, Gastrodiae Rhizoma) 15 g, Chinese Taxillus Twig (Sangjisheng, Herba Taxilli) 30 g, Eucommia Bark (Duzhong, Cortex Eucommiae Ulmoidis) 15 g, and Coptis Rhizome (Huanglian, Rhizoma Coptidis) 9 g.

Abbreviations: JLD: Jian Ling Decoction.

Table 3. Methodological quality of included studies based on the Cochrane handbook.

Included trials	A	B	C	D	E	F	G
Tong 2013 [40]	?	?	?	?	+	?	?
He et al. 2012 [41]	+	?	?	?	+	?	?
Fan 2005 [42]	?	?	?	?	+	?	?
Cai 1995 [43]	?	+	?	?	+	?	?
Zhang 2004 [44]	+	+	+	?	+	?	?
Zhang 2009 [45]	+	?	+	?	+	?	?
Jiang and Cao 2012 [46]	?	?	?	?	+	?	?
Chu and Xu 2013 [47]	?	?	?	?	+	?	?
Liu et al. 2008 [48]	+	+	+	?	+	?	?
Li 2013 [49]	?	?	?	?	+	?	?

Abbreviations: A: Adequate sequence generation; B: Concealment of allocation; C: Blinding (participants and personnel); D: Blinding (assessor); E: Incomplete outcome data addressed (ITT analysis); F: Free of selective reporting; G: other potential threat to validity; +: low risk; -: high risk; ?: unclear.

Figure 1. Flow diagram of study selection and identification.







Figure 2. Effect of JLD on BP. (a) JLD versus AD and (b) JPAD versus AD.**(a) JLD versus AD: BP****(b) JPAD versus AD: SBP (mmHg)****(b) JPAD versus AD: DBP (mmHg)**

AD: antihypertensive drugs; BP: blood pressure; DBP: diastolic blood pressure; JLD:

Jian Ling Decoction; JPAD: Jian Ling Decoction plus antihypertensive drugs; SBP:

systolic blood pressure.



PRISMA 2009 Checklist

Section/Topic	#	Checklist Item	Reported on Page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	P1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	P2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	P5-8
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	P8
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	NA
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	P9-11
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	P8-9
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	P9
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	P11
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	P11-12
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	P11-12
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	P12
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	P12-13
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	P12-13



PRISMA 2009 Checklist

Section/Topic	#	Checklist Item	Reported on Page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	P12-13
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	P12-13
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	P13
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	P13-15
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	P15
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	P16-17
Synthesis of results	21	Present the main results of the review. If meta-analyses done, include for each, confidence intervals and measures of consistency.	P16-17
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	P15
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	P18
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	P18-19
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	P19-21
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	P21
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	P21

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.






Fig 1 Flow diagram of study selection and identification.
159x171mm (300 x 300 DPI)




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



(a) JLD versus AD: BP



(b) JPAD versus AD: SBP (mmHg)



(b) JPAD versus AD: DBP (mmHg)

Figure 2. Effect of JLD on BP. (a) JLD versus AD and (b) JPAD versus AD. AD: antihypertensive drugs; BP: blood pressure; DBP: diastolic blood pressure; JLD: Jian Ling Decoction; JPAD: Jian Ling Decoction plus antihypertensive drugs; SBP: systolic blood pressure.
145x156mm (300 x 300 DPI)

BMJ Open

Chinese herbal medicine Jian Ling Decoction for essential hypertension: A systematic review and meta-analysis of randomized controlled trials

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-006502.R2
Article Type:	Research
Date Submitted by the Author:	10-Nov-2014
Complete List of Authors:	Xiong, Xing-jiang; Guang'anmen Hospital, Wang, Pengqian; China Academy of Chinese Medical Sciences, Institute of Basic Research in Clinical Medicine Li, Xiaoke; McLean Hospital, Harvard medical school, Bio-organic and Natural Products Laboratory Zhang, Yuqing; McMaster University, Department of Clinical Epidemiology and Biostatistics
Primary Subject Heading:	Complementary medicine
Secondary Subject Heading:	Complementary medicine, Cardiovascular medicine
Keywords:	essential hypertension, Chinese herbal medicine, Jian Ling Decoction, systematic review, blood pressure

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

Chinese herbal medicine Jian Ling Decoction for essential hypertension: A systematic review and meta-analysis of randomized controlled trials

Xingjiang Xiong^{1*}, Pengqian Wang², Xiaoke Li³, and Yuqing Zhang⁴

¹ Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China

² Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China

³ Bio-organic and Natural Products Laboratory, McLean Hospital, Harvard Medical School, Belmont, MA, USA

⁴ Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada

Total word count: 3200.

Number of tables and figures: 3 tables and 2 figures.

Running head: Jian Ling Decoction for essential hypertension.

53
54
55
56
57
58
59
60

* *BMJ Open* 2014

Correspondence to: Xingjiang Xiong, MD, Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beixiange 5#, Xicheng District, Beijing 100053, China. Tel: +10 88001817. Fax: +10 88001229. E-mail: xiongxingjiangtcm@163.com or 5administration@163.com.

ABSTRACT

Objectives: Jian Ling Decoction (JLD) is often prescribed to improve hypertension-related symptoms in China. However, this treatment has not been systematically reviewed for its efficacy against essential hypertension (EH). This review aims to assess the current clinical evidence of JLD in the treatment of EH.

Design: Seven electronic databases including the Cochrane Central Register of Controlled Trials, PubMed, EMBASE, the Chinese National Knowledge Infrastructure (CNKI), the Chinese Scientific Journal Database (VIP), the Chinese Biomedical Literature Database (CBM), and the Wanfang Database were searched up to March 2014. Randomized control trials (RCTs) comparing JLD or combined with antihypertensive drugs versus antihypertensive drugs were included. We assessed the methodological quality, extracted the valid data, and conducted the meta-analysis according to criteria from the Cochrane group. The primary outcome was categorical or continuous blood pressure (BP), and the secondary outcome was quality of life (QOL).

Results: Ten trials (655 patients) with unclear-to-high risk of bias were identified. Meta-analysis showed that JLD used alone showed no BP reduction effect; however, improvement on QOL was found when compared to antihypertensive drugs. A significant reduction on systolic BP and diastolic BP were observed for JLD plus antihypertensive drugs when compared to antihypertensive drugs alone. No serious adverse effects were reported.

Conclusion: Due to insufficient clinical data, it is difficult to draw a definite

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

conclusion regarding the effectiveness and safety of JLD for EH, and better trials are needed.

For peer review only

KEY WORDS

essential hypertension; blood pressure; Chinese herbal medicine; Jian Ling Decoction;
systematic review

For peer review only

ARTICLE SUMMARY

Article focus

- Jian Ling Decoction (JLD), a traditional Chinese herbal formula, is often prescribed for patients with essential hypertension (EH).

Key messages

- No definitive conclusion regarding the efficacy and safety of JLD for EH could be drawn based on the insufficient clinical data

Strengths and limitations of this study

- The strength of this article is its use of a comprehensive and unbiased literature searching of seven electronic databases without language and publication restrictions.
- The included trials were of small sample size, with poor methodological quality and significant heterogeneity.

INTRODUCTION

Hypertension is one of the most important preventable causes of death and one of the most common conditions treated in primary health care. In addition, hypertension represents an important public health challenge because of its high prevalence and the concomitant increase in the risk of cardiovascular, cerebrovascular and renal diseases.^{1,2} This condition has been ranked as the leading global risk factor for mortality and is the third leading risk factor for disease burden according to the comparative Risk Assessment Collaborating Group.^{3,4} Currently, about one billion patients have been affected.⁵ The association between blood pressure (BP) and mortality was discovered approximately 100 years ago.⁶ Recent studies also confirmed that BP is closely related to vascular outcomes, and even a minor reduction in BP could reduce cardiovascular events, especially stroke.^{7,8} Therefore, early diagnosis and effective treatment is of great importance for patients with essential hypertension (EH). Nevertheless, despite remarkable achievements in the research and development of antihypertensive drugs, the current awareness, curative and control rates of hypertension among different age groups is still far from satisfactory.^{9,10} Additionally, in the light of the adverse effects of antihypertensive drugs and hoping for an adjunctive approach with few adverse effects, patients in Western countries with EH and other cardiovascular diseases increasingly use complementary and alternative medicine (CAM),¹¹⁻¹³ including traditional Chinese medicine (TCM).¹⁴⁻¹⁶

1
2
3
4 Chinese herbal medicine (CHM), one of the commonly used TCM therapies, has
5
6 played an important role in relieving hypertension-related signs and symptoms for
7
8 centuries in East Asia.^{17,18} Recently, more robust evidence from systematic reviews
9
10 (SRs) has suggested the efficacy and safety of CHM for EH.¹⁹⁻²⁶ In TCM theory, liver
11
12 yang hyperactivity syndrome (LYHS) and liver-kidney yin deficiency syndrome
13
14 (LKYDS) are the two most important patterns of EH, which often appear at the same
15
16 time.¹⁷ These patterns manifest as headache, vertigo, tinnitus, irritability, insomnia,
17
18 lassitude in the waist and legs, dysphoria with feverish sensation, dry mouth, bright
19
20 red tongue with less fur, and a wiry pulse.^{14,17,21,27,28} Jian Ling Decoction (JLD) is a
21
22 traditional CHM invented by *Zhang Xichun* in *Yixue Zhongzhong Canxilu* (Records of
23
24 Traditional Chinese in Combination with Western Medicine) in the 1920s. It contains
25
26 the following eight commonly used herbs: Dioscorea Root (Shanyao, *Dioscoreae*
27
28 *Rhizoma*), Achyranthes Root (Niuxi, *Achyranthis Bidentatae Radix*), Hematite
29
30 (Daizheshi, *Haematitum*), Fossilized Mammal Bones (Longgu, *Os Draconis*), Oyster
31
32 Shell (Muli, *Concha Ostreae*), Rehmannia (Dihuang, *Radix Rehmanniae Glutinosae*),
33
34 White Peony Root (Baishao, *Radix Albus Paeoniae Lactiflorae*), and Arbor Vitae
35
36 Seed (Baiziren, *Semen Platycladi*). All of these herbs have been recorded in the
37
38 Pharmacopoeia of the People's Republic of China (2010 edition). Both LYHS and
39
40 LKYDS can be effectively treated with JLD.¹⁹ Currently, JLD is often prescribed for
41
42 the management of EH by TCM practitioners in China. It is worth noting that in the
43
44 context of CAM therapies, add-on designs are very popular for the treatment of
45
46 hypertension.^{14,20-25} JLD is usually used in combination with antihypertensive drugs
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 to achieve greater improvement in the signs and symptoms of hypertension and to
5
6 enhance the antihypertensive effect of conventional drugs with less adverse effects.
7
8
9 The pharmacological mechanisms of these effects may be related to the reduction in
10
11 levels of angiotensin II, IL-6, tumor necrosis factor- α (TNF- α), and leptin, as well as
12
13 insulin resistance and decreased blood lipids.²⁹⁻³⁴ Regarding the clinical use of JLD, a
14
15 large number of studies (including case reports, case series, controlled observational
16
17 studies, and randomized trials) have reported its effects on EH, including lowering BP,
18
19 reducing inflammation, reversing cardiovascular risk factors, and improving clinical
20
21 symptoms and quality of life (QOL).³⁵⁻³⁷ However, there has been no comprehensive
22
23 evaluation of clinical trials on the efficacy and adverse effects of JLD. This review
24
25 aims to systematically review the published and unpublished randomized controlled
26
27 trials (RCTs) to evaluate the current evidence for JLD in treating EH.
28
29
30
31
32
33
34
35
36

37 **METHODS**

38
39
40
41 This study was conducted according to the Cochrane practice.³⁸
42
43
44
45

46 **Search strategies**

47
48
49
50
51 RCTs of JLD for the treatment of hypertensive patients were screened through
52
53 the following electronic databases from their respective inceptions to March 2014:
54
55
56 Cochrane Central Register of Controlled Trials (CENTRAL, 1996-2014), PubMed
57
58
59
60

1
2
3
4 (1959-2014), and EMBASE (1980-2014). In addition, as JLD is mainly prescribed in
5
6 China, four Chinese electronic databases including the Chinese National Knowledge
7
8 Infrastructure (CNKI, 1980-2014), Chinese Scientific Journal Database (VIP,
9
10 1989-2014), Chinese Biomedical Literature Database (CBM, 1978-2014), and
11
12 Wanfang Database (1998-2014) were searched to retrieve the maximum possible
13
14 number of trials. We also conducted a literature search of the website of the Chinese
15
16 clinical trial registry (available at <http://www.chictr.org/>) and international clinical
17
18 trial registry hosted by the US National Institutes of Health (available at
19
20 <http://clinicaltrials.gov/>) for all of the relevant ongoing registered clinical trials and
21
22 unpublished articles. The bibliographies of the studies identified in the systematic
23
24 search were reviewed for potentially relevant additional publications. No restriction
25
26 on publication status or language was imposed.
27
28
29
30
31
32

33
34 The keywords for databases searching were listed as follows: (“hypertension”
35
36 OR “essential hypertension” OR “primary hypertension” OR “high blood pressure”
37
38 OR “blood pressure”) AND (“*jian ling* decoction” OR “*jianling* decoction” OR “*jian*
39
40 *ling tang*” OR “*jianling tang*” OR “*jianlingtang*”) AND (“clinical trial” OR
41
42 “randomized controlled trial” OR “randomised controlled trial”).
43
44
45
46
47
48

49 **Study selection**

50 **Types of studies**

1
2
3 RCTs on the use of JLD for the treatment of EH were included.
4
5

6 Quasi-randomized trials and animal experiments were excluded.
7
8
9

10 11 **Types of participants** 12

13
14
15
16 Trials focused on the patients suffering from EH were included. All of the
17
18 participants who were enrolled in the trials were required to meet at least one of the
19
20 current or past definitions of EH.² Trials without a description of the detailed
21
22 diagnostic criteria but which reported patients with definite EH were also included .
23
24 Patients with secondary hypertension were excluded. There was no restriction on
25
26 gender, age, or ethnic origin of the participants.
27
28
29
30
31
32
33

34 **Types of interventions** 35

36
37
38 Only studies that tested JLD used alone versus antihypertensive drugs, or JLD
39
40 combined with antihypertensive drugs versus antihypertensive drugs were included.
41
42 However, trials assessing the combined effect of JLD with other interventions (*e.g.*,
43
44 another CHM, qigong, Tai Chi, acupuncture, moxibustion and massage) were
45
46 excluded given that the therapeutic effect of JLD could not be distinguished.
47
48
49 Interventions in the control group included antihypertensive drugs. Studies that used
50
51 non-conventional medicine or CAM as control groups were also excluded. The
52
53 duration of treatment was required to be at least two weeks.
54
55
56
57
58
59
60

1
2
3
4 According to the principle of similarity of the TCM formula,³⁹ modified JLD
5
6 should contain at least six out of eight herbs used in JLD, and only a few herbs could
7
8 be added into the JLD based on TCM syndrome theory. However, the resulting
9
10 prescription should contain the following four principal drugs: Achyranthes Root
11
12 (Niuxi, Achyranthis Bidentatae Radix), Hematite (Daizheshi, Haematitum), Fossilized
13
14 Mammal Bones (Longgu, Os Draconis), and Oyster Shell (Muli, Concha Ostreae).
15
16
17
18
19
20

21 **Types of outcome measures**

22
23
24
25

26 The primary outcome analyzed for this meta-analysis was categorical or
27
28 continuous BP, and secondary outcome was QOL.
29
30
31
32

33 **Data extraction**

34
35
36
37
38

39 All of the articles were read by two independent reviewers. Then, the eligible
40
41 studies were retrieved for further identification according to the above inclusion and
42
43 exclusion criteria. Duplicate papers were excluded. The data extraction form
44
45 comprised the authors, title, publication year, sample size, age, sex distribution,
46
47 diagnosis standard, study design, interventions in the treatment and control groups,
48
49 the composition of JLD or modified JLD, trial duration, outcome measures, and
50
51 adverse effects. If missing or unclear information regarding the original study was
52
53 found, we contacted the primary authors via email, telephone or fax whenever
54
55
56
57
58
59
60

possible. Any disagreement was resolved by discussion between the reviewers.

Methodological quality

The risk of bias of the included studies was independently evaluated by two reviewers according to the criteria in the Cochrane Handbook for Systematic Review of Interventions Version 5.1.0 (updated March 2011).³⁸ The following seven items were included: (a) sequence generation (selection bias); (b) allocation concealment (selection bias); (c) blinding of participants and personnel (performance bias); (d) blinding of outcome assessments (detection bias); (e) incomplete outcome data (attrition bias); (f) selective reporting (reporting bias); and (g) other sources of bias (from Chapter 8: assessing risk of bias in included studies).³⁸ Each domain was assessed as a “high”, “unclear”, or “low” risk of bias based on the above criteria. Then, the methodological quality of the trials was ranked into three levels: low risk of bias (all items with low risk of bias), high risk of bias (at least one item with high risk of bias), or unclear risk of bias (at least one item with an unclear domain).

Data synthesis

Review Manager, Version 5.1 (The Nordic Cochrane Centre, Copenhagen, Denmark) was used for data analysis. The values of the outcome measures after treatment were retrieved to assess differences between the JLD and control groups.

1
2
3
4 The weighted mean difference (WMD) was used for continuous data, while the risk
5
6 ratio (RR) was used for binary data. Subgroups analysis was conducted among
7
8 different types of comparisons (including JLD *versus* antihypertensive drugs and JLD
9
10 plus antihypertensive drugs *versus* antihypertensive drugs). If high quality trials could
11
12 be found, comparisons between all of the studies and studies with high quality would
13
14 be conducted. In a three-group design study that had two treatment groups of JLD and
15
16 JLD plus antihypertensive drugs, the two comparisons were split in the meta-analysis.
17
18 Heterogeneity was assessed by I^2 statistics.³⁸ Funnel plots were applied to detect for
19
20 publication bias when the number of included studies of any particular outcome was
21
22 more than ten. $P < 0.05$ was considered to be statistically significant.
23
24
25
26
27
28
29
30
31

32 RESULTS

33 34 35 36 Study characteristics

37
38
39
40
41 Figure 1 shows the process of study selection. We identified 308 potentially
42
43 relevant articles in the initial screening of the seven databases. Ten RCTs, with a total
44
45 of 655 participants, met the eligibility criteria and were included.⁴⁰⁻⁴⁹ The basic
46
47 characteristics of included trials are summarized in Table 1. Six diagnostic criteria of
48
49 EH were specified: two trials^{40,41} used the Guidelines of Clinical Research of New
50
51 Drugs of Traditional Chinese Medicine (GCRNDTCM); four trials^{42,44,46,47} used the
52
53 WHO-ISH guidelines for the management of hypertension-1999 (WHO -ISH
54
55
56
57
58
59
60

1
2
3
4 GMH-1999); one trial⁴³ used the WHO-ISH GMH-1985; one trial⁴⁵ used the Chinese
5
6 Guidelines for the Management of Hypertension-2005 (CGMH-2005); one trial⁴⁸ used
7
8 the Seventh Report of the Joint National Committee on Prevention, Detection,
9
10 Evaluation, and Treatment of High Blood Pressure (JNC 7); and one trial⁴⁹ used the
11
12 Chinese Guidelines for the Management of Hypertension-2010 (CGMH-2010). All of
13
14 the studies were conducted in China and published in Chinese language. One trial was
15
16 a three-arm design (two intervention groups versus one control group),⁴⁴ and the
17
18 others used a two-arm study design (one intervention group versus one control group).
19
20 The clinical efficacy of JLD was observed in all of the trials. However, the evaluation
21
22 criteria on BP was different: three trials used the categorical BP recommended by
23
24 Chinese government in GCRNDTCM,⁴⁰⁻⁴² and seven used continuous BP.⁴³⁻⁴⁹ QOL
25
26 was only tested in one trial.⁴²
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Treatment groups

The types of intervention were classified as JLD (n = 4) or combination therapy (JLD plus antihypertensive drugs, n = 7). The variable prescriptions based on JLD are presented in Table 1. Different compositions of either JLD or modified JLD are presented in Table 2.

Control groups

1
2
3
4 All of the patients in the control groups received antihypertensive drug treatment,
5
6 including felodipine,⁴⁰⁻⁴² nifedipine,^{43,47,49} enalapril,^{44,45,48} and benazepril
7
8 hydrochloride.⁴⁶
9
10

11 12 13 14 **Treatment duration**

15
16
17
18
19 The total treatment duration in the trials ranged from three to four weeks, with
20
21 most being four weeks (n = 8). The duration of follow-up was only mentioned in one
22
23 trial, being three months.⁴³
24
25
26
27

28 29 **Methodological quality**

30
31
32
33
34 As shown in Table 3, four trials reported the method used to generate the
35
36 allocation sequence (random number table).^{41,44,45,48} Information regarding allocation
37
38 concealment was provided in two trials.^{44,48} Blinding of participants and personnel
39
40 was reported in three trials;^{44,45,48} however, no trial used blinding of outcome
41
42 assessment. Drop-out and withdrawal data were provided for three trials.^{44,45,49} No
43
44 trial had a pre-trial estimation of sample size. Selective reporting could not be
45
46
47
48
49 evaluated as no preregistered protocols could be obtained from the primary authors.
50
51
52
53

54 55 56 57 58 59 **Outcome measures**

Primary outcome: BP

JLD *versus* antihypertensive drugs (4 studies)

The clinical efficacy of JLD as monotherapy for BP was assessed in four trials.^{40-42,44} Three trials⁴⁰⁻⁴² did not use continuous BP to evaluate the efficacy of JLD, but used categorical BP, the evaluation criteria of which has been authoritatively recommended by China Food and Drug Administration (available at <http://www.sda.gov.cn>). It was defined as follows: “significant improvement” (DBP decreased by 10 mmHg, reaching the normal range, or DBP not returning to normal but reduced by more than 20 mmHg), “improvement” (DBP decreased by less than 10 mmHg but reaching the normal range, DBP decreased by 10 to 19 mmHg but not reaching the normal range, or SBP decreased by more than 30 mmHg), and “no improvement” (not meeting the above standards).⁵⁰ These outcomes were converted into binary data for further overall analysis. Both “significant improvement” and “improvement” were classified as “effective”, and “no improvement” was classified as “ineffective”. The meta-analysis showed that JLD had no BP reduction effect compared with antihypertensive drugs ($n = 170$; RR: 0.99; 95% CI: 0.90 to 1.08; $P = 0.79$; Figure 2a), with no significant heterogeneity (chi-square = 0.22, $P = 0.90$; $I^2 = 0\%$). Another trial used continuous BP to evaluate the efficacy of modified JLD when compared with enalapril.⁴⁴ No significant difference was found for either SBP or DBP ($P > 0.05$).

JLD plus antihypertensive drugs *versus* antihypertensive drugs (7 studies)

Seven RCTs evaluated the effect of JLD combined with antihypertensive drugs versus antihypertensive drugs.⁴³⁻⁴⁹ Continuous BP was measured in all of these studies. SBP was significantly reduced in the JLD plus antihypertensive drugs group when compared with antihypertensive drugs (n = 485; WMD: -8.37 mmHg; 95% CI: -9.84 to -6.90; $P < 0.00001$; Figure 2b), with no significant heterogeneity (chi-square = 8.45, $P = 0.21$; $I^2 = 29\%$). For DBP, a significant beneficial effect was also found in the JLD plus antihypertensive drugs group (n = 485; WMD: -6.71 mmHg; 95% CI: -9.32, -4.10; $P < 0.00001$; Figure 2c), with significant heterogeneity (chi-square = 9.47, $P < 0.0001$; $I^2 = 80\%$).

Secondary outcome: QOL

Only one trial,⁴² conducted by Fan et al, used the Croog Scale⁵¹ to assess the effectiveness of JLD on QOL in aged hypertension patients. At the end of the trial, QOL was significantly improved by JLD when compared with the felodipine group ($P < 0.05$). The trial demonstrated that long-term use of JLD might improve QOL for hypertensive patients.

Adverse effects

1
2
3
4
5
6 Adverse effect monitoring was only reported in five studies [43-45, 48, 49] and
7
8 was not mentioned in the other five trials. Among the former, no severe adverse
9
10 effects were reported in two trials.^{43,49} Three trials reported dry cough caused by
11
12 enalapril in both the JLD and antihypertensive drugs groups.^{44,45,48} Two trials reported
13
14 severe dry cough in the antihypertensive drugs groups.^{44,45} None of the adverse effects
15
16 were serious in the JLD groups.
17
18
19
20
21
22
23

24 **Evaluation of publication bias**

25
26
27
28 As the number of included trials was so small, it was not possible to conduct a
29
30 sufficient additional analysis of publication bias.
31
32
33
34
35

36 **DISCUSSION**

37 38 39 40 41 **Summary of evidence**

42
43
44
45
46 Taking into account the gap between the lack of scientific evidence regarding the
47
48 efficacy of JLD and the widespread application by TCM practitioners, the objective of
49
50 this study was to systematically review the current English and Chinese literature to
51
52 evaluate the efficacy and safety of JLD for EH. To our knowledge, this is the first SR
53
54 of JLD in English.
55
56
57
58
59
60

1
2
3
4 Ten claimed RCTs, with a total of 655 hypertensive patients, met the inclusion
5
6 criteria and were included in this review. The results suggested that both SBP and
7
8 DBP were significantly improved in patients receiving JLD plus antihypertensive
9
10 drugs therapy, although the effect was not significant in the JLD alone group.
11
12 Moreover, JLD was found to be effective in terms of improving QOL when compared
13
14 with antihypertensive drugs. However, the evidence for JLD as an effective modality
15
16 for treating EH was restricted by a limited number of trials, small sample sizes, poor
17
18 methodological quality, and a high risk of bias in primary studies.
19
20
21
22
23
24
25
26

27 **Limitations**

28
29
30
31 The following limitations should be considered before accepting the findings of
32
33 this review.
34

35
36 (1) Although there were two randomized, single-blind, controlled trials, the
37
38 methodology of most of the included trials was assessed to be generally poor. The
39
40 main reasons are analyzed as follows:
41
42

43
44 Firstly, although all studies claimed randomization, only four trials demonstrated
45
46 the random sequence generation, and two trials reported allocation concealment;
47
48 therefore, selection bias may exist. Secondly, only three trials described the blinding
49
50 of the participants and personnel; however, no trials reported the blinding of outcome
51
52 assessment. Therefore, both selection bias and detection bias might have occurred.
53
54

55
56 Thirdly, only three trials reported drop-out or withdraw statistics, suggesting a high
57
58
59
60

1
2
3 risk of attrition bias. Fourthly, most of the included studies did not mention intention
4
5
6 to treat analysis, which may lead to some other bias. Fifthly, no trials had a
7
8
9 pre-estimation of sample size. Sixthly, no trial had a placebo control, which might
10
11 decrease the quality of positive conclusions.
12

13
14 (2) As shown in Figure 2c, heterogeneity is another critical issue that should be
15
16 considered, which may be associated with variations in study quality, participants,
17
18 JLD compositions, and antihypertensive drugs.
19

20
21 (3) Limited number of included trials and different interventions in both the JLD
22
23 and antihypertensive drugs groups restricted us from conducting meaningful subgroup
24
25 analyses to explore effect modifiers such as duration of intervention and types of
26
27 antihypertensive drug therapies.
28
29

30
31 (4) Publication bias should also be considered. In this review, all of the included
32
33 trials were conducted in China and published in Chinese. Almost all studies claimed a
34
35 similar beneficial effect or a better effect when compared with antihypertensive drugs
36
37 alone. No negative conclusions were found. What is more, a funnel plot checking for
38
39 possible publication bias for BP could not be conducted due to the small number of
40
41 included studies.
42
43
44

45
46 (5) Although one trial had a short-term follow up, most of the studies had no
47
48 follow up, indicating a lack of knowledge for some critical outcomes, such as
49
50 all-cause mortality and progression to severe complications due to high BP, which is
51
52 the most common problem for TCM studies in general.
53
54

55
56 (6) As the use of natural products is very common among patients in a variety of
57
58
59
60

1
2
3
4 health care settings, the safety of CHM and potential herb-drug interactions has hence
5
6 become a concern. This review suggested that JLD may be safe for the management
7
8 of EH. In fact, no parallel double blind randomized placebo-controlled trials
9
10 indicating the adverse effects of JLD for EH could be found. Due to the insufficient
11
12 clinical data, it is difficult to draw a definitive conclusion regarding the safety of JLD
13
14 for EH at present. We therefore suggest that the adverse effects of JLD need to be
15
16 monitored rigorously in future studies.
17
18
19
20
21
22
23

24 **CONCLUSION**

25
26
27
28
29 Due to the insufficient clinical data, poor methodological design, and high risk of
30
31 bias, it is difficult to draw a definite conclusion regarding the effectiveness and safety
32
33 of JLD for EH. More rigorously designed trials reported according to the CONSORT
34
35 Statement are needed.⁵²⁻⁵⁴
36
37
38
39
40

41 **Funding**

42
43 XJX was supported by the National Natural Science Foundation Project of China (No.
44
45 81403375). The funders had no role in study design, data collection and analysis,
46
47 decision to publish, or preparation of the manuscript.
48
49
50

51 **Competing interests**

52
53
54
55
56 None.
57
58
59
60

Contributors

XX conceived the idea for the study and designed the method of this systematic review and meta-analysis including the inclusion and exclusion criteria. XX also performed data collection and extraction, conducted the statistical analysis, and wrote the first draft of the article. PW, XL, and YZ searched the articles and assessed their methodological quality. Disagreement was resolved by discussion between XX, PW, XL, and YZ. PW performed the major revision, interpreted the results, and made comments. All of the authors approved the final version of the manuscript.

Acknowledgements

The author would like to thank Cheryl C. from American Journal Experts (AJE) in revising the English language of the manuscript.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data sharing statement

No additional data available.

REFERENCES

1. Lawes CM, Hoorn SV, Rodgers A, and for the International Society of Hypertension. Global burden of blood-pressure-related disease 2001. *Lancet* 2008;

- 1
2
3
4 371: 1513-1518.
5
6 2. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the
7
8 management of high blood pressure in adults report from the panel members
9
10 appointed to the Eighth Joint National Committee (JNC 8). *J Am Med Assoc* 2014;
11
12 311: 507-520.
13
14 3. Ezzati M, Lopez AD, Rodgers A, et al. Comparative risk assessment
15
16 collaborative group: selected major risk factors and global and regional burden of
17
18 disease. *Lancet* 2002; 360: 1347-1360.
19
20
21 4. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension:
22
23 analysis of worldwide data. *Lancet* 2005; 365: 217-223.
24
25
26 5. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease
27
28 and risk factors 2001: systematic analysis of population health data. *Lancet* 2006;
29
30 367: 1747-1757.
31
32
33 6. Fisher JW. The diagnostic value of the sphygmomanometer in examinations for
34
35 life insurance. *J Am Med Assoc* 1914; 63: 1752-1754.
36
37
38 7. Lewington S, Clarke R, Qizilbash N, et al. Prospective Studies Collaboration.
39
40 Age-specific relevance of usual blood pressure to vascular mortality: a
41
42 meta-analysis of individual data for one million adults in 61 prospective studies.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 2009; 338: b1665, 1-19.
9. Xiong XJ, Yang XC, Liu YM, et al. Chinese herbal formulas for treating hypertension in traditional Chinese medicine: perspective of modern science. *Hypertens Res* 2013; 36: 570-579.
 10. Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. *J Am Med Assoc* 2013; 310: 1-10.
 11. Brook RD, Appel LJ, Rubenfire M, et al. Beyond medications and diet: alternative approaches to lowering blood pressure. *Hypertension* 2013; 61: 1360-1383.
 12. Mansoor GA. Herbs and alternative therapies in the hypertension clinic. *Am J Hypertens* 2001; 14: 971-975.
 13. Xiong XJ, Borrelli F, Ferreira AS, et al. Herbal medicines for cardiovascular diseases. *Evid Based Complement Alternat Med* 2014; 2014: e809741, 1-3.
 14. Wang J, Xiong XJ. Current situation and perspectives of clinical study in integrative medicine in China. *Evid Based Complement Alternat Med* 2012; 2012: e268542, 1-11.
 15. Wang J, Feng B, Yang XC, et al. Chinese herbal medicine for the treatment of prehypertension. *Evid Based Complement Alternat Med* 2013; 2013: e493521, 1-9.
 16. Tachjian A, Maria V, Jahangir A. Use of herbal products and potential interactions in patients with cardiovascular diseases. *J Am Coll Cardiol* 2010; 55:

- 1
2
3
4 515-525.
5
6
7 17. Xiong XJ, Yang XC, Liu W, et al. Trends in the treatment of hypertension from
8
9 the perspective of traditional Chinese medicine. *Evid Based Complement Alternat*
10
11 *Med* 2013; 2013: e275279, 1-13.
12
13
14 18. Wang J, Xiong XJ. Control strategy on hypertension in Chinese medicine. *Evid*
15
16 *Based Complement Alternat Med* 2012; 2012: e284847, 1-6.
17
18
19 19. Wang J, Xiong XJ. Evidence-based Chinese Medicine for Hypertension. *Evid*
20
21 *Based Complement Alternat Med* 2013; 2013: e978398, 1-12.
22
23
24 20. Wang J, Xiong XJ. Outcome measures of Chinese herbal medicine for
25
26 hypertension: an overview of systematic reviews. *Evid Based Complement*
27
28 *Alternat Med* 2012; 2012: e697237, 1-10.
29
30
31 21. Wang J, Feng B, Yang XC, et al. Tianma gouteng yin as adjunctive treatment for
32
33 essential hypertension: a systematic review of randomized controlled trials. *Evid*
34
35 *Based Complement Alternat Med* 2013; 2013: e706125, 1-18.
36
37
38
39 22. Xiong XJ, Yang XC, Feng B, et al. Zhen gan xi feng decoction, a traditional
40
41 Chinese herbal formula, for the treatment of essential hypertension: a systematic
42
43 review of randomized controlled trials. *Evid Based Complement Alternat Med*
44
45 2013; 2013: e982380, 1-9.
46
47
48
49 23. Wang J, Yang XC, Feng B, et al. Is Yangxue Qingnao Granule combined with
50
51 antihypertensive drugs, a new integrative medicine therapy, more effective than
52
53 antihypertensive therapy alone in treating essential hypertension?. *Evid Based*
54
55 *Complement Alternat Med* 2013; 2013: e540613, 1-8.
56
57
58
59
60

- 1
2
3
4 24. Xiong XJ, Liu W, Yang XC, et al. Ginkgo biloba extract for essential
5
6 hypertension: a systemic review. *Phytomedicine* 2014; 21: 1131-1136.
7
8
9 25. Wang J, Yao KW, Yang XC, et al. Chinese patent medicine liu wei di huang wan
10
11 combined with antihypertensive drugs, a new integrative medicine therapy, for
12
13 the treatment of essential hypertension: a systematic review of randomized
14
15 controlled trials. *Evid Based Complement Alternat Med* 2012; 2012: e714805,
16
17 1-7.
18
19
20
21 26. Wang J, Feng B, Xiong XJ. Chinese herbal medicine for the treatment of
22
23 obesity-related hypertension. *Evid Based Complement Alternat Med* 2013; 2013:
24
25 e757540, 1-11.
26
27
28
29 27. Lu AP, Jia HW, Xiao C, et al. Theory of traditional Chinese medicine and
30
31 therapeutic method of diseases. *World J Gastroenterol* 2004; 10: 1854-1856.
32
33
34 28. Jiang WY. Therapeutic wisdom in traditional Chinese medicine: a perspective
35
36 from modern science. *Trends Pharmacol Sci* 2005; 26: 558-563.
37
38
39 29. Ge HX, Dai XM, Zhang ZX, et al. Modern application and experimental research
40
41 progress of jian ling decoction. *Acta Chin Med Pharm* 2002; 30: 21-23.
42
43
44 30. Yu HW. Effect of modified jian ling decoction on insulin resistance and serum
45
46 levels of TNF- α in patients with essential hypertension. *Haerbin: Heilongjiang*
47
48 *Univ Chin Med* 2008; 1-56.
49
50
51 31. Cao JM. Effect of modified jian ling decoction on serum leptin and angiotensin II
52
53 in hypertension with insulin resistance. *Haerbin: Heilongjiang Univ Chin Med*
54
55 2012; 1-51.
56
57
58
59
60

- 1
2
3
4 32. Jiang CX. Effect of modified jian ling decoction on blood pressure and
5
6 angiotensin II in elderly hypertensive patients. *Haerbin: Heilongjiang Univ Chin*
7
8 *Med* 2012; 1-51.
9
- 10
11 33. Zhang N, Sun JL, Dong ZZ, et al. Effect of modified jian ling decoction on
12
13 insulin resistance and serum interleukin-6 of essential hypertension patients. *Chin*
14
15 *J Inform Tradit Chin Med* 2011; 18: 19-21.
16
17
- 18 34. Feng DR, Wei B. Effects of jian ling decoction on the blood lipid and lipid
19
20 peroxidation in experimental hyperlipidemia rats with yin deficiency of liver
21
22 and kidney. *Guangxi J Tradit Chin Med* 2009; 32: 51-54.
23
24
- 25 35. Huang YT, Wu CB, Zeng QM. Effect of jian ling decoction on 120 patients of
26
27 essential hypertension. *Chin J Integr Tradit West Med* 1996; 16: 561.
28
29
- 30 36. Hao HY, Wang QH, Sun CJ, et al. Effect of modified jian ling decoction on 30
31
32 patients of essential hypertension. *Shanxi J Tradit Chin Med* 1998; 19: 541.
33
34
- 35 37. Guan DM, Du SQ. Clinical observation on the effect of jian ling decoction
36
37 combined with urapidil on stage III hypertension with high-risk. *Chin Commun*
38
39 *Doct* 2013; 15: 214-215.
40
41
- 42 38. Higgins JPT, Green S. *Cochrane Handbook for Systematic Reviews of*
43
44 *Interventions, Version 5.1.0.* The Cochrane Collaboration.
45
46 <http://handbook.cochrane.org/>. 2011.
47
48
- 49 39. Li YB, Cui M, Yang Y, et al. Similarity of traditional Chinese medicine formula.
50
51 *Chin Arch Tradit Chin Med* 2012; 30: 1096-1097.
52
53
- 54 40. Tong WH. Analysis on clinical therapeutic effect of jian ling decoction on
55
56
57
58
59
60

- 1
2
3
4 essential hypertension with yin deficiency and yang hyperactivity syndrome.
5
6 *Guide China Med* 2013; 11: 258-259.
7
8
9 41. He T, Zhu YQ, Xu SX. Effect of jian ling decoction on 30 hypertensive patients
10
11 with yin deficiency and yang hyperactivity syndrome. *Guid J Tradit Chin Med*
12
13 *Pharm* 2012; 18: 50-51.
14
15
16 42. Fan R, Zhou H, Tan HY. Effect of jian ling decoction on aged hypertension
17
18 patient's life mass and CAT. *China J Mod Med* 2005; 15: 1706-1708.
19
20
21 43. Cai XP. Combined traditional Chinese and western medicine in the treatment of
22
23 50 patients with essential hypertension. *Guagndong Med J* 1995; 16: 400-402.
24
25
26 44. Zhang N. Effect of modified jian ling decoction on essential hypertension.
27
28 *Haerbin: Heilongjiang Univ Chin Med* 2004; 1-34.
29
30
31 45. Zhang N. Effect of modified jian ling decoction on insulin resistance and serum
32
33 levels of IL-6 in essential hypertension. *Haerbin: Heilongjiang Univ Chin Med*
34
35 2009; 1-51.
36
37
38 46. Jiang CX, Cao JM. Effect of modified jian ling decoction on renin-angiotensin II
39
40 in patients with senile hypertension. *Chin J Tradit Med Sci Technol* 2012; 19:
41
42 145.
43
44
45 47. Chu GM, Xu JY. Effect of modified jian ling decoction on high-sensitivity
46
47 C-reactive protein on 67 cases of hypertensive patients. *J Inform Tradit Chin Med*
48
49 2013; 30: 66-67.
50
51
52
53 48. Liu L, Jin J, Yu HW. Effect of modified jian ling decoction on insulin resistance
54
55 and TNF- α level in patients of EH. *J Inform Tradit Chin Med* 2008; 25: 68-70, 80.
56
57
58
59
60

- 1
2
3
4 49. Li CM. Effect of modified jian ling decoction on senile primary hypertension.
5
6 *Jinan: Shandong Univ Chin Med* 2013; 1-30.
7
8
9 50. Xiong XJ, Liu W, Yang XC, et al. Moxibustion for essential hypertension.
10
11 *Complement Ther Med* 2014; 22: 187-195.
12
13
14 51. Croog SH, Levine S, Testa MA, et al. The effect of antihypertensive therapy on
15
16 the quality of life. *N Engl J Med* 1986; 314: 1657-1659.
17
18
19 52. Liu JP, Han M, Li XX, et al. Prospective registration, bias risk and
20
21 outcome-reporting bias in randomised clinical trials of traditional Chinese
22
23 medicine: An empirical methodological study. *BMJ Open* 2013; 3: e002968, 1-7.
24
25
26 53. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines
27
28 for reporting parallel group randomized trials. *Ann Intern Med* 2012; 152:
29
30 726-732.
31
32
33 54. Gagnier JJ, Boon H, Rochon P, et al. Reporting randomized, controlled trials of
34
35 herbal interventions: an elaborated CONSORT statement. *Ann Intern Med* 2006;
36
37 144: 364-367.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **Table 1. Basic characteristics of the included studies.**
5
6
7

8
9 **Table 2. Herbal medicines in the included studies.**
10
11

12
13
14 **Table 3. Methodological quality of included studies based on the Cochrane**
15 **handbook.**
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FIGURE LEGENDS**Figure 1.****Flow diagram of study selection and identification.****Figure 2.****Effect of JLD on BP. (a) JLD *versus* AD and (b) JPAD *versus* AD.**

AD: antihypertensive drugs; BP: blood pressure; DBP: diastolic blood pressure; JLD:

Jian Ling Decoction; JPAD: Jian Ling Decoction plus antihypertensive drugs; SBP:

systolic blood pressure.

Table 1. Basic characteristics of the included studies.

Study ID	Sample size (randomized /analyzed) M/F	Age(yrs)	Diagnosis standard	Intervention	Control	Course (week)	Outcome measures
Tong 2013 [40]	60/60 T: 30 C: 30 F/M: NR	40-60 (T/C: NR)	GCRNDTC M	JLD (1 dose/d)	felodipine (5 mg, qd)	4	BP
He et al. 2012 [41]	60/60 T: 15/15 C: 17/13	T: 54.89 ± 5.34 C: 57.36 ± 6.47	GCRNDTC M	JLD (1 dose/d)	felodipine (5 mg, qd)	4	BP
Fan 2005 [42]	50/50 T: 14/11 C: 13/12	T: 64.80 ± 7.40 C: 63.70 ± 6.90	WHO -ISH GMH-1999	JLD (1 dose/d)	felodipine (2.5 mg, qd)	4	BP; QOL
Cai 1995 [43]	100/100 T: 35/15 C: 34/16	T: 50-81 C: 47-84	WHO -ISH GMH-1985	modified JLD (1 dose/d) + control	nifedipine (10 mg, tid)	4	BP; adverse effect
Zhang 2004 [44]	90/89 T1: 16/14 T2: 17/13 C: 15/14	T1: 58.23 ± 8.26 T2: 58.45 ± 6.87 C: 59.16 ± 9.28	WHO -ISH GMH-1999	T1: modified JLD (1 dose/d) T2: modified JLD (1 dose/d) + control	enalapril (10 mg, bid)	4	BP; adverse effect
Zhang 2009 [45]	60/57 T: 15/14 C: 12/16	T: 56.41 ± 10.98 C: 58.57 ± 8.21	CGMH-200 5	modified JLD (1 dose/d) + control	enalapril (10 mg, bid)	3	BP; adverse effect
Jiang and Cao 2012 [46]	82/82 T: 26/16 C: 23/17	T: 60-75 C: 62-75	WHO -ISH GMH-1999	modified JLD (100 ml/d) + control	benazepril hydrochloride (10 mg, tid)	4	BP
Chu and Xu 2013 [47]	67/67 T: 19/15 C: 17/16	T: 67.00 ± 7.20 C: 68.00 ± 5.90	WHO -ISH GMH-1999	modified JLD (100 ml/d) + control	nifedipine controlled release tablet (30 mg, qd)	4	BP
Liu et al. 2008 [48]	60/60 T: 30 C: 30 F/M: NR	18-70 (T/C: NR)	JNC 7	modified JLD (100 ml/d) + control	enalapril (10 mg, bid)	3	BP; adverse effect
Li 2013 [49]	60/60 T: 16/14 C: 17/13	T: 64.33 ± 7.96 C: 61.20 ± 10.23	CGMH-201 0	modified JLD (400 ml/d) + control	nifedipine controlled release tablet (30 mg, qd) and irbesartan (150 mg, qd)	4	BP; adverse effect

Abbreviations: BP: blood pressure; C: control group; CGMH: Chinese Guidelines for the Management of Hypertension; F: female; GCRNDTCM: Guidelines of Clinical Research of New Drugs of Traditional Chinese Medicine; JLD: Jian Ling Decoction; JNC 7: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; M: male; NR: not reported; QOL: quality of life; T: treatment group; WHO-ISH GMH: WHO-ISH guidelines for the management of hypertension.

Table 2. Herbal medicines in the included studies.

Study ID	Formula	Composition of formula
Tong 2013 [40]	JLD	Arbor Vitae Seed (Baiziren, Semen Platycladi) 10 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 10 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 15 g, Oyster Shell (Muli, Concha Ostreae) 10 g, Fossilized Mammal Bones (Longgu, Os Draconis) 10 g, Hematite (Daizheshi, Haematitum) 10 g, Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 15 g, and Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 20 g.
He et al. 2012 [41]	JLD	Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 15 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 20 g, Hematite (Daizheshi, Haematitum) 10 g, Oyster Shell (Muli, Concha Ostreae) 10 g, Fossilized Mammal Bones (Longgu, Os Draconis) 10 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 15 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 10 g, and Arbor Vitae Seed (Baiziren, Semen Platycladi) 10 g.
Fan 2005 [42]	JLD	Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 30 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 30 g, Hematite (Daizheshi, Haematitum) 24 g, Oyster Shell (Muli, Concha Ostreae) 18 g, Fossilized Mammal Bones (Longgu, Os Draconis) 18 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 18 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 12 g, and Arbor Vitae Seed (Baiziren, Semen Platycladi) 12 g.
Cai 1995 [43]	modified JLD	Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 30 g, Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 30 g, Abalone Shell (Shijueming, Haliotidis Concha) 30 g, Hematite (Daizheshi, Haematitum) 24 g, Oyster Shell (Muli, Concha Ostreae) 18 g, Fossilized Mammal Bones (Longgu, Os Draconis) 18 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 18 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 12 g, and Arbor Vitae Seed (Baiziren, Semen Platycladi) 12 g. Headache plus Puncturevine Caltrop Fruit (Cijili, Tribulus terrestris Linn) 10 g; constipation plus Rhubarb Root and Rhizome (Daihuang, Radix Et Rhizoma Rhei) 5 g.
Zhang 2004 [44]	modified JLD	Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 30 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 30 g, Hematite (Daizheshi, Haematitum) 24 g, Oyster Shell (Muli, Concha Ostreae) 18 g, Fossilized Mammal Bones (Longgu, Os Draconis) 18 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 18 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 12 g, and Arbor Vitae Seed (Baiziren, Semen Platycladi) 12 g. Headache, dizziness, and irritability plus Gastrodia (Tianma, Gastrodiae Rhizoma) 15 g and Abalone Shell (Shijueming, Haliotidis Concha) 30 g; irritability, bitty mouth and red face plus Coptis Rhizome (Huanglian, Rhizoma Coptidis) 10 g and Gardenia (Zhizi, Fructus Gardeniae Jasminoidis) 10 g; and constipation plus Rhubarb Root and Rhizome (Daihuang, Radix Et Rhizoma Rhei) 5 g.
Zhang 2009 [45]	modified JLD	Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 30 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 30 g, Hematite (Daizheshi, Haematitum) 24 g, Oyster Shell (Muli, Concha Ostreae) 18 g, Fossilized Mammal Bones (Longgu, Os Draconis) 18 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 18 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 12 g, and Arbor Vitae Seed (Baiziren, Semen Platycladi) 12 g. Excessive accumulation of phlegm-dampness plus Pinellia Rhizome (Banxia, Rhizoma Pinelliae Tematae) 15 g, Sclerotium of Tuckahoe (Fuling, Scierotium Poriae Cocos) 15 g, Tangerine Peel (Chenpi, Pericarpium Citri Reticulatae) 10 g, Bamboo Shavings (Zhuru, Bambusae Caulis in Taeniam) 10 g, and Liquoric Root (Gancao, Radix Glycyrrhizae) 3 g.
Jiang and Cao	modified	Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 30 g, Fresh Water Turtle Shell (Guijia, Plastrum

2012 [46]	JLD	Testudinis) 30 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 30 g, Hematite (Daizheshi, Haematitum) 20 g, Oyster Shell (Muli, Concha Ostreae) 20 g, Fossilized Mammal Bones (Longgu, Os Draconis) 20 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 20 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 15 g, and Arbor Vitae Seed (Baiziren, Semen Platycladi) 15 g.
Chu and Xu 2013 [47]	modified JLD	Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 25 g, Fresh Water Turtle Shell (Guijia, Plastrum Testudinis) 25 g, Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 30 g, Hematite (Daizheshi, Haematitum) 15 g, Oyster Shell (Muli, Concha Ostreae) 25 g, Fossilized Mammal Bones (Longgu, Os Draconis) 25 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 25 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 20 g, and Arbor Vitae Seed (Baiziren, Semen Platycladi) 20 g.
Liu et al. 2008 [48]	modified JLD	Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 30 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 18 g, Hematite (Daizheshi, Haematitum) 24 g, Oyster Shell (Muli, Concha Ostreae) 18 g, Fossilized Mammal Bones (Longgu, Os Draconis) 18 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 30 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 20 g, and Arbor Vitae Seed (Baiziren, Semen Platycladi) 20 g. Excessive accumulation of phlegm-dampness plus Pinellia Rhizome (Banxia, Rhizoma Pinelliae Tematae) 15 g, Sclerotium of Tuckahoe (Fuling, Scierotium Poriae Cocos) 15 g, Tangerine Peel (Chenpi, Pericarpium Citri Reticulatae) 10 g, Bamboo Shavings (Zhuru, Bambusae Caulis in Taeniam) 10 g, and Liquoric Root (Gancao, Radix Glycyrrhizae) 3 g.
Li 2013 [49]	modified JLD	Fossilized Mammal Bones (Longgu, Os Draconis) 30 g, Oyster Shell (Muli, Concha Ostreae) 30 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 20 g, Hematite (Daizheshi, Haematitum) 20 g, Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 30 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 30 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 20 g, Arbor Vitae Seed (Baiziren, Semen Platycladi) 15 g, Gambir Vine Stems and Thorns (Gouteng, Ramulus Uncariae Cum Uncis) 30 g, Pueraria (Gegen, Radix Puerariae) 30 g, Gastrodia (Tianma, Gastrodiae Rhizoma) 15 g, Chinese Taxillus Twig (Sangjiisheng, Herba Taxilli) 30 g, Eucommia Bark (Duzhong, Cortex Eucommiae Ulmoidis) 15 g, and Coptis Rhizome (Huanglian, Rhizoma Coptidis) 9 g.

Abbreviations: JLD: Jian Ling Decoction.

Table 3. Methodological quality of included studies based on the Cochrane handbook.

Included trials	A	B	C	D	E	F	G
Tong 2013 [40]	?	?	?	?	+	?	?
He et al. 2012 [41]	+	?	?	?	+	?	?
Fan 2005 [42]	?	?	?	?	+	?	?
Cai 1995 [43]	?	+	?	?	+	?	?
Zhang 2004 [44]	+	+	+	?	+	?	?
Zhang 2009 [45]	+	?	+	?	+	?	?
Jiang and Cao 2012 [46]	?	?	?	?	+	?	?
Chu and Xu 2013 [47]	?	?	?	?	+	?	?
Liu et al. 2008 [48]	+	+	+	?	+	?	?
Li 2013 [49]	?	?	?	?	+	?	?

Abbreviations: A: Adequate sequence generation; B: Concealment of allocation; C: Blinding (participants and personnel); D: Blinding (assessor); E: Incomplete outcome data addressed (ITT analysis); F: Free of selective reporting; G: other potential threat to validity; +: low risk; -: high risk; ?: unclear.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60






Fig 1 Flow diagram of study selection and identification.
159x171mm (300 x 300 DPI)






(a) JLD versus AD: BP



(b) JPAD versus AD: SBP (mmHg)



(b) JPAD versus AD: DBP (mmHg)

Figure 2. Effect of JLD on BP. (a) JLD versus AD and (b) JPAD versus AD. AD: antihypertensive drugs; BP: blood pressure; DBP: diastolic blood pressure; JLD: Jian Ling Decoction; JPAD: Jian Ling Decoction plus antihypertensive drugs; SBP: systolic blood pressure.
145x156mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

Chinese herbal medicine Jian Ling Decoction for essential hypertension: A systematic review and meta-analysis of randomized controlled trials

Xingjiang Xiong^{1*}, Pengqian Wang², Xiaoke Li³, and Yuqing Zhang⁴

¹ Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China

² Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China

³ Bio-organic and Natural Products Laboratory, McLean Hospital, Harvard Medical School, Belmont, MA, USA

⁴ Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada

Total word count: 3200.

Number of tables and figures: 3 tables and 2 figures.

Running head: Jian Ling Decoction for essential hypertension.

* *BMJ Open* 2014

Correspondence to: Xingjiang Xiong, MD, Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beixiange 5#, Xicheng District, Beijing 100053, China. Tel: +10 88001817. Fax: +10 88001229. E-mail: xiongxingjiangtcm@163.com or 5administration@163.com.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives: Jian Ling Decoction (JLD) is often prescribed to improve hypertension-related symptoms in China. However, this treatment has not been systematically reviewed for its efficacy against essential hypertension (EH). This review aims to assess the current clinical evidence of JLD in the treatment of EH.

Design: Seven electronic databases including the Cochrane Central Register of Controlled Trials, PubMed, EMBASE, the Chinese National Knowledge Infrastructure (CNKI), the Chinese Scientific Journal Database (VIP), the Chinese Biomedical Literature Database (CBM), and the Wanfang Database were searched up to March 2014. Randomized control trials (RCTs) comparing JLD or combined with antihypertensive drugs versus antihypertensive drugs were included. We assessed the methodological quality, extracted the valid data, and conducted the meta-analysis according to criteria from the Cochrane group. The primary outcome was categorical or continuous blood pressure (BP), and the secondary outcome was quality of life (QOL).

Results: Ten trials (655 patients) with unclear-to-high risk of bias were identified. Meta-analysis showed that JLD used alone showed no BP reduction effect; however, improvement on QOL was found when compared to antihypertensive drugs. A significant reduction on systolic BP and diastolic BP were observed for JLD plus antihypertensive drugs when compared to antihypertensive drugs alone. No serious adverse effects were reported.

Conclusion: Due to insufficient clinical data, it is difficult to draw a definite

1
2
3
4 conclusion regarding the effectiveness and safety of JLD for EH, and better trials are
5
6 needed.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

KEY WORDS

essential hypertension; blood pressure; Chinese herbal medicine; Jian Ling Decoction;
systematic review

For peer review only

ARTICLE SUMMARY

Article focus

- Jian Ling Decoction (JLD), a traditional Chinese herbal formula, is often prescribed for patients with essential hypertension (EH).

Key messages

- No definitive conclusion regarding the efficacy and safety of JLD for EH could be drawn based on the insufficient clinical data

Strengths and limitations of this study

- The strength of this article is its use of a comprehensive and unbiased literature searching of seven electronic databases without language and publication restrictions.
- The included trials were of small sample size, with poor methodological quality and significant heterogeneity.

INTRODUCTION

Hypertension is one of the most important preventable causes of death and one of the most common conditions treated in primary health care. In addition, hypertension represents an important public health challenge because of its high prevalence and the concomitant increase in the risk of cardiovascular, cerebrovascular and renal diseases.^{1,2} This condition has been ranked as the leading global risk factor for mortality and is the third leading risk factor for disease burden according to the comparative Risk Assessment Collaborating Group.^{3,4} Currently, about one billion patients have been affected.⁵ The association between blood pressure (BP) and mortality was discovered approximately 100 years ago.⁶ Recent studies also confirmed that BP is closely related to vascular outcomes, and even a minor reduction in BP could reduce cardiovascular events, especially stroke.^{7,8} Therefore, early diagnosis and effective treatment is of great importance for patients with essential hypertension (EH). Nevertheless, despite remarkable achievements in the research and development of antihypertensive drugs, the current awareness, curative and control rates of hypertension among different age groups is still far from satisfactory.^{9,10} Additionally, in the light of the adverse effects of antihypertensive drugs and hoping for an adjunctive approach with few adverse effects, patients in Western countries with EH and other cardiovascular diseases increasingly use complementary and alternative medicine (CAM),¹¹⁻¹³ including traditional Chinese medicine (TCM).¹⁴⁻¹⁶

1
2
3
4 Chinese herbal medicine (CHM), one of the commonly used TCM therapies, has
5
6 played an important role in relieving hypertension-related signs and symptoms for
7
8 centuries in East Asia.^{17,18} Recently, more robust evidence from systematic reviews
9
10 (SRs) has suggested the efficacy and safety of CHM for EH.¹⁹⁻²⁶ In TCM theory, liver
11
12 yang hyperactivity syndrome (LYHS) and liver-kidney yin deficiency syndrome
13
14 (LKYDS) are the two most important patterns of EH, which often appear at the same
15
16 time.¹⁷ These patterns manifest as headache, vertigo, tinnitus, irritability, insomnia,
17
18 lassitude in the waist and legs, dysphoria with feverish sensation, dry mouth, bright
19
20 red tongue with less fur, and a wiry pulse.^{14,17,21,27,28} Jian Ling Decoction (JLD) is a
21
22 traditional CHM invented by *Zhang Xichun* in *Yixue Zhongzhong Canxilu* (Records of
23
24 Traditional Chinese in Combination with Western Medicine) in the 1920s. It contains
25
26 the following eight commonly used herbs: Dioscorea Root (Shanyao, *Dioscoreae*
27
28 *Rhizoma*), Achyranthes Root (Niuxi, *Achyranthis Bidentatae Radix*), Hematite
29
30 (*Daizheshi*, *Haematitum*), Fossilized Mammal Bones (Longgu, *Os Draconis*), Oyster
31
32 Shell (*Muli*, *Concha Ostreae*), Rehmannia (*Dihuang*, *Radix Rehmanniae Glutinosae*),
33
34 White Peony Root (*Baishao*, *Radix Albus Paeoniae Lactiflorae*), and Arbor Vitae
35
36 Seed (*Baiziren*, *Semen Platycladi*). All of these herbs have been recorded in the
37
38 Pharmacopoeia of the People's Republic of China (2010 edition). Both LYHS and
39
40 LKYDS can be effectively treated with JLD.¹⁹ Currently, JLD is often prescribed for
41
42 the management of EH by TCM practitioners in China. It is worth noting that in the
43
44 context of CAM therapies, add-on designs are very popular for the treatment of
45
46 hypertension.^{14,20-25} JLD is usually used in combination with antihypertensive drugs
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 to achieve greater improvement in the signs and symptoms of hypertension and to
5
6 enhance the antihypertensive effect of conventional drugs with less adverse effects.
7
8
9 The pharmacological mechanisms of these effects may be related to the reduction in
10
11 levels of angiotensin II, IL-6, tumor necrosis factor- α (TNF- α), and leptin, as well as
12
13 insulin resistance and decreased blood lipids.²⁹⁻³⁴ Regarding the clinical use of JLD, a
14
15 large number of studies (including case reports, case series, controlled observational
16
17 studies, and randomized trials) have reported its effects on EH, including lowering BP,
18
19 reducing inflammation, reversing cardiovascular risk factors, and improving clinical
20
21 symptoms and quality of life (QOL).³⁵⁻³⁷ However, there has been no comprehensive
22
23 evaluation of clinical trials on the efficacy and adverse effects of JLD. This review
24
25 aims to systematically review the published and unpublished randomized controlled
26
27 trials (RCTs) to evaluate the current evidence for JLD in treating EH.
28
29
30
31
32
33
34
35
36

37 **METHODS**

38
39
40
41 This study was conducted according to the Cochrane practice.³⁸
42
43
44
45

46 **Search strategies**

47
48
49
50
51 RCTs of JLD for the treatment of hypertensive patients were screened through
52
53 the following electronic databases from their respective inceptions to March 2014:
54
55
56 Cochrane Central Register of Controlled Trials (CENTRAL, 1996-2014), PubMed
57
58
59
60

1
2
3
4 (1959-2014), and EMBASE (1980-2014). In addition, as JLD is mainly prescribed in
5
6 China, four Chinese electronic databases including the Chinese National Knowledge
7
8 Infrastructure (CNKI, 1980-2014), Chinese Scientific Journal Database (VIP,
9
10 1989-2014), Chinese Biomedical Literature Database (CBM, 1978-2014), and
11
12 Wanfang Database (1998-2014) were searched to retrieve the maximum possible
13
14 number of trials. We also conducted a literature search of the website of the Chinese
15
16 clinical trial registry (available at <http://www.chictr.org/>) and international clinical
17
18 trial registry hosted by the US National Institutes of Health (available at
19
20 <http://clinicaltrials.gov/>) for all of the relevant ongoing registered clinical trials and
21
22 unpublished articles. The bibliographies of the studies identified in the systematic
23
24 search were reviewed for potentially relevant additional publications. No restriction
25
26 on publication status or language was imposed.
27
28
29
30
31
32

33
34 The keywords for databases searching were listed as follows: (“hypertension”
35
36 OR “essential hypertension” OR “primary hypertension” OR “high blood pressure”
37
38 OR “blood pressure”) AND (“*jian ling* decoction” OR “*jianling* decoction” OR “*jian*
39
40 *ling tang*” OR “*jianling tang*” OR “*jianlingtang*”) AND (“clinical trial” OR
41
42 “randomized controlled trial” OR “randomised controlled trial”).
43
44
45
46
47
48

49 **Study selection**

50 51 52 53 54 **Types of studies**

1
2
3
4 RCTs on the use of JLD for the treatment of EH were included.

5
6 Quasi-randomized trials and animal experiments were excluded.

7
8
9
10
11 **Types of participants**

12
13
14
15
16 Trials focused on the patients suffering from EH were included. All of the
17
18 participants who were enrolled in the trials were required to meet at least one of the
19
20 current or past definitions of EH.² Trials without a description of the detailed
21
22 diagnostic criteria but which reported patients with definite EH were also included .
23
24 Patients with secondary hypertension were excluded. There was no restriction on
25
26 gender, age, or ethnic origin of the participants.
27
28
29
30
31
32

33
34 **Types of interventions**

35
36
37
38
39 Only studies that tested JLD used alone versus antihypertensive drugs, or JLD
40
41 combined with antihypertensive drugs versus antihypertensive drugs were included.
42
43 However, trials assessing the combined effect of JLD with other interventions (*e.g.*,
44
45 another CHM, qigong, Tai Chi, acupuncture, moxibustion and massage) were
46
47 excluded given that the therapeutic effect of JLD could not be distinguished.
48
49 Interventions in the control group included antihypertensive drugs. Studies that used
50
51 non-conventional medicine or CAM as control groups were also excluded. The
52
53 duration of treatment was required to be at least two weeks.
54
55
56
57
58
59
60

1
2
3
4 According to the principle of similarity of the TCM formula,³⁹ modified JLD
5
6 should contain at least six out of eight herbs used in JLD, and only a few herbs could
7
8 be added into the JLD based on TCM syndrome theory. However, the resulting
9
10 prescription should contain the following four principal drugs: Achyranthes Root
11
12 (Niuxi, Achyranthis Bidentatae Radix), Hematite (Daizheshi, Haematitum), Fossilized
13
14 Mammal Bones (Longgu, Os Draconis), and Oyster Shell (Muli, Concha Ostreae).
15
16
17
18
19
20

21 **Types of outcome measures**

22
23
24
25
26 The primary outcome analyzed for this meta-analysis was categorical or
27
28 continuous BP, and secondary outcome was QOL.
29
30
31
32

33 **Data extraction**

34
35
36
37
38 All of the articles were read by two independent reviewers. Then, the eligible
39
40 studies were retrieved for further identification according to the above inclusion and
41
42 exclusion criteria. Duplicate papers were excluded. The data extraction form
43
44 comprised the authors, title, publication year, sample size, age, sex distribution,
45
46 diagnosis standard, study design, interventions in the treatment and control groups,
47
48 the composition of JLD or modified JLD, trial duration, outcome measures, and
49
50 adverse effects. If missing or unclear information regarding the original study was
51
52 found, we contacted the primary authors via email, telephone or fax whenever
53
54
55
56
57
58
59
60

possible. Any disagreement was resolved by discussion between the reviewers.

Methodological quality

The risk of bias of the included studies was independently evaluated by two reviewers according to the criteria in the Cochrane Handbook for Systematic Review of Interventions Version 5.1.0 (updated March 2011).³⁸ The following seven items were included: (a) sequence generation (selection bias); (b) allocation concealment (selection bias); (c) blinding of participants and personnel (performance bias); (d) blinding of outcome assessments (detection bias); (e) incomplete outcome data (attrition bias); (f) selective reporting (reporting bias); and (g) other sources of bias (from Chapter 8: assessing risk of bias in included studies).³⁸ Each domain was assessed as a “high”, “unclear”, or “low” risk of bias based on the above criteria. Then, the methodological quality of the trials was ranked into three levels: low risk of bias (all items with low risk of bias), high risk of bias (at least one item with high risk of bias), or unclear risk of bias (at least one item with an unclear domain).

Data synthesis

Review Manager, Version 5.1 (The Nordic Cochrane Centre, Copenhagen, Denmark) was used for data analysis. The values of the outcome measures after treatment were retrieved to assess differences between the JLD and control groups.

1
2
3
4 The weighted mean difference (WMD) was used for continuous data, while the risk
5
6 ratio (RR) was used for binary data. Subgroups analysis was conducted among
7
8 different types of comparisons (including JLD *versus* antihypertensive drugs and JLD
9
10 plus antihypertensive drugs *versus* antihypertensive drugs). If high quality trials could
11
12 be found, comparisons between all of the studies and studies with high quality would
13
14 be conducted. In a three-group design study that had two treatment groups of JLD and
15
16 JLD plus antihypertensive drugs, the two comparisons were split in the meta-analysis.
17
18 Heterogeneity was assessed by I^2 statistics.³⁸ Funnel plots were applied to detect for
19
20 publication bias when the number of included studies of any particular outcome was
21
22 more than ten. $P < 0.05$ was considered to be statistically significant.
23
24
25
26
27
28
29
30
31

32 RESULTS

33 34 35 36 Study characteristics

37
38
39
40
41 Figure 1 shows the process of study selection. We identified 308 potentially
42
43 relevant articles in the initial screening of the seven databases. Ten RCTs, with a total
44
45 of 655 participants, met the eligibility criteria and were included.⁴⁰⁻⁴⁹ The basic
46
47 characteristics of included trials are summarized in Table 1. Six diagnostic criteria of
48
49 EH were specified: two trials^{40,41} used the Guidelines of Clinical Research of New
50
51 Drugs of Traditional Chinese Medicine (GCRNDTCM); four trials^{42,44,46,47} used the
52
53 WHO-ISH guidelines for the management of hypertension-1999 (WHO -ISH
54
55
56
57
58
59
60

1
2
3
4 GMH-1999); one trial⁴³ used the WHO-ISH GMH-1985; one trial⁴⁵ used the Chinese
5
6 Guidelines for the Management of Hypertension-2005 (CGMH-2005); one trial⁴⁸ used
7
8 the Seventh Report of the Joint National Committee on Prevention, Detection,
9
10 Evaluation, and Treatment of High Blood Pressure (JNC 7); and one trial⁴⁹ used the
11
12 Chinese Guidelines for the Management of Hypertension-2010 (CGMH-2010). All of
13
14 the studies were conducted in China and published in Chinese language. One trial was
15
16 a three-arm design (two intervention groups versus one control group),⁴⁴ and the
17
18 others used a two-arm study design (one intervention group versus one control group).
19
20 The clinical efficacy of JLD was observed in all of the trials. However, the evaluation
21
22 criteria on BP was different: three trials used the categorical BP recommended by
23
24 Chinese government in GCRNDTCM,⁴⁰⁻⁴² and seven used continuous BP.⁴³⁻⁴⁹ QOL
25
26 was only tested in one trial.⁴²
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Treatment groups

The types of intervention were classified as JLD (n = 4) or combination therapy (JLD plus antihypertensive drugs, n = 7). The variable prescriptions based on JLD are presented in Table 1. Different compositions of either JLD or modified JLD are presented in Table 2.

Control groups

1
2
3
4 All of the patients in the control groups received antihypertensive drug treatment,
5
6 including felodipine,⁴⁰⁻⁴² nifedipine,^{43,47,49} enalapril,^{44,45,48} and benazepril
7
8 hydrochloride.⁴⁶
9
10

11 12 13 14 **Treatment duration**

15
16
17
18
19 The total treatment duration in the trials ranged from three to four weeks, with
20
21 most being four weeks (n = 8). The duration of follow-up was only mentioned in one
22
23 trial, being three months.⁴³
24
25
26
27

28 29 **Methodological quality**

30
31
32
33
34 As shown in Table 3, four trials reported the method used to generate the
35
36 allocation sequence (random number table).^{41,44,45,48} Information regarding allocation
37
38 concealment was provided in two trials.^{44,48} Blinding of participants and personnel
39
40 was reported in three trials;^{44,45,48} however, no trial used blinding of outcome
41
42 assessment. Drop-out and withdrawal data were provided for three trials.^{44,45,49} No
43
44 trial had a pre-trial estimation of sample size. Selective reporting could not be
45
46
47
48
49 evaluated as no preregistered protocols could be obtained from the primary authors.
50
51
52
53

54 55 **Outcome measures**

Primary outcome: BP

JLD *versus* antihypertensive drugs (4 studies)

The clinical efficacy of JLD as monotherapy for BP was assessed in four trials.^{40-42,44} Three trials⁴⁰⁻⁴² did not use continuous BP to evaluate the efficacy of JLD, but used categorical BP, the evaluation criteria of which has been authoritatively recommended by China Food and Drug Administration (available at <http://www.sda.gov.cn>). It was defined as follows: “significant improvement” (DBP decreased by 10 mmHg, reaching the normal range, or DBP not returning to normal but reduced by more than 20 mmHg), “improvement” (DBP decreased by less than 10 mmHg but reaching the normal range, DBP decreased by 10 to 19 mmHg but not reaching the normal range, or SBP decreased by more than 30 mmHg), and “no improvement” (not meeting the above standards).⁵⁰ These outcomes were converted into binary data for further overall analysis. Both “significant improvement” and “improvement” were classified as “effective”, and “no improvement” was classified as “ineffective”. The meta-analysis showed that JLD had no BP reduction effect compared with antihypertensive drugs ($n = 170$; RR: 0.99; 95% CI: 0.90 to 1.08; $P = 0.79$; Figure 2a), with no significant heterogeneity (chi-square = 0.22, $P = 0.90$; $I^2 = 0\%$). Another trial used continuous BP to evaluate the efficacy of modified JLD when compared with enalapril.⁴⁴ No significant difference was found for either SBP or DBP ($P > 0.05$).

JLD plus antihypertensive drugs *versus* antihypertensive drugs (7 studies)

Seven RCTs evaluated the effect of JLD combined with antihypertensive drugs versus antihypertensive drugs.⁴³⁻⁴⁹ Continuous BP was measured in all of these studies. SBP was significantly reduced in the JLD plus antihypertensive drugs group when compared with antihypertensive drugs (n = 485; WMD: -8.37 mmHg; 95% CI: -9.84 to -6.90; $P < 0.00001$; Figure 2b), with no significant heterogeneity (chi-square = 8.45, $P = 0.21$; $I^2 = 29\%$). For DBP, a significant beneficial effect was also found in the JLD plus antihypertensive drugs group (n = 485; WMD: -6.71 mmHg; 95% CI: -9.32, -4.10; $P < 0.00001$; Figure 2c), with significant heterogeneity (chi-square = 9.47, $P < 0.0001$; $I^2 = 80\%$).

Secondary outcome: QOL

Only one trial,⁴² conducted by Fan et al, used the Croog Scale⁵¹ to assess the effectiveness of JLD on QOL in aged hypertension patients. At the end of the trial, QOL was significantly improved by JLD when compared with the felodipine group ($P < 0.05$). The trial demonstrated that long-term use of JLD might improve QOL for hypertensive patients.

Adverse effects

1
2
3
4
5
6 Adverse effect monitoring was only reported in five studies [43-45, 48, 49] and
7
8 was not mentioned in the other five trials. Among the former, no severe adverse
9
10 effects were reported in two trials.^{43,49} Three trials reported dry cough caused by
11
12 enalapril in both the JLD and antihypertensive drugs groups.^{44,45,48} Two trials reported
13
14 severe dry cough in the antihypertensive drugs groups.^{44,45} None of the adverse effects
15
16 were serious in the JLD groups.
17
18
19
20
21
22
23

24 **Evaluation of publication bias**

25
26
27
28 As the number of included trials was so small, it was not possible to conduct a
29
30 sufficient additional analysis of publication bias.
31
32
33
34
35

36 **DISCUSSION**

37 **Summary of evidence**

38
39
40
41 Taking into account the gap between the lack of scientific evidence regarding the
42
43 efficacy of JLD and the widespread application by TCM practitioners, the objective of
44
45 this study was to systematically review the current English and Chinese literature to
46
47 evaluate the efficacy and safety of JLD for EH. To our knowledge, this is the first SR
48
49 of JLD in English.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Ten claimed RCTs, with a total of 655 hypertensive patients, met the inclusion
5
6 criteria and were included in this review. The results suggested that both SBP and
7
8 DBP were significantly improved in patients receiving JLD plus antihypertensive
9
10 drugs therapy, although the effect was not significant in the JLD alone group.
11
12 Moreover, JLD was found to be effective in terms of improving QOL when compared
13
14 with antihypertensive drugs. However, the evidence for JLD as an effective modality
15
16 for treating EH was restricted by a limited number of trials, small sample sizes, poor
17
18 methodological quality, and a high risk of bias in primary studies.
19
20
21
22
23
24
25
26

27 **Limitations**

28
29
30
31 The following limitations should be considered before accepting the findings of
32
33 this review.
34

35
36 (1) Although there were two randomized, single-blind, controlled trials, the
37
38 methodology of most of the included trials was assessed to be generally poor. The
39
40 main reasons are analyzed as follows:
41
42

43
44 Firstly, although all studies claimed randomization, only four trials demonstrated
45
46 the random sequence generation, and two trials reported allocation concealment;
47
48 therefore, selection bias may exist. Secondly, only three trials described the blinding
49
50 of the participants and personnel; however, no trials reported the blinding of outcome
51
52 assessment. Therefore, both selection bias and detection bias might have occurred.
53
54

55
56 Thirdly, only three trials reported drop-out or withdraw statistics, suggesting a high
57
58
59
60

1
2
3 risk of attrition bias. Fourthly, most of the included studies did not mention intention
4
5
6 to treat analysis, which may lead to some other bias. Fifthly, no trials had a
7
8
9 pre-estimation of sample size. Sixthly, no trial had a placebo control, which might
10
11 decrease the quality of positive conclusions.
12

13
14 (2) As shown in Figure 2c, heterogeneity is another critical issue that should be
15
16 considered, which may be associated with variations in study quality, participants,
17
18 JLD compositions, and antihypertensive drugs.
19

20
21 (3) Limited number of included trials and different interventions in both the JLD
22
23 and antihypertensive drugs groups restricted us from conducting meaningful subgroup
24
25 analyses to explore effect modifiers such as duration of intervention and types of
26
27 antihypertensive drug therapies.
28
29

30
31 (4) Publication bias should also be considered. In this review, all of the included
32
33 trials were conducted in China and published in Chinese. Almost all studies claimed a
34
35 similar beneficial effect or a better effect when compared with antihypertensive drugs
36
37 alone. No negative conclusions were found. What is more, a funnel plot checking for
38
39 possible publication bias for BP could not be conducted due to the small number of
40
41 included studies.
42
43
44

45
46 (5) Although one trial had a short-term follow up, most of the studies had no
47
48 follow up, indicating a lack of knowledge for some critical outcomes, such as
49
50 all-cause mortality and progression to severe complications due to high BP, which is
51
52 the most common problem for TCM studies in general.
53
54

55
56 (6) As the use of natural products is very common among patients in a variety of
57
58
59
60

1
2
3 health care settings, the safety of CHM and potential herb-drug interactions has hence
4
5 become a concern. This review suggested that JLD may be safe for the management
6
7 of EH. In fact, no parallel double blind randomized placebo-controlled trials
8
9 indicating the adverse effects of JLD for EH could be found. Due to the insufficient
10
11 clinical data, it is difficult to draw a definitive conclusion regarding the safety of JLD
12
13 for EH at present. We therefore suggest that the adverse effects of JLD need to be
14
15 monitored rigorously in future studies.
16
17
18
19
20
21
22
23

24 CONCLUSION

25
26
27
28
29 Due to the insufficient clinical data, poor methodological design, and high risk of
30
31 bias, it is difficult to draw a definite conclusion regarding the effectiveness and safety
32
33 of JLD for EH. **More rigorously designed trials reported according to the CONSORT**
34
35 **Statement are needed.**⁵²⁻⁵⁴
36
37
38
39
40

41 Funding

42
43 XJX was supported by the National Natural Science Foundation Project of China (No.
44
45 81403375). The funders had no role in study design, data collection and analysis,
46
47 decision to publish, or preparation of the manuscript.
48
49
50

51 Competing interests

52
53
54
55
56 None.
57
58
59
60

Contributors

XX conceived the idea for the study and designed the method of this systematic review and meta-analysis including the inclusion and exclusion criteria. XX also performed data collection and extraction, conducted the statistical analysis, and wrote the first draft of the article. PW, XL, and YZ searched the articles and assessed their methodological quality. Disagreement was resolved by discussion between XX, PW, XL, and YZ. PW performed the major revision, interpreted the results, and made comments. All of the authors approved the final version of the manuscript.

Acknowledgements

The author would like to thank Cheryl C. from American Journal Experts (AJE) in revising the English language of the manuscript.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data sharing statement

No additional data available.

REFERENCES

1. Lawes CM, Hoorn SV, Rodgers A, and for the International Society of Hypertension. Global burden of blood-pressure-related disease 2001. *Lancet* 2008;

- 1
2
3
4 371: 1513-1518.
- 5
6 2. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the
7
8 management of high blood pressure in adults report from the panel members
9
10 appointed to the Eighth Joint National Committee (JNC 8). *J Am Med Assoc* 2014;
11
12 311: 507-520.
- 13
14 3. Ezzati M, Lopez AD, Rodgers A, et al. Comparative risk assessment
15
16 collaborative group: selected major risk factors and global and regional burden of
17
18 disease. *Lancet* 2002; 360: 1347-1360.
- 19
20 4. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension:
21
22 analysis of worldwide data. *Lancet* 2005; 365: 217-223.
- 23
24 5. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease
25
26 and risk factors 2001: systematic analysis of population health data. *Lancet* 2006;
27
28 367: 1747-1757.
- 29
30 6. Fisher JW. The diagnostic value of the sphygmomanometer in examinations for
31
32 life insurance. *J Am Med Assoc* 1914; 63: 1752-1754.
- 33
34 7. Lewington S, Clarke R, Qizilbash N, et al. Prospective Studies Collaboration.
35
36 Age-specific relevance of usual blood pressure to vascular mortality: a
37
38 meta-analysis of individual data for one million adults in 61 prospective studies.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Lancet 2002; 360: 1903-1913.
8. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the
prevention of cardiovascular disease: meta-analysis of 147 randomised trials in
the context of expectations from prospective epidemiological studies. *Brit Med J*

- 2009; 338: b1665, 1-19.
9. Xiong XJ, Yang XC, Liu YM, et al. Chinese herbal formulas for treating hypertension in traditional Chinese medicine: perspective of modern science. *Hypertens Res* 2013; 36: 570-579.
 10. Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. *J Am Med Assoc* 2013; 310: 1-10.
 11. Brook RD, Appel LJ, Rubenfire M, et al. Beyond medications and diet: alternative approaches to lowering blood pressure. *Hypertension* 2013; 61: 1360-1383.
 12. Mansoor GA. Herbs and alternative therapies in the hypertension clinic. *Am J Hypertens* 2001; 14: 971-975.
 13. Xiong XJ, Borrelli F, Ferreira AS, et al. Herbal medicines for cardiovascular diseases. *Evid Based Complement Alternat Med* 2014; 2014: e809741, 1-3.
 14. Wang J, Xiong XJ. Current situation and perspectives of clinical study in integrative medicine in China. *Evid Based Complement Alternat Med* 2012; 2012: e268542, 1-11.
 15. Wang J, Feng B, Yang XC, et al. Chinese herbal medicine for the treatment of prehypertension. *Evid Based Complement Alternat Med* 2013; 2013: e493521, 1-9.
 16. Tachjian A, Maria V, Jahangir A. Use of herbal products and potential interactions in patients with cardiovascular diseases. *J Am Coll Cardiol* 2010; 55:

- 1
2
3
4 515-525.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
17. Xiong XJ, Yang XC, Liu W, et al. Trends in the treatment of hypertension from the perspective of traditional Chinese medicine. *Evid Based Complement Alternat Med* 2013; 2013: e275279, 1-13.
18. Wang J, Xiong XJ. Control strategy on hypertension in Chinese medicine. *Evid Based Complement Alternat Med* 2012; 2012: e284847, 1-6.
19. Wang J, Xiong XJ. Evidence-based Chinese Medicine for Hypertension. *Evid Based Complement Alternat Med* 2013; 2013: e978398, 1-12.
20. Wang J, Xiong XJ. Outcome measures of Chinese herbal medicine for hypertension: an overview of systematic reviews. *Evid Based Complement Alternat Med* 2012; 2012: e697237, 1-10.
21. Wang J, Feng B, Yang XC, et al. Tianma gouteng yin as adjunctive treatment for essential hypertension: a systematic review of randomized controlled trials. *Evid Based Complement Alternat Med* 2013; 2013: e706125, 1-18.
22. Xiong XJ, Yang XC, Feng B, et al. Zhen gan xi feng decoction, a traditional Chinese herbal formula, for the treatment of essential hypertension: a systematic review of randomized controlled trials. *Evid Based Complement Alternat Med* 2013; 2013: e982380, 1-9.
23. Wang J, Yang XC, Feng B, et al. Is Yangxue Qingnao Granule combined with antihypertensive drugs, a new integrative medicine therapy, more effective than antihypertensive therapy alone in treating essential hypertension?. *Evid Based Complement Alternat Med* 2013; 2013: e540613, 1-8.

- 1
2
3
4 24. Xiong XJ, Liu W, Yang XC, et al. Ginkgo biloba extract for essential
5
6 hypertension: a systemic review. *Phytomedicine* 2014; 21: 1131-1136.
7
8
9 25. Wang J, Yao KW, Yang XC, et al. Chinese patent medicine liu wei di huang wan
10
11 combined with antihypertensive drugs, a new integrative medicine therapy, for
12
13 the treatment of essential hypertension: a systematic review of randomized
14
15 controlled trials. *Evid Based Complement Alternat Med* 2012; 2012: e714805,
16
17 1-7.
18
19
20
21 26. Wang J, Feng B, Xiong XJ. Chinese herbal medicine for the treatment of
22
23 obesity-related hypertension. *Evid Based Complement Alternat Med* 2013; 2013:
24
25 e757540, 1-11.
26
27
28
29 27. Lu AP, Jia HW, Xiao C, et al. Theory of traditional Chinese medicine and
30
31 therapeutic method of diseases. *World J Gastroenterol* 2004; 10: 1854-1856.
32
33
34 28. Jiang WY. Therapeutic wisdom in traditional Chinese medicine: a perspective
35
36 from modern science. *Trends Pharmacol Sci* 2005; 26: 558-563.
37
38
39 29. Ge HX, Dai XM, Zhang ZX, et al. Modern application and experimental research
40
41 progress of jian ling decoction. *Acta Chin Med Pharm* 2002; 30: 21-23.
42
43
44 30. Yu HW. Effect of modified jian ling decoction on insulin resistance and serum
45
46 levels of TNF- α in patients with essential hypertension. *Haerbin: Heilongjiang*
47
48 *Univ Chin Med* 2008; 1-56.
49
50
51 31. Cao JM. Effect of modified jian ling decoction on serum leptin and angiotensin II
52
53 in hypertension with insulin resistance. *Haerbin: Heilongjiang Univ Chin Med*
54
55 2012; 1-51.
56
57
58
59
60

- 1
2
3
4 32. Jiang CX. Effect of modified jian ling decoction on blood pressure and
5
6 angiotensin II in elderly hypertensive patients. *Haerbin: Heilongjiang Univ Chin*
7
8 *Med* 2012; 1-51.
9
10
11 33. Zhang N, Sun JL, Dong ZZ, et al. Effect of modified jian ling decoction on
12
13 insulin resistance and serum interleukin-6 of essential hypertension patients. *Chin*
14
15 *J Inform Tradit Chin Med* 2011; 18: 19-21.
16
17
18 34. Feng DR, Wei B. Effects of jian ling decoction on the blood lipid and lipid
19
20 peroxidation in experimental hyperlipidemia rats with yin deficiency of liver
21
22 and kidney. *Guangxi J Tradit Chin Med* 2009; 32: 51-54.
23
24
25 35. Huang YT, Wu CB, Zeng QM. Effect of jian ling decoction on 120 patients of
26
27 essential hypertension. *Chin J Integr Tradit West Med* 1996; 16: 561.
28
29
30 36. Hao HY, Wang QH, Sun CJ, et al. Effect of modified jian ling decoction on 30
31
32 patients of essential hypertension. *Shanxi J Tradit Chin Med* 1998; 19: 541.
33
34
35 37. Guan DM, Du SQ. Clinical observation on the effect of jian ling decoction
36
37 combined with urapidil on stage III hypertension with high-risk. *Chin Commun*
38
39 *Doct* 2013; 15: 214-215.
40
41
42 38. Higgins JPT, Green S. *Cochrane Handbook for Systematic Reviews of*
43
44 *Interventions, Version 5.1.0.* The Cochrane Collaboration.
45
46 <http://handbook.cochrane.org/>. 2011.
47
48
49 39. Li YB, Cui M, Yang Y, et al. Similarity of traditional Chinese medicine formula.
50
51 *Chin Arch Tradit Chin Med* 2012; 30: 1096-1097.
52
53
54 40. Tong WH. Analysis on clinical therapeutic effect of jian ling decoction on
55
56
57
58
59
60

essential hypertension with yin deficiency and yang hyperactivity syndrome.

Guide China Med 2013; 11: 258-259.

41. He T, Zhu YQ, Xu SX. Effect of jian ling decoction on 30 hypertensive patients with yin deficiency and yang hyperactivity syndrome. *Guid J Tradit Chin Med Pharm* 2012; 18: 50-51.
42. Fan R, Zhou H, Tan HY. Effect of jian ling decoction on aged hypertension patient's life mass and CAT. *China J Mod Med* 2005; 15: 1706-1708.
43. Cai XP. Combined traditional Chinese and western medicine in the treatment of 50 patients with essential hypertension. *Guagndong Med J* 1995; 16: 400-402.
44. Zhang N. Effect of modified jian ling decoction on essential hypertension. *Haerbin: Heilongjiang Univ Chin Med* 2004; 1-34.
45. Zhang N. Effect of modified jian ling decoction on insulin resistance and serum levels of IL-6 in essential hypertension. *Haerbin: Heilongjiang Univ Chin Med* 2009; 1-51.
46. Jiang CX, Cao JM. Effect of modified jian ling decoction on renin-angiotensin II in patients with senile hypertension. *Chin J Tradit Med Sci Technol* 2012; 19: 145.
47. Chu GM, Xu JY. Effect of modified jian ling decoction on high-sensitivity C-reactive protein on 67 cases of hypertensive patients. *J Inform Tradit Chin Med* 2013; 30: 66-67.
48. Liu L, Jin J, Yu HW. Effect of modified jian ling decoction on insulin resistance and TNF- α level in patients of EH. *J Inform Tradit Chin Med* 2008; 25: 68-70, 80.

- 1
2
3
4 49. Li CM. Effect of modified jian ling decoction on senile primary hypertension.
5
6 *Jinan: Shandong Univ Chin Med* 2013; 1-30.
7
8
9 50. Xiong XJ, Liu W, Yang XC, et al. Moxibustion for essential hypertension.
10
11 *Complement Ther Med* 2014; 22: 187-195.
12
13
14 51. Croog SH, Levine S, Testa MA, et al. The effect of antihypertensive therapy on
15
16 the quality of life. *N Engl J Med* 1986; 314: 1657-1659.
17
18
19 52. Liu JP, Han M, Li XX, et al. Prospective registration, bias risk and
20
21 outcome-reporting bias in randomised clinical trials of traditional Chinese
22
23 medicine: An empirical methodological study. *BMJ Open* 2013; 3: e002968, 1-7.
24
25
26 53. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines
27
28 for reporting parallel group randomized trials. *Ann Intern Med* 2012; 152:
29
30 726-732.
31
32
33 54. Gagnier JJ, Boon H, Rochon P, et al. Reporting randomized, controlled trials of
34
35 herbal interventions: an elaborated CONSORT statement. *Ann Intern Med* 2006;
36
37 144: 364-367.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Basic characteristics of the included studies.

Table 2. Herbal medicines in the included studies.

Table 3. Methodological quality of included studies based on the Cochrane handbook.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FIGURE LEGENDS

Figure 1.

Flow diagram of study selection and identification.

Figure 2.

Effect of JLD on BP. (a) JLD *versus* AD and (b) JPAD *versus* AD.

AD: antihypertensive drugs; BP: blood pressure; DBP: diastolic blood pressure; JLD:

Jian Ling Decoction; JPAD: Jian Ling Decoction plus antihypertensive drugs; SBP:

systolic blood pressure.

Table 1. Basic characteristics of the included studies.

Study ID	Sample size (randomized /analyzed) M/F	Age(yrs)	Diagnosis standard	Intervention	Control	Course (week)	Outcome measures
Tong 2013 [40]	60/60 T: 30 C: 30 F/M: NR	40-60 (T/C: NR)	GCRNDTC M	JLD (1 dose/d)	felodipine (5 mg, qd)	4	BP
He et al. 2012 [41]	60/60 T: 15/15 C: 17/13	T: 54.89 ± 5.34 C: 57.36 ± 6.47	GCRNDTC M	JLD (1 dose/d)	felodipine (5 mg, qd)	4	BP
Fan 2005 [42]	50/50 T: 14/11 C: 13/12	T: 64.80 ± 7.40 C: 63.70 ± 6.90	WHO -ISH GMH-1999	JLD (1 dose/d)	felodipine (2.5 mg, qd)	4	BP; QOL
Cai 1995 [43]	100/100 T: 35/15 C: 34/16	T: 50-81 C: 47-84	WHO -ISH GMH-1985	modified JLD (1 dose/d) + control	nifedipine (10 mg, tid)	4	BP; adverse effect
Zhang 2004 [44]	90/89 T1: 16/14 T2: 17/13 C: 15/14	T1: 58.23 ± 8.26 T2: 58.45 ± 6.87 C: 59.16 ± 9.28	WHO -ISH GMH-1999	T1: modified JLD (1 dose/d) T2: modified JLD (1 dose/d) + control	enalapril (10 mg, bid)	4	BP; adverse effect
Zhang 2009 [45]	60/57 T: 15/14 C: 12/16	T: 56.41 ± 10.98 C: 58.57 ± 8.21	CGMH-200 5	modified JLD (1 dose/d) + control	enalapril (10 mg, bid)	3	BP; adverse effect
Jiang and Cao 2012 [46]	82/82 T: 26/16 C: 23/17	T: 60-75 C: 62-75	WHO -ISH GMH-1999	modified JLD (100 ml/d) + control	benazepril hydrochloride (10 mg, tid)	4	BP
Chu and Xu 2013 [47]	67/67 T: 19/15 C: 17/16	T: 67.00 ± 7.20 C: 68.00 ± 5.90	WHO -ISH GMH-1999	modified JLD (100 ml/d) + control	nifedipine controlled release tablet (30 mg, qd)	4	BP
Liu et al. 2008 [48]	60/60 T: 30 C: 30 F/M: NR	18-70 (T/C: NR)	JNC 7	modified JLD (100 ml/d) + control	enalapril (10 mg, bid)	3	BP; adverse effect
Li 2013 [49]	60/60 T: 16/14 C: 17/13	T: 64.33 ± 7.96 C: 61.20 ± 10.23	CGMH-201 0	modified JLD (400 ml/d) + control	nifedipine controlled release tablet (30 mg, qd) and irbesartan (150 mg, qd)	4	BP; adverse effect

Abbreviations: BP: blood pressure; C: control group; CGMH: Chinese Guidelines for the Management of Hypertension; F: female; GCRNDTCM: Guidelines of Clinical Research of New Drugs of Traditional Chinese Medicine; JLD: Jian Ling Decoction; JNC 7: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; M: male; NR: not reported; QOL: quality of life; T: treatment group; WHO-ISH GMH: WHO-ISH guidelines for the management of hypertension.

Table 2. Herbal medicines in the included studies.

Study ID	Formula	Composition of formula
Tong 2013 [40]	JLD	Arbor Vitae Seed (Baiziren, Semen Platycladi) 10 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 10 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 15 g, Oyster Shell (Muli, Concha Ostreae) 10 g, Fossilized Mammal Bones (Longgu, Os Draconis) 10 g, Hematite (Daizheshi, Haematitum) 10 g, Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 15 g, and Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 20 g.
He et al. 2012 [41]	JLD	Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 15 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 20 g, Hematite (Daizheshi, Haematitum) 10 g, Oyster Shell (Muli, Concha Ostreae) 10 g, Fossilized Mammal Bones (Longgu, Os Draconis) 10 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 15 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 10 g, and Arbor Vitae Seed (Baiziren, Semen Platycladi) 10 g.
Fan 2005 [42]	JLD	Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 30 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 30 g, Hematite (Daizheshi, Haematitum) 24 g, Oyster Shell (Muli, Concha Ostreae) 18 g, Fossilized Mammal Bones (Longgu, Os Draconis) 18 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 18 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 12 g, and Arbor Vitae Seed (Baiziren, Semen Platycladi) 12 g.
Cai 1995 [43]	modified JLD	Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 30 g, Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 30 g, Abalone Shell (Shijueming, Haliotidis Concha) 30 g, Hematite (Daizheshi, Haematitum) 24 g, Oyster Shell (Muli, Concha Ostreae) 18 g, Fossilized Mammal Bones (Longgu, Os Draconis) 18 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 18 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 12 g, and Arbor Vitae Seed (Baiziren, Semen Platycladi) 12 g. Headache plus Puncturevine Caltrop Fruit (Cijili, Tribulus terrestris Linn) 10 g; constipation plus Rhubarb Root and Rhizome (Daihuang, Radix Et Rhizoma Rhei) 5 g.
Zhang 2004 [44]	modified JLD	Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 30 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 30 g, Hematite (Daizheshi, Haematitum) 24 g, Oyster Shell (Muli, Concha Ostreae) 18 g, Fossilized Mammal Bones (Longgu, Os Draconis) 18 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 18 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 12 g, and Arbor Vitae Seed (Baiziren, Semen Platycladi) 12 g. Headache, dizziness, and irritability plus Gastrodia (Tianma, Gastrodiae Rhizoma) 15 g and Abalone Shell (Shijueming, Haliotidis Concha) 30 g; irritability, bitty mouth and red face plus Coptis Rhizome (Huanglian, Rhizoma Coptidis) 10 g and Gardenia (Zhizi, Fructus Gardeniae Jasminoidis) 10 g; and constipation plus Rhubarb Root and Rhizome (Daihuang, Radix Et Rhizoma Rhei) 5 g.
Zhang 2009 [45]	modified JLD	Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 30 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 30 g, Hematite (Daizheshi, Haematitum) 24 g, Oyster Shell (Muli, Concha Ostreae) 18 g, Fossilized Mammal Bones (Longgu, Os Draconis) 18 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 18 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 12 g, and Arbor Vitae Seed (Baiziren, Semen Platycladi) 12 g. Excessive accumulation of phlegm-dampness plus Pinellia Rhizome (Banxia, Rhizoma Pinelliae Tematae) 15 g, Sclerotium of Tuckahoe (Fuling, Scierotium Poriae Cocos) 15 g, Tangerine Peel (Chenpi, Pericarpium Citri Reticulatae) 10 g, Bamboo Shavings (Zhuru, Bambusae Caulis in Taeniam) 10 g, and Licorice Root (Gancao, Radix Glycyrrhizae) 3 g.
Jiang and Cao	modified	Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 30 g, Fresh Water Turtle Shell (Guijia, Plastrum

2012 [46]	JLD	Testudinis) 30 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 30 g, Hematite (Daizheshi, Haematitum) 20 g, Oyster Shell (Muli, Concha Ostreae) 20 g, Fossilized Mammal Bones (Longgu, Os Draconis) 20 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 20 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 15 g, and Arbor Vitae Seed (Baiziren, Semen Platycladi) 15 g.
Chu and Xu 2013 [47]	modified JLD	Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 25 g, Fresh Water Turtle Shell (Guijia, Plastrum Testudinis) 25 g, Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 30 g, Hematite (Daizheshi, Haematitum) 15 g, Oyster Shell (Muli, Concha Ostreae) 25 g, Fossilized Mammal Bones (Longgu, Os Draconis) 25 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 25 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 20 g, and Arbor Vitae Seed (Baiziren, Semen Platycladi) 20 g.
Liu et al. 2008 [48]	modified JLD	Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 30 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 18 g, Hematite (Daizheshi, Haematitum) 24 g, Oyster Shell (Muli, Concha Ostreae) 18 g, Fossilized Mammal Bones (Longgu, Os Draconis) 18 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 30 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 20 g, and Arbor Vitae Seed (Baiziren, Semen Platycladi) 20 g. Excessive accumulation of phlegm-dampness plus Pinellia Rhizome (Banxia, Rhizoma Pinelliae Tematae) 15 g, Sclerotium of Tuckahoe (Fuling, Scierotium Poriae Cocos) 15 g, Tangerine Peel (Chenpi, Pericarpium Citri Reticulatae) 10 g, Bamboo Shavings (Zhuru, Bambusae Caulis in Taeniam) 10 g, and Liquoric Root (Gancao, Radix Glycyrrhizae) 3 g.
Li 2013 [49]	modified JLD	Fossilized Mammal Bones (Longgu, Os Draconis) 30 g, Oyster Shell (Muli, Concha Ostreae) 30 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 20 g, Hematite (Daizheshi, Haematitum) 20 g, Dioscorea Root (Shanyao, Dioscoreae Rhizoma) 30 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 30 g, White Peony Root (Baishao, Radix Albus Paeoniae Lactiflorae) 20 g, Arbor Vitae Seed (Baiziren, Semen Platycladi) 15 g, Gambir Vine Stems and Thorns (Gouteng, Ramulus Uncariae Cum Uncis) 30 g, Pueraria (Gegen, Radix Puerariae) 30 g, Gastrodia (Tianma, Gastrodiae Rhizoma) 15 g, Chinese Taxillus Twig (Sangjiisheng, Herba Taxilli) 30 g, Eucommia Bark (Duzhong, Cortex Eucommiae Ulmoidis) 15 g, and Coptis Rhizome (Huanglian, Rhizoma Coptidis) 9 g.

Abbreviations: JLD: Jian Ling Decoction.

Table 3. Methodological quality of included studies based on the Cochrane handbook.

Included trials	A	B	C	D	E	F	G
Tong 2013 [40]	?	?	?	?	+	?	?
He et al. 2012 [41]	+	?	?	?	+	?	?
Fan 2005 [42]	?	?	?	?	+	?	?
Cai 1995 [43]	?	+	?	?	+	?	?
Zhang 2004 [44]	+	+	+	?	+	?	?
Zhang 2009 [45]	+	?	+	?	+	?	?
Jiang and Cao 2012 [46]	?	?	?	?	+	?	?
Chu and Xu 2013 [47]	?	?	?	?	+	?	?
Liu et al. 2008 [48]	+	+	+	?	+	?	?
Li 2013 [49]	?	?	?	?	+	?	?

Abbreviations: A: Adequate sequence generation; B: Concealment of allocation; C: Blinding (participants and personnel); D: Blinding (assessor); E: Incomplete outcome data addressed (ITT analysis); F: Free of selective reporting; G: other potential threat to validity; +: low risk; -: high risk; ?: unclear.



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Section/Topic	#	Checklist Item	Reported on Page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	P1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	P2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	P5-8
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	P8
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	NA
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	P9-11
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	P8-9
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	P9
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	P11
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	P11-12
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	P11-12
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	P12
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	P12-13
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2 for each meta-analysis).	P12-13



PRISMA 2009 Checklist

Page 1 of 2

Section/Topic	#	Checklist Item	Reported on Page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	P12-13
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	P12-13
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	P13
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	P13-15
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	P15
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	P16-17
Synthesis of results	21	Present the main results of the review. If meta-analyses done, include for each, confidence intervals and measures of consistency.	P16-17
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	P15
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	P18
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	P18-19
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	P19-21
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	P21
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	P21

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>